

[19]	INTELLECTUAL PROPERTY PHILIPPINES		
[12]	INVENTION PUBLICATION		
[11]	Publication Number:	12015500935	Document Code: B1
[22]	Publication Date:	29/6/2015	
[21]	Application Number:	12015500935	Document Code: A
[22]	Date Filed:	27/4/2015	
[54]	Title:	CANCER TREATMENT	
[71]	Applicant(s):	ISIS PHARMACEUTICALS INC	
[72]	Inventor(s):	CROOKE STANLEY T YAMASHITA MASON	
[30]	Priority Data:	12/3/2013 US201361777875P	
[51]	International Class 8:	C12N 15/113 20100101AFI20180806BHPH;	
[57]	Abstract:	In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of STAT3 mRNA or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate B-cell lymphoma or hepatocellular carcinoma. The STAT (signal transducers and activators of transcription) family of proteins are DNA-binding proteins that play a dual role in signal transduction and activation of transcription.	

"Gapmer" means a chimeric antisense compound in which an internal region having a plurality of nucleosides that support RNase H cleavage is positioned between external regions having one or more nucleosides, wherein the nucleosides comprising the internal region are chemically distinct from the nucleoside or nucleosides comprising the external regions. The internal region may be referred to as the "gap" and the external regions may be referred to as the "wings."

"Gap-widened" means a chimeric antisense compound having a gap segment of 12 or more contiguous 2'-deoxyribonucleosides positioned between and immediately adjacent to 5' and 3' wing segments having from one to six nucleosides.

"HCC" means hepatocellular carcinoma. It is the most common form of liver cancer and also referred to as malignant hepatoma.

"Hybridization" means the annealing of complementary nucleic acid molecules. In certain embodiments, complementary nucleic acid molecules include an antisense compound and a target nucleic acid.

"Hyperproliferative disease" means a disease characterized by rapid or excessive growth and reproduction of cells. Examples of hyperproliferative diseases include cancer, e.g., carcinomas, sarcomas, lymphomas, and leukemias as well as associated malignancies and metastases.

"Identifying an animal at risk for hyperproliferative disease" means identifying an animal having been diagnosed with a hyperproliferative disease or identifying an animal predisposed to develop a hyperproliferative disease. Individuals predisposed to develop a hyperproliferative disease include those having one or more risk factors for hyperproliferative disease including older age; history of other hyperproliferative diseases; history of tobacco use; history of exposure to sunlight and/or ionizing radiation; prior contact with certain chemicals, especially continuous contact; past or current infection with certain viruses and bacteria; prior or current use of certain hormone therapies; genetic predisposition; alcohol use; and certain lifestyle choices including poor diet, lack of physical activity, and/or being overweight. Such identification may be accomplished by any method including evaluating an individual's medical history and standard clinical tests or assessments.

"Immediately adjacent" means there are no intervening elements between the immediately adjacent elements.

"Inhibiting STAT3" means reducing expression of STAT3 mRNA and/or protein levels in the presence of a STAT3 antisense compound, including a STAT3 antisense oligonucleotide, as compared to expression of STAT3 mRNA and/or protein levels in the absence of a STAT3 antisense compound, such as an antisense oligonucleotide.

5 "Individual" means a human or non-human animal selected for treatment or therapy.

"Internucleoside linkage" refers to the chemical bond between nucleosides.

"ISIS 481464" means a STAT3 antisense oligonucleotide having the nucleobase sequence "CTATTTGGATGTCAGC", incorporated herein as SEQ ID NO: 12, where each
10 internucleoside linkage is a phosphorothioate internucleoside linkage, each cytosine is a 5-methylcytosine, and each of nucleosides 1-3 and 14-16 comprise a cEt moiety. ISIS 481464 is complementary to nucleobases 3016-3031 of the sequence of GENBANK Accession No. NM_139276.2, incorporated herein as SEQ ID NO:1.

"Linked nucleosides" means adjacent nucleosides which are bonded together.

15 "Loading phase" means a dosing phase during which administration is initiated and steady state concentrations of pharmaceutical agents are achieved in a target tissue. For example, a loading phase is a dosing phase during which steady state concentrations of antisense oligonucleotide are achieved in liver.

"Maintenance phase" means a dosing phase after target tissue steady state
20 concentrations of pharmaceutical agents have been achieved. For example, a maintenance phase is a dosing phase after which steady state concentrations of antisense oligonucleotide are achieved in liver.

"Mismatch" or "non-complementary nucleobase" refers to the case when a
25 nucleobase of a first nucleic acid is not capable of pairing with the corresponding nucleobase of a second or target nucleic acid.

"Modified internucleoside linkage" refers to a substitution or any change from a naturally occurring internucleoside bond (i.e. a phosphodiester internucleoside bond).

"Modified nucleobase" refers to any nucleobase other than adenine, cytosine, guanine, thymidine, or uracil. An "unmodified nucleobase" means the purine bases
30 adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U).

"Modified nucleotide" means a nucleotide having, independently, a modified sugar moiety, modified internucleoside linkage, or modified nucleobase. A "modified nucleoside" means a nucleoside having, independently, a modified sugar moiety or modified nucleobase.

5 "Modified oligonucleotide" means an oligonucleotide comprising a modified internucleoside linkage, a modified sugar, and/or a modified nucleobase.

"Modified sugar" refers to a substitution or change from a natural sugar.

"Motif" means the pattern of chemically distinct regions in an antisense compound.

10 "Naturally occurring internucleoside linkage" means a 3' to 5' phosphodiester linkage.

"Natural sugar moiety" means a sugar found in DNA (2'-H) or RNA (2'-OH).

15 "Nucleic acid" refers to molecules composed of monomeric nucleotides. A nucleic acid includes ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids, double-stranded nucleic acids, small interfering ribonucleic acids (siRNA), and microRNAs (miRNA).

"Nucleobase" means a heterocyclic moiety capable of pairing with a base of another nucleic acid.

"Nucleobase sequence" means the order of contiguous nucleobases independent of any sugar, linkage, or nucleobase modification.

20 "Nucleoside" means a nucleobase linked to a sugar.

"Nucleoside mimetic" includes those structures used to replace the sugar or the sugar and the base and not necessarily the linkage at one or more positions of an oligomeric compound such as for example nucleoside mimetics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl, bicyclo or tricyclo sugar mimetics, *e.g.*, non
25 furanose sugar units. Nucleotide mimetic includes those structures used to replace the nucleoside and the linkage at one or more positions of an oligomeric compound such as for example peptide nucleic acids or morpholinos (morpholinos linked by -N(H)-C(=O)-O- or other non-phosphodiester linkage). Sugar surrogate overlaps with the slightly broader term nucleoside mimetic but is intended to indicate replacement of the sugar unit (furanose ring)
30 only. The tetrahydropyranyl rings provided herein are illustrative of an example of a sugar

surrogate wherein the furanose sugar group has been replaced with a tetrahydropyranyl ring system.

"Nucleotide" means a nucleoside having a phosphate group covalently linked to the sugar portion of the nucleoside.

5 "Off-target effect" refers to an unwanted or deleterious biological effect associated with modulation of RNA or protein expression of a gene other than the intended target nucleic acid.

"Oligomeric compound" or "oligomer" means a polymer of linked monomeric subunits which is capable of hybridizing to at least a region of a nucleic acid molecule.

10 "Oligonucleotide" means a polymer of linked nucleosides each of which can be modified or unmodified, independent one from another.

"Parenteral administration" means administration through injection (e.g., bolus injection) or infusion. Parenteral administration includes subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration,
15 intraperitoneal administration, or intracranial administration, e.g., intrathecal or intracerebroventricular administration.

"Peptide" means a molecule formed by linking at least two amino acids by amide bonds. Peptide refers to polypeptides and proteins.

"Pharmaceutical composition" means a mixture of substances suitable for
20 administering to an individual. For example, a pharmaceutical composition may comprise one or more active pharmaceutical agents and a sterile aqueous solution. In certain embodiments, a pharmaceutical composition shows activity in free uptake assay in certain cell lines.

"Pharmaceutically acceptable derivative" encompasses pharmaceutically
25 acceptable salts, conjugates, prodrugs or isomers of the compounds described herein.

"Pharmaceutically acceptable salts" means physiologically and pharmaceutically acceptable salts of antisense compounds, i.e., salts that retain the desired biological activity of the parent oligonucleotide and do not impart undesired toxicological effects thereto.

"Phosphorothioate linkage" means a linkage between nucleosides where the
30 phosphodiester bond is modified by replacing one of the non-bridging oxygen atoms with a sulfur atom. A phosphorothioate linkage (P=S) is a modified internucleoside linkage.

"Portion" means a defined number of contiguous (i.e., linked) nucleobases of a nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of a target nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of an antisense compound.

5 "Prevent" refers to delaying or forestalling the onset or development of a disease, disorder, or condition for a period of time from minutes to indefinitely. Prevent also means reducing risk of developing a disease, disorder, or condition.

 "Prodrug" means a therapeutic agent that is prepared in an inactive form that is converted to an active form within the body or cells thereof by the action of endogenous
10 enzymes or other chemicals or conditions.

 "Side effects" means physiological responses attributable to a treatment other than the desired effects. In certain embodiments, side effects include injection site reactions, liver function test abnormalities, renal function abnormalities, liver toxicity, renal toxicity, central nervous system abnormalities, myopathies, and malaise. For example, increased
15 aminotransferase levels in serum may indicate liver toxicity or liver function abnormality. For example, increased bilirubin may indicate liver toxicity or liver function abnormality.

 "Signal Transducer and Activator of Transcription 3 nucleic acid" or "STAT3 nucleic acid" means any nucleic acid encoding STAT3. For example, in certain embodiments, a STAT3 nucleic acid includes a DNA sequence encoding STAT3, an RNA
20 sequence transcribed from DNA encoding STAT3 (including genomic DNA comprising introns and exons), and an mRNA sequence encoding STAT3. "STAT3 mRNA" means an mRNA encoding a STAT3 protein.

 "Single-stranded oligonucleotide" means an oligonucleotide which is not hybridized to a complementary strand.

25 "Specifically hybridizable" refers to an antisense compound having a sufficient degree of complementarity between an antisense oligonucleotide and a target nucleic acid to induce a desired effect, while exhibiting minimal or no effects on non-target nucleic acids under conditions in which specific binding is desired, i.e., under physiological conditions in the case of *in vivo* assays and therapeutic treatments.

30 "Subject" means a human selected for treatment or therapy.

"Targeting" or "targeted" means the process of design and selection of an antisense compound that will specifically hybridize to a target nucleic acid and induce a desired effect.

"Target nucleic acid," "target RNA," "target mRNA," and "target RNA transcript" all refer to a nucleic acid capable of being targeted by antisense compounds.

"Target segment" means the sequence of nucleotides of a target nucleic acid to which an antisense compound is targeted. "5' target site" refers to the 5'-most nucleotide of a target segment. "3' target site" refers to the 3'-most nucleotide of a target segment.

"Therapeutically effective amount" means an amount of a pharmaceutical agent that provides a therapeutic benefit to an individual.

"Treat" refers to administering a pharmaceutical composition to effect an alteration or improvement of a disease, disorder, or condition.

"Unmodified nucleotide" means a nucleotide composed of naturally occurring nucleobases, sugar moieties, and internucleoside linkages. In certain embodiments, an unmodified nucleotide is an RNA nucleotide (i.e. β -D-ribonucleosides) or a DNA nucleotide (i.e. β -D-deoxyribonucleoside).

Certain Embodiments

In certain aspects, there is provided a method of treating cancer in a subject which comprises administering to the subject an inhibitor of the JAK-STAT pathway. In certain embodiments the cancer is B-cell lymphoma or hepatocellular carcinoma (HCC).

In certain aspects, there is provided a method of treating B-cell lymphoma in a subject which comprises administering to the subject an inhibitor of the JAK-STAT pathway.

In certain aspects, there is provided a method of treating cancer, such as B-cell lymphoma or HCC, in a subject which comprises administering to the subject a weekly dose of an antisense compound complementary to a nucleic acid encoding human STAT3, wherein the dose comprises about 0.2 to 3.5 milligrams of the antisense compound per kilogram of the subject's body weight per week (0.2-3.5 mg/kg/wk). In certain embodiments, the dose is about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg,

about 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.1 mg, about 3.2 mg, about 3.3 mg, about 3.4 mg, or about 3.5 mg of the antisense compound per kilogram of the subject's body weight. In certain embodiments, the dose comprises about 1.5 to 3.5 milligrams of the antisense compound per kilogram of the subject's body weight (1.5-3.5 mg/kg/wk. In certain embodiments, the dose is 2.0 milligrams of the antisense compound per kilogram of the subject's body weight per week (2.0 mg/kg/wk). In certain embodiments, the dose is effective to treat cancer and acceptably tolerable. The dose can be administered for at least 1-52 weeks, at least 1-10 weeks, at least 1-7 weeks, at least 1-5 weeks, at least 5 weeks, at least 6 weeks, or at least 7 weeks. In certain embodiments, the dose can be administered to the subject 1, 2, 3, 4, 5, 6, or 7 times per week. In certain embodiments, the dose is administered to the subject 1-6 times per week. In several embodiments, the dose can be administered 6 times during the first week and 1 time each subsequent week. In certain embodiments, the subject's body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch}$ over 5 feet; for women (in kg) = $45.5 + 2.3 \text{ kg/inch}$ over 5 feet.

In certain embodiments, a method comprises administering to a subject having cancer, such as B-cell lymphoma or HCC, a single dose of a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3, wherein the single dose comprises an amount of the compound in the range of about 15-250 mg. In certain embodiments, the single dose comprises an amount of the compound in the range of about 100-250 mg. In certain embodiments, the single dose is an amount of any of about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, or about 250 mg. In certain embodiments, the dose is effective to treat cancer and acceptably tolerable.

In certain embodiments, a method comprises administering to a subject having cancer, such as B-cell lymphoma or HCC, a total weekly dose of a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3, wherein the total weekly dose comprises an amount of the compound in

the range of about 15-750 mg weekly. In certain embodiments, the total weekly dose comprises an amount of the compound in the range of about 100-750 mg weekly. In certain embodiments, the total weekly dose is an amount of any of about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, or about 750 mg. In certain embodiments, the dose is effective to treat cancer and acceptably tolerable. The total weekly dose can be administered in 2, 3, 4, 5, 6, or 7 equal doses within a week, such that the total weekly dose does not exceed about 750 mg. In certain embodiments, the total weekly dose is administered in 3 equal doses within a week. It will be understood that the aforementioned total weekly dose ranges can be readily represented as milligrams of the antisense compound per kilogram of the subject's body weight per week (mg/kg/wk) by simply dividing the total weekly dose by the subject's body weight, such as the subject's ideal body weight. For example, dividing the aforementioned total weekly dose by an average adult body weight of 70 kg, in certain embodiments the total weekly dose can be represented as an amount of about 15 mg/70 kg (0.2 mg/kg/wk) to 750 mg/70 kg (10.7 mg/kg/wk). In certain embodiments, the total weekly dose can be represented as any of about 15 mg/70 kg (0.2 mg/kg/wk), about 20 mg/70 kg (0.3 mg/kg/wk), about 30 mg/70 kg (0.4 mg/kg/wk), about 40 mg/70 kg (0.6 mg/kg/wk), about 50 mg/70 kg (0.7 mg/kg/wk), about 75 mg/70 kg (1.1 mg/kg/wk), about 100 mg/70 kg (1.4 mg/kg/wk), about 125 mg/70 kg (1.8 mg/kg/wk), about 150 mg/70 kg (2.1 mg/kg/wk), about 175 mg/70 kg (2.5 mg/kg/wk), about 200 mg/70 kg (2.9 mg/kg/wk), about 225 mg/70 kg (3.2 mg/kg/wk), about 250 mg/70 kg (3.6 mg/kg/wk), about 275 mg/70 kg (3.9 mg/kg/wk), about 300 mg/70 kg (4.3 mg/kg/wk), about 325 mg/70 kg (4.6 mg/kg/wk), about 350 mg/70 kg (5.0 mg/kg/wk), about 375 mg/70 kg (5.4 mg/kg/wk), about 400 mg/70 kg (5.7 mg/kg/wk), about 425 mg/70 kg (6.1 mg/kg/wk), about 450 mg/70 kg (6.4 mg/kg/wk), about 475 mg/70 kg (6.8 mg/kg/wk), about 500 mg/70 kg (7.1 mg/kg/wk), about 525 mg/70 kg (7.5 mg/kg/wk), about 550 mg/70 kg (7.9 mg/kg/wk), about 575 mg/70 kg (8.2 mg/kg/wk), about 600 mg/70 kg (8.6 mg/kg/wk), about 625 mg/70 kg (8.9 mg/kg/wk), about 650 mg/70 kg (9.3 mg/kg/wk), about 675 mg/70 kg (9.6 mg/kg/wk), about 700 mg/70 kg (10.0 mg/kg/wk), about 725 mg/70 kg (10.4 mg/kg/wk), or about 750 mg/70 kg (10.7 mg/kg/wk). In certain embodiments, body weight is calculated as the ideal

body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain aspects, a method comprises administering to a subject having cancer, such as B-cell lymphoma or HCC, a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3, wherein administering the antisense compound comprises:

a loading phase comprising a total weekly dose in the range of about 15-750 mg for the first 1-10 weeks, and

a maintenance phase comprising a total weekly dose in the range of 15-250 mg for at least 1 week after the loading phase.

In certain embodiments, the loading phase is 1 week, 2 weeks, 3 weeks, 4 weeks, or 5 weeks. In certain embodiments, the loading phase comprises administering the compound in 2, 3, 4, 5, 6, or 7 equal doses within a week. In certain embodiments, the loading phase comprises administering the compound in 3 equal doses within a week. In several embodiments, the total weekly dose of the antisense compound in the loading phase is an amount of any of about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, or about 750 mg. It will be understood that the aforementioned total weekly dose ranges in the loading phase can be readily represented as milligrams of the antisense compound per kilogram of the subject's body weight per week (mg/kg/wk) by simply dividing the total weekly dose by the subject's body weight, such as the subject's ideal body weight. For example, dividing the aforementioned total weekly dose in the loading phase by an average adult body weight of 70 kg, in certain embodiments the total weekly dose can be represented as an amount of about 15 mg/70 kg (0.2 mg/kg/wk) to 750 mg/70 kg (10.7 mg/kg/wk). In certain embodiments, the total weekly dose in the loading phase can be represented as any of about 15 mg/70 kg (0.2 mg/kg/wk), about 20 mg/70 kg (0.3 mg/kg/wk), about 30 mg/70 kg (0.4 mg/kg/wk), about 40 mg/70 kg (0.6 mg/kg/wk), about 50 mg/70 kg (0.7 mg/kg/wk),

about 75 mg/70 kg (1.1 mg/kg/wk), about 100 mg/70 kg (1.4 mg/kg/wk), about 125 mg/70 kg (1.8 mg/kg/wk), about 150 mg/70 kg (2.1 mg/kg/wk), about 175 mg/70 kg (2.5 mg/kg/wk), about 200 mg/70 kg (2.9 mg/kg/wk), about 225 mg/70 kg (3.2 mg/kg/wk), about 250 mg/70 kg (3.6 mg/kg/wk), about 275 mg/70 kg (3.9 mg/kg/wk), about 300 mg/70 kg (4.3 mg/kg/wk), about 325 mg/70 kg (4.6 mg/kg/wk), about 350 mg/70 kg (5.0 mg/kg/wk), about 375 mg/70 kg (5.4 mg/kg/wk), about 400 mg/70 kg (5.7 mg/kg/wk), about 425 mg/70 kg (6.1 mg/kg/wk), about 450 mg/70 kg (6.4 mg/kg/wk), about 475 mg/70 kg (6.8 mg/kg/wk), about 500 mg/70 kg (7.1 mg/kg/wk), about 525 mg/70 kg (7.5 mg/kg/wk), about 550 mg/70 kg (7.9 mg/kg/wk), about 575 mg/70 kg (8.2 mg/kg/wk), about 600 mg/70 kg (8.6 mg/kg/wk), about 625 mg/70 kg (8.9 mg/kg/wk), about 650 mg/70 kg (9.3 mg/kg/wk), about 675 mg/70 kg (9.6 mg/kg/wk), about 700 mg/70 kg (10.0 mg/kg/wk), about 725 mg/70 kg (10.4 mg/kg/wk), or about 750 mg/70 kg (10.7 mg/kg/wk). In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, the maintenance phase comprises administering the compound in 2, 3, 4, 5, 6, or 7 equal doses within a week. In several embodiments, the total weekly dose of the antisense compound in the maintenance phase is an amount of any of about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, or about 250 mg. In certain embodiments, the total weekly dose in the maintenance phase is administered as a single dose per week. It will be understood that the aforementioned total weekly dose ranges in the maintenance phase can be readily represented as milligrams of the antisense compound per kilogram of the subject's body weight per week (mg/kg/wk) by simply dividing the total weekly dose by the subject's body weight, such as the subject's ideal body weight. For example, dividing the aforementioned total weekly dose by an average adult body weight of 70 kg, in certain embodiments the total weekly dose in the maintenance phase can be represented as an amount of about 15 mg/70 kg (0.2 mg/kg/wk) to 250 mg/70 kg (3.6 mg/kg/wk). In certain embodiments, the total weekly dose can be represented as any of about 15 mg/70 kg (0.2 mg/kg/wk), about 20 mg/70 kg

(0.3 mg/kg/wk), about 30 mg/70 kg (0.4 mg/kg/wk), about 40 mg/70 kg (0.6 mg/kg/wk), about 50 mg/70 kg (0.7 mg/kg/wk), about 75 mg/70 kg (1.1 mg/kg/wk), about 100 mg/70 kg (1.4 mg/kg/wk), about 125 mg/70 kg (1.8 mg/kg/wk), about 150 mg/70 kg (2.1 mg/kg/wk), about 175 mg/70 kg (2.5 mg/kg/wk), about 200 mg/70 kg (2.9 mg/kg/wk), about 225 mg/70 kg (3.2 mg/kg/wk), or about 250 mg/70 kg (3.6 mg/kg/wk). In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$;

In certain embodiments, a method comprises administering to a subject having cancer, such as B-cell lymphoma or HCC, a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3, wherein administering the antisense compound comprises:

a loading phase about 6, 7, 8, 9, or 10 weeks, and

a maintenance phase comprising a dose of about 2 mg/kg/wk for at least 1 week after the loading phase. In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, a method comprises administering to a subject having cancer, such as B-cell lymphoma, a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3, wherein administering the antisense compound comprises:

a loading phase comprising a dose in the range of about 3 to 4 mg/kg/wk for about 6, 7, 8, 9, or 10 weeks, and

a maintenance phase comprising a dose of about 2 mg/kg/wk for at least 1 week after the loading phase. In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, a method comprises administering to a subject having cancer, such as B-cell lymphoma or HCC, a pharmaceutical composition comprising an

antisense compound complementary to a nucleic acid encoding human STAT3, wherein administering the antisense compound comprises:

a loading phase comprising a dose of about 3 mg/kg/wk for about 8 weeks, and

5 a maintenance phase comprising a dose of about 2 mg/kg/wk for at least 1 week after the loading phase. In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

10 In certain embodiments, a method comprises administering to a subject having cancer, such as B-cell lymphoma or HCC, a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3, wherein administering the antisense compound comprises:

a first phase comprising a total weekly dose in the range of about 15-750 mg for the first 1-10 weeks, and

15 a second phase comprising a total weekly dose in the range of 15-250 mg for at least 1 week after the loading phase.

In certain embodiments, the first phase is 1 week, 2 weeks, 3 weeks, 4 weeks, or 5 weeks. In certain embodiments, the first phase comprises administering the compound in 2, 3, 4, 5, 6, or 7 equal doses within a week. In certain embodiments, the first phase
20 comprises administering the compound in 3 equal doses within a week. In several embodiments, the total weekly dose of the antisense compound in the first phase is an amount of any of about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg,
25 about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, or about 750 mg. It will be understood that the aforementioned total weekly dose ranges in the first phase can be readily represented as milligrams of the antisense compound per kilogram of the subject's body weight per week
30 (mg/kg/wk) by simply dividing the total weekly dose by the subject's body weight, such as the subject's ideal body weight. For example, dividing the aforementioned total weekly dose in the first phase by an average adult body weight of 70 kg, in certain embodiments

the total weekly dose can be represented as an amount of about 15 mg/70 kg (0.2 mg/kg/wk) to 750 mg/70 kg (10.7 mg/kg/wk). In certain embodiments, the total weekly dose in the first phase can be represented as any of about 15 mg/70 kg (0.2 mg/kg/wk), about 20 mg/70 kg (0.3 mg/kg/wk), about 30 mg/70 kg (0.4 mg/kg/wk), about 40 mg/70 kg (0.6 mg/kg/wk), about 50 mg/70 kg (0.7 mg/kg/wk), about 75 mg/70 kg (1.1 mg/kg/wk), about 100 mg/70 kg (1.4 mg/kg/wk), about 125 mg/70 kg (1.8 mg/kg/wk), about 150 mg/70 kg (2.1 mg/kg/wk), about 175 mg/70 kg (2.5 mg/kg/wk), about 200 mg/70 kg (2.9 mg/kg/wk), about 225 mg/70 kg (3.2 mg/kg/wk), about 250 mg/70 kg (3.6 mg/kg/wk), about 275 mg/70 kg (3.9 mg/kg/wk), about 300 mg/70 kg (4.3 mg/kg/wk), about 325 mg/70 kg (4.6 mg/kg/wk), about 350 mg/70 kg (5.0 mg/kg/wk), about 375 mg/70 kg (5.4 mg/kg/wk), about 400 mg/70 kg (5.7 mg/kg/wk), about 425 mg/70 kg (6.1 mg/kg/wk), about 450 mg/70 kg (6.4 mg/kg/wk), about 475 mg/70 kg (6.8 mg/kg/wk), about 500 mg/70 kg (7.1 mg/kg/wk), about 525 mg/70 kg (7.5 mg/kg/wk), about 550 mg/70 kg (7.9 mg/kg/wk), about 575 mg/70 kg (8.2 mg/kg/wk), about 600 mg/70 kg (8.6 mg/kg/wk), about 625 mg/70 kg (8.9 mg/kg/wk), about 650 mg/70 kg (9.3 mg/kg/wk), about 675 mg/70 kg (9.6 mg/kg/wk), about 700 mg/70 kg (10.0 mg/kg/wk), about 725 mg/70 kg (10.4 mg/kg/wk), or about 750 mg/70 kg (10.7 mg/kg/wk). In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, the second phase comprises administering the compound in 2, 3, 4, 5, 6, or 7 equal doses within a week. In several embodiments, the total weekly dose of the antisense compound in the second phase is an amount of any of about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, or about 250 mg. In certain embodiments, the total weekly dose in the second phase is administered as a single dose per week. It will be understood that the aforementioned total weekly dose ranges in the second phase can be readily represented as milligrams of the antisense compound per kilogram of the subject's body weight per week (mg/kg/wk) by simply dividing the total weekly dose by the subject's body weight, such as the subject's ideal body weight. For example, dividing the aforementioned total weekly dose by an average adult body weight

of 70 kg, in certain embodiments the total weekly dose in the second phase can be represented as an amount of about 15 mg/70 kg (0.2 mg/kg/wk) to 250 mg/70 kg (3.6 mg/kg/wk). In certain embodiments, the total weekly dose can be represented as any of about 15 mg/70 kg (0.2 mg/kg/wk), about 20 mg/70 kg (0.3 mg/kg/wk), about 30 mg/70 kg (0.4 mg/kg/wk), about 40 mg/70 kg (0.6 mg/kg/wk), about 50 mg/70 kg (0.7 mg/kg/wk), about 75 mg/70 kg (1.1 mg/kg/wk), about 100 mg/70 kg (1.4 mg/kg/wk), about 125 mg/70 kg (1.8 mg/kg/wk), about 150 mg/70 kg (2.1 mg/kg/wk), about 175 mg/70 kg (2.5 mg/kg/wk), about 200 mg/70 kg (2.9 mg/kg/wk), about 225 mg/70 kg (3.2 mg/kg/wk), or about 250 mg/70 kg (3.6 mg/kg/wk). In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, a method comprises administering to a subject having cancer, such as B-cell lymphoma or HCC, a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3, wherein administering the antisense compound comprises:

a first phase for about 6, 7, 8, 9, or 10 weeks, and

a second phase comprising a dose of about 2 mg/kg/wk for at least 1 week after the loading phase. In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, a method comprises administering to a subject having cancer, such as B-cell lymphoma or HCC, a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3, wherein administering the antisense compound comprises:

a first phase comprising a dose in the range of about 3 to 4 mg/kg/wk for about 6, 7, 8, 9, or 10 weeks, and

a second phase comprising a dose of about 2 mg/kg/wk for at least 1 week after the loading phase. In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-

1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, a method comprises administering to a subject having cancer, such as B-cell lymphoma or HCC, a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3, wherein
5 administering the antisense compound comprises:

a first phase comprising a dose of about 3 mg/kg/wk for about 8 weeks, and

a second phase comprising a dose of about 2 mg/kg/wk for at least 1 week after the loading phase. In certain embodiments, body weight is calculated as the ideal body weight
10 using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In any of the above embodiments, the B-cell lymphoma is a non-Hodgkin's B-cell lymphoma. Examples of non-Hodgkin's B-cell lymphoma of certain aspects include, but
15 are not limited to, diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mucosa-associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma (MCL), Burkitt lymphoma, mediastinal large B cell lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large
20 B-cell lymphoma, primary effusion lymphoma, and lymphomatoid granulomatosis. In certain embodiments, the non-Hodgkin's B-cell lymphoma is diffuse large B cell lymphoma (DLBCL).

In any of the above embodiments, the B-cell lymphoma is Hodgkin's B-cell lymphoma.

25 In any of the foregoing embodiments, administering the dose of the antisense compound reduces tumor size or tumor volume in the subject. In certain embodiments, administering the dose of the antisense compound prolongs survival of the subject. In certain embodiments, administering the dose of the antisense compound treats cancer, such as B-cell lymphoma, in the subject. In any of the above embodiments, the method is
30 effective to treat cancer and acceptably tolerable in a subject.

In certain of the foregoing embodiments, the subject is identified as having cancer, such as B-cell lymphoma, prior to administering the antisense compound to the subject. In

certain embodiments, the subject identified as having cancer, such as B-cell lymphoma, received or is currently receiving anti-cancer treatment, such as a first-line treatment regimen. For example, in certain embodiments the first-line treatment regimen is a combination of cyclophosphamide, hydroxydanuorubicin, oncovin (vincristine),
5 prednisone or prednisolone (CHOP). In certain embodiments, the first-line treatment regimen is a combination of rituximab and CHOP (R-CHOP). In certain embodiments, the subject is refractory to a first-line treatment regimen such as CHOP and/or R-CHOP.

In any of the foregoing embodiments, the antisense compound comprises a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase
10 sequence comprising a portion of at least 12 contiguous nucleobases complementary to an equal length portion of nucleobases 3008 to 3033 of SEQ ID NO: 1, wherein the nucleobase sequence is complementary to SEQ ID NO: 1.

In any of the foregoing embodiment, the antisense compound comprises a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence
15 comprising a portion of at least 12 contiguous nucleobases complementary to an equal length portion of nucleobases 3016 to 3031 of SEQ ID NO: 1, wherein the nucleobase sequence is complementary to SEQ ID NO: 1.

In any of the foregoing embodiments, the antisense compound comprises a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase
20 sequence comprising a portion of at least 12 contiguous nucleobases complementary to an equal length portion of nucleobases 6476 to 6491 of SEQ ID NO: 2, wherein the nucleobase sequence is complementary to SEQ ID NO: 2.

In any of the foregoing embodiments, the antisense compound comprises a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase
25 sequence comprising a portion of at least 12 contiguous nucleobases complementary to an equal length portion of nucleobases 250-286; 250-285; 264-285; 264-282; 728-745; 729-745; 729-744; 787-803; 867-883; 955-978; 1146-1170; 1896-1920; 1899-1920; 1899-1919; 1899-1918; 1899-1916; 1901-1916; 1946-1963; 1947-1963; 2155-2205; 2155-2187; 2156-2179; 2204-2221; 2681-2696; 2699-2716; 3001-3033; 3008-3033, 3010-3033, 3010-
30 3032, 3015-3033, 3015-3032, 3015-3031, 3016-3033, 3016-3032, 3016-3033; 3452-3499; 3460-3476; 3583-3608; 3591-3616; 3595-3615; 3595-3614; 3595-3612; 3675-3706; 3713-3790; 3715-3735; 3833-3878; 3889-3932; 3977-4012; 4067-4100; 4225-4256; 4234-4252;

4235-4252; 4235-4251; 4236-4252; 4306-4341; 4431-4456; 4439-4454; 4471-4510; 4488-4505; 4530-4558; 4539-4572; 4541-4558; 4636-4801; 4782-4796; 4800-4823; 4811-4847; 4813-4859; 4813-4815; 4813-4831; 4827-4859; 4827-4844; or 4842-4859 of SEQ ID NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is complementary to
5 SEQ ID NO: 1.

In any of the foregoing embodiments, the antisense compound comprises a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 12 contiguous nucleobases complementary to an equal length portion of nucleobases 2668-2688; 2703-2720; 5000-5021; 5001-5017; 5697-
10 5722; 5699-5716; 6475 - 6490; 6475 - 6491; 6476 - 6491; 7682-7705; 8078-8097; 8079-8095; 9862-9811; 9870-9897; 9875-9893; 9875-9891; 9877-9893; 11699-11719; 12342-12366; 12345-12364; 12346-12364; 12347-12364; 12353-12380; 12357-12376; 12358-12376; 12358-12373; 12360-12376; 14128-14148; 16863-16883; 46091-46111; 50692-50709; 50693-50709; 50693-50708; 61325-61349; 66133-66157; 66136-66157; 66136 -
15 66155; 66136-66153; 66138-66153; 66184-66200; 67067-67083; 4171-74220; 74199-74220; 74202-74220; 74171-74219; 74199-74219; 74202-74219; 74171-74218; 74199-74218; 74202-74218; 74723-74768; 74764-74803; 74782-74802; 74782-74801; 74782-74800; 74782-74799; 74783-74802; 74783-74801; 74783-74800; 74783-74799; 74862-74893; 74900-74977; 74902-74922; 74902-74920; 75070-75119; 75164-75199; 75254-
20 75287; 75412-75443; 75421-75439; 75422-75439; 75422-75438; 75423-75439; 75423-75438; 75493-75528; 75616-75643; 75626-75641; 75658-75699; 75676-75692; 75717-75745; 75726-75759; 75726-75745; 75727-75745; 75728-75745; 75831-75988; 75852-75969; 75969-75984; 75987-76056; 76000-76046; 76000-76032; 76000-76018; 76014-76046; 76014-76032; 76029-76046; or 76031-76046 of SEQ ID NO: 2, wherein the
25 nucleobase sequence of the modified oligonucleotide is complementary to SEQ ID NO: 2.

In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises the sequence of SEQ ID NO: 12 or consists of the sequence of SEQ ID NO: 12. In certain embodiments, the modified oligonucleotide is 100% complementary to SEQ ID NO: 1 or 2.

30 In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises the sequence of any of the STAT3 antisense oligonucleotides described in WO 2012/135736, which is incorporated by reference in its entirety herein.

In certain embodiments, the modified oligonucleotide is a single-stranded modified oligonucleotide. In certain embodiments, the modified oligonucleotide comprises at least one modified internucleoside linkage. In several embodiments, each internucleoside linkage is a phosphorothioate internucleoside linkage. In certain
5 embodiments, at least one nucleoside comprises a modified sugar, such as a bicyclic sugar including, but not limited to, a 4'-CH₂-O-2' bridge or a 4'-CH(CH₃)-O-2' bridge. In certain embodiments, the modified sugar comprises a 2'-O(CH₂)₂-OCH₃ group. In certain embodiments, at least one nucleoside comprises a modified nucleobase, such as a 5-methylcytosine.

10 In certain embodiments, the modified oligonucleotide comprises:

a 5'-wing consisting of 1 to 5 linked nucleosides;

a 3'-wing consisting of 1 to 5 linked nucleosides; and

a gap between the 5'-wing and the 3'-wing consisting of 8 to 12 linked 2'-deoxynucleosides;

15 wherein at least one of the 5'-wing and the 3'-wing comprises at least one bicyclic nucleoside or one 2'-substituted nucleoside. In certain embodiments, the 2'-substituted nucleoside comprises a 2'-O(CH₂)₂-OCH₃ group or a 2'-O-CH₃ group. In certain embodiments, the bicyclic nucleoside comprises a 4'-CH₂-O-2' bridge or a 4'-CH(CH₃)-O-2' bridge.

20 In certain embodiments, pharmaceutical compositions described herein are administered in the form of a dosage unit (e.g., injection, infusion, etc.). In certain embodiments, such pharmaceutical compositions comprise an antisense oligonucleotide in an amount of any of about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg,
25 about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, or about 750 mg. It will be understood that the aforementioned amounts of antisense oligonucleotide can be readily represented as
30 milligrams of the antisense compound per kilogram of the subject's body weight per week (mg/kg/wk) by simply dividing the amount by the subject's body weight per week. For example, dividing the aforementioned amounts by an average adult body weight of 70 kg,

in certain embodiments the dosage unit can be represented as any of about 15 mg/70 kg (0.2 mg/kg/wk), about 20 mg/70 kg (0.3 mg/kg/wk), about 30 mg/70 kg (0.4 mg/kg/wk), about 40 mg/70 kg (0.6 mg/kg/wk), about 50 mg/70 kg (0.7 mg/kg/wk), about 75 mg/70 kg (1.1 mg/kg/wk), about 100 mg/70 kg (1.4 mg/kg/wk), about 125 mg/70 kg (1.8 mg/kg/wk),
5 about 150 mg/70 kg (2.1 mg/kg/wk), about 175 mg/70 kg (2.5 mg/kg/wk), about 200 mg/70 kg (2.9 mg/kg/wk), about 225 mg/70 kg (3.2 mg/kg/wk), about 250 mg/70 kg (3.6 mg/kg/wk), about 275 mg/70 kg (3.9 mg/kg/wk), about 300 mg/70 kg (4.3 mg/kg/wk), about 325 mg/70 kg (4.6 mg/kg/wk), about 350 mg/70 kg (5.0 mg/kg/wk), about 375 mg/70 kg (5.4 mg/kg/wk), about 400 mg/70 kg (5.7 mg/kg/wk), about 425 mg/70 kg (6.1 mg/kg/wk), about 450 mg/70 kg (6.4 mg/kg/wk), about 475 mg/70 kg (6.8 mg/kg/wk),
10 about 500 mg/70 kg (7.1 mg/kg/wk), about 525 mg/70 kg (7.5 mg/kg/wk), about 550 mg/70 kg (7.9 mg/kg/wk), about 575 mg/70 kg (8.2 mg/kg/wk), about 600 mg/70 kg (8.6 mg/kg/wk), about 625 mg/70 kg (8.9 mg/kg/wk), about 650 mg/70 kg (9.3 mg/kg/wk), about 675 mg/70 kg (9.6 mg/kg/wk), about 700 mg/70 kg (10.0 mg/kg/wk), about 725 mg/70 kg (10.4 mg/kg/wk), or about 750 mg/70 kg (10.7 mg/kg/wk). In certain
15 embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = 50 + 2.3 kg/inch over 5 feet; for women (in kg) = 45.5 + 2.3 kg/inch over 5 feet.

In certain embodiments, the antisense oligonucleotide has the nucleobase sequence
20 of SEQ ID NO: 12. In certain embodiments, the antisense oligonucleotide is ISIS 481464.

In certain embodiments, pharmaceutical compositions described herein comprise a dose of antisense oligonucleotide in an amount in the range of about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about
25 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, or about 750 mg. It will be understood that the aforementioned amounts of antisense oligonucleotide can be readily represented as milligrams of the antisense compound per
30 kilogram of the subject's body weight per week (mg/kg/wk) by simply dividing the amount by the subject's body weight per week. For example, dividing the aforementioned amounts by an average adult body weight of 70 kg, in certain embodiments the dose of antisense oligonucleotide can be represented as any of about 15 mg/70 kg (0.2 mg/kg/wk),

about 20 mg/70 kg (0.3 mg/kg/wk), about 30 mg/70 kg (0.4 mg/kg/wk), about 40 mg/70 kg (0.6 mg/kg/wk), about 50 mg/70 kg (0.7 mg/kg/wk), about 75 mg/70 kg (1.1 mg/kg/wk), about 100 mg/70 kg (1.4 mg/kg/wk), about 125 mg/70 kg (1.8 mg/kg/wk), about 150 mg/70 kg (2.1 mg/kg/wk), about 175 mg/70 kg (2.5 mg/kg/wk), about 200 mg/70 kg (2.9 mg/kg/wk), about 225 mg/70 kg (3.2 mg/kg/wk), about 250 mg/70 kg (3.6 mg/kg/wk), about 275 mg/70 kg (3.9 mg/kg/wk), about 300 mg/70 kg (4.3 mg/kg/wk), about 325 mg/70 kg (4.6 mg/kg/wk), about 350 mg/70 kg (5.0 mg/kg/wk), about 375 mg/70 kg (5.4 mg/kg/wk), about 400 mg/70 kg (5.7 mg/kg/wk), about 425 mg/70 kg (6.1 mg/kg/wk), about 450 mg/70 kg (6.4 mg/kg/wk), about 475 mg/70 kg (6.8 mg/kg/wk), about 500 mg/70 kg (7.1 mg/kg/wk), about 525 mg/70 kg (7.5 mg/kg/wk), about 550 mg/70 kg (7.9 mg/kg/wk), about 575 mg/70 kg (8.2 mg/kg/wk), about 600 mg/70 kg (8.6 mg/kg/wk), about 625 mg/70 kg (8.9 mg/kg/wk), about 650 mg/70 kg (9.3 mg/kg/wk), about 675 mg/70 kg (9.6 mg/kg/wk), about 700 mg/70 kg (10.0 mg/kg/wk), about 725 mg/70 kg (10.4 mg/kg/wk), or about 750 mg/70 kg (10.7 mg/kg/wk). In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch}$ over 5 feet; for women (in kg) = $45.5 + 2.3 \text{ kg/inch}$ over 5 feet.

The compositions described herein may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions described herein. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, and/or aromatic substances and the like which do not deleteriously interact with the oligonucleotide(s) of the formulation.

Antisense oligonucleotides may be covalently linked to one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the antisense oligonucleotides. Typical conjugate groups include cholesterol moieties and lipid moieties. Additional conjugate groups include carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.

CANCER TREATMENT

INTELLECTUAL PROPERTY OFFICE
RECEIVED
2018 JUL -6 PM 12:17

5

Field

In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma by inhibiting expression of STAT3 mRNA or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate B-cell lymphoma or hepatocellular carcinoma.

Background

The STAT (signal transducers and activators of transcription) family of proteins are DNA-binding proteins that play a dual role in signal transduction and activation of transcription. Presently, there are six distinct members of the STAT family (STAT1, STAT2, STAT3, STAT4, STAT5, and STAT6) and several isoforms (STAT1 α , STAT1 β , STAT3 α and STAT3 β). The activities of the STATs are modulated by various cytokines and mitogenic stimuli. Binding of a cytokine to its receptor results in the activation of Janus protein tyrosine kinases (JAKs) associated with these receptors. This phosphorylates STAT, resulting in translocation to the nucleus and transcriptional activation of STAT responsive genes. Phosphorylation on a specific tyrosine residue on the STATs results in their activation, resulting in the formation of homodimers and/or heterodimers of STAT which bind to specific gene promoter sequences. Events mediated by cytokines through STAT activation include cell proliferation and differentiation and prevention of apoptosis.

The specificity of STAT activation is due to specific cytokines, i.e., each STAT is responsive to a small number of specific cytokines. Other non-cytokine signaling molecules, such as growth factors, have also been found to activate STATs. Binding of these factors to a cell surface receptor associated with protein tyrosine kinase also results in phosphorylation of STAT.

STAT3 (also acute phase response factor (APRF)), in particular, has been found to be responsive to interleukin-6 (IL-6) as well as epidermal growth factor (EGF) (Darnell,

Antisense oligonucleotides can also be modified to have one or more stabilizing groups that are generally attached to one or both termini of antisense compounds to enhance properties such as, for example, nuclease stability. Included in stabilizing groups are cap structures. These terminal modifications protect the antisense oligonucleotide
5 having terminal nucleic acid from exonuclease degradation, and can help in delivery and/or localization within a cell. The cap can be present at the 5'-terminus (5'-cap), or at the 3'-terminus (3'-cap), or can be present on both termini. Cap structures are well known in the art and include, for example, inverted deoxy abasic caps. Further 3' and 5'-stabilizing groups that can be used to cap one or both ends of an antisense compound to impart
10 nuclease stability include those disclosed in WO 03/004602 published on January 16, 2003.

Certain treatments

In certain aspects there is provided a method of treating a subject suffering from cancer comprising administering to the subject an antisense compound complementary to
15 human STAT3. In certain embodiments the antisense compound complementary to human STAT3 is as described herein or as disclosed in WO2012/135736.

In certain embodiments the cancer is selected from B-cell lymphoma or hepatocellularcarcinoma. In certain aspects there is provided an antisense compound complementary to human STAT3 for use in treating cancer. In certain embodiments the
20 antisense compound complementary to human STAT3 is as described herein or as disclosed in WO2012/135736. In certain embodiments the cancer is selected from B-cell lymphoma or hepatocellularcarcinoma.

In certain aspects there is provided an antisense compound complementary to human STAT3 for use in a method of treating cancer in a subject in need thereof, wherein
25 the method comprises administering to the subject the antisense compound in a loading phase and then a maintenance phase, wherein the loading phase involves administering a total weekly dose of the compound in the range of about 15-750 mg for the first 1-10 weeks, and the maintenance phase involves administering a total weekly dose in the range of 15-250 mg for at least 1 week after the loading phase. In certain embodiments the
30 antisense compound complementary to human STAT3 is as described herein or as disclosed in WO2012/135736. In certain embodiments the cancer is selected from B-cell lymphoma or hepatocellularcarcinoma.

Certain aspects are directed to use of an antisense compound complementary to human STAT3 for the manufacture of a medicament for treating cancer. In certain embodiments the antisense compound complementary to human STAT3 is as described herein or as disclosed in WO2012/135736. In certain embodiments the cancer is selected from B-cell lymphoma or hepatocellular carcinoma.

In particular embodiments of any of these aspects, the B-cell lymphoma is a non-Hodgkin's B-cell lymphoma. Examples of non-Hodgkin's B-cell lymphoma of certain aspects include, but are not limited to, diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mucosa-associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma (MCL), Burkitt lymphoma, mediastinal large B cell lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large B-cell lymphoma, primary effusion lymphoma, and lymphomatoid granulomatosis. In certain embodiments, the non-Hodgkin's B-cell lymphoma is diffuse large B cell lymphoma (DLBCL).

Certain Dosing Regimens

In certain embodiments, pharmaceutical compositions are administered according to a dosing regimen. In certain such embodiments, the dosing regimen comprises a loading phase and a maintenance phase. In certain such embodiments, the dosing regimen is effective to treat cancer and acceptably tolerable in a subject. In certain embodiments, the pharmaceutical composition comprises an antisense oligonucleotide. In certain embodiments, the antisense oligonucleotide has the nucleobase sequence of SEQ ID NO: 12. In certain embodiments, the antisense oligonucleotide is ISIS 481464.

In certain embodiments, the loading phase includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or more than 20 doses.

In certain embodiments, the loading phase lasts from 1 day to 6 months. In certain embodiments a loading phase lasts 1 day, 2 days, 3, days, 4, days, 5 days, 6 days, or 7 days as measured from administration of the first dose of the loading phase to administration of the first dose of the maintenance phase. In certain embodiments a loading phase lasts 1 week, 2 weeks, 3, weeks, 4, weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, or 26

weeks as measured from administration of the first dose of the loading phase to administration of the first dose of the maintenance phase. In certain embodiments, the loading phase lasts 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months as measured from administration of the first dose of the loading phase to administration of the first dose of the maintenance phase.

In certain embodiments, the dose administered during the loading phase is lower than the dose administered during the maintenance phase. In certain embodiments, the dose administered during the loading phase is lower than the dose administered during the maintenance phase to avoid undesired side effects. In certain embodiments, the undesired side effect is increased liver markers. In certain embodiments, the undesired side effect is increased ALT. In certain embodiments, the undesired side effect is increased AST. In certain embodiments, the undesired side effect is thrombocytopenia or neutropenia.

In certain embodiments, the dose administered during the loading phase is higher than the dose administered during the maintenance phase. In certain embodiments, the dose administered during the loading phase is higher than the dose administered during the maintenance phase to quickly achieve steady state reduction of STAT3 mRNA expression, STAT3 protein expression, and/or STAT3 activity. In certain embodiments, the dose administered during the loading phase is higher than the dose administered during the maintenance phase to avoid undesired side effects in the maintenance phase. In certain embodiments, the undesired side effect is increased liver markers. In certain embodiments, the undesired side effect is increased ALT. In certain embodiments, the undesired side effect is increased AST. In certain embodiments, the undesired side effect is thrombocytopenia or neutropenia.

In certain embodiments where the loading phase includes more than one dose, the doses administered during the loading phase are all the same amount as one another. In certain embodiments, the doses administered during the loading phase are not all the same amount. In certain embodiments, the doses given during the loading phase increase over time. In certain embodiments, the doses given during the loading phase decrease over time.

In certain embodiments, a loading dose is administered by parenteral administration. In certain embodiments, the parenteral administration is subcutaneous administration. In certain embodiments, the parenteral administration is intravenous

infusion.

In certain embodiments, the doses administered during the loading phase are about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.1 mg, about 3.2 mg, about 3.3 mg, about 3.4 mg, or about 3.5 mg of the antisense compound per kilogram of the subject's body weight. In certain embodiments, the dose is 2.0 milligrams of the antisense compound per kilogram of the subject's body weight per week (2.0 mg/kg/wk). In certain embodiments, the subject's body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, the doses administered during the loading phase are about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, or about 750 mg. It will be understood that the aforementioned doses of antisense oligonucleotide can be readily represented as milligrams of the antisense compound per kilogram of the subject's body weight per week (mg/kg/wk) by simply dividing the amount by the subject's body weight per week. For example, dividing the aforementioned amounts by an average adult body weight of 70 kg, in certain embodiments the doses can be represented as any of about 15 mg/70 kg (0.2 mg/kg/wk), about 20 mg/70 kg (0.3 mg/kg/wk), about 30 mg/70 kg (0.4 mg/kg/wk), about 40 mg/70 kg (0.6 mg/kg/wk), about 50 mg/70 kg (0.7 mg/kg/wk), about 75 mg/70 kg (1.1 mg/kg/wk), about 100 mg/70 kg (1.4 mg/kg/wk), about 125 mg/70 kg (1.8 mg/kg/wk), about 150 mg/70 kg (2.1 mg/kg/wk), about 175 mg/70 kg (2.5 mg/kg/wk), about 200 mg/70 kg (2.9 mg/kg/wk), about 225 mg/70 kg (3.2 mg/kg/wk), about 250 mg/70 kg (3.6 mg/kg/wk), about 275 mg/70 kg (3.9 mg/kg/wk), about 300 mg/70 kg (4.3 mg/kg/wk), about 325 mg/70 kg (4.6 mg/kg/wk), about 350 mg/70 kg (5.0 mg/kg/wk), about 375 mg/70 kg (5.4

mg/kg/wk), about 400 mg/70 kg (5.7 mg/kg/wk), about 425 mg/70 kg (6.1 mg/kg/wk), about 450 mg/70 kg (6.4 mg/kg/wk), about 475 mg/70 kg (6.8 mg/kg/wk), about 500 mg/70 kg (7.1 mg/kg/wk), about 525 mg/70 kg (7.5 mg/kg/wk), about 550 mg/70 kg (7.9 mg/kg/wk), about 575 mg/70 kg (8.2 mg/kg/wk), about 600 mg/70 kg (8.6 mg/kg/wk),
5 about 625 mg/70 kg (8.9 mg/kg/wk), about 650 mg/70 kg (9.3 mg/kg/wk), about 675 mg/70 kg (9.6 mg/kg/wk), about 700 mg/70 kg (10.0 mg/kg/wk), about 725 mg/70 kg (10.4 mg/kg/wk), or about 750 mg/70 kg (10.7 mg/kg/wk). In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch}$
10 over 5 feet; for women (in kg) = $45.5 + 2.3 \text{ kg/inch}$ over 5 feet.

In certain embodiments, dose, dose frequency, and duration of the loading phase may be selected to achieve a desired effect. In certain embodiments, those variables are adjusted to result in a desired concentration of pharmaceutical agent in a subject. For example, in certain embodiments, dose and dose frequency are adjusted to provide plasma
15 concentration of a pharmaceutical agent at an amount sufficient to achieve a desired effect. In certain embodiments, the plasma concentration is maintained above the minimal effective concentration (MEC). In certain embodiments, pharmaceutical compositions described herein are administered with a dosage regimen designed to maintain a concentration above the MEC for 10-90% of the time, between 30-90% of the time, or
20 between 50-90% of the time. In certain embodiments, the pharmaceutical composition comprises an antisense oligonucleotide. In certain embodiments, the antisense oligonucleotide has the nucleobase sequence of SEQ ID NO: 12. In certain embodiments, the antisense oligonucleotide is ISIS 481464.

In certain embodiments, doses, dose frequency, and duration of the loading phase
25 may be selected to achieve a desired plasma trough concentration of a pharmaceutical composition. In certain embodiments, the pharmaceutical composition comprises an antisense oligonucleotide. In certain embodiments, the antisense oligonucleotide has the nucleobase sequence of SEQ ID NO: 12. In certain embodiments, the antisense oligonucleotide is ISIS 481464. In certain embodiments, the desired plasma trough concentration is from 5-100 ng/mL. In certain embodiments, the desired plasma trough
30 concentration is from 5-50 ng/mL. In certain embodiments, the desired plasma trough concentration is from 10-40 ng/mL. In certain embodiments, the desired plasma trough concentration is from 15-35 ng/mL. In certain embodiments, the desired plasma trough

concentration is from 20-30 ng/mL.

In certain embodiments, dose, dose frequency, and duration of the loading phase may be selected to achieve a desired effect within 1 to 26 weeks. In certain embodiments, the dose is the same and the dose frequency is varied to achieve the desired effect within 1
5 to 26 weeks. In certain embodiments, the dose increases over time and the dose frequency remains constant. In certain embodiments, one or more doses of the loading phase are greater than one or more doses of the maintenance phase. In certain embodiments, each of the loading doses is greater than each of the maintenance doses. In certain embodiments, it is desirable to achieve a desired effect as quickly as possible. In certain embodiments, a
10 loading phase with a high dose and/or high dose frequency may be desirable.

In certain embodiments, doses, dose frequency, and duration of the loading phase may be selected to achieve an acceptable safety profile. For example, in certain embodiments, such variables may be selected to mitigate toxicity of the pharmaceutical composition. In certain embodiments, such variables are selected to mitigate liver toxicity.
15 In certain embodiments, such variables are selected to mitigate renal toxicity. In certain embodiments, such variables are selected to mitigate thrombocytopenia or neutropenia.

In certain embodiments, doses increase over time. In certain embodiments, one or more doses of the loading phase are lower than one or more doses of the maintenance phase. In certain embodiments, a safety profile is not acceptable when ALT is 5-10 times
20 the upper limit of normal. In certain embodiments, a safety profile is not acceptable when ALT is 5-10 times the upper limit of normal, and bilirubin is elevated two or more times the upper limit of normal. In certain embodiments, an acceptable safety profile comprises ALT elevations that are above three times the upper limit of normal, but do not exceed five times the upper limit of normal. In certain embodiments, an acceptable safety profile
25 comprises ALT elevations that are above three times the upper limit of normal, but do not exceed five times the upper limit of normal, and bilirubin elevations that do not exceed two times the upper limit of normal. In certain embodiments, when administration of a pharmaceutical composition of the invention results in ALT elevations that are above three times the upper limit of normal, the dose and/or dose frequency is adjusted to mitigate the
30 ALT elevation.

In certain embodiments, the maintenance phase includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more than 20 doses.

In certain embodiments, the maintenance phase lasts from one day to the lifetime of the subject. In certain embodiments, the maintenance phase lasts 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days as measured from administration of the last dose of the loading phase to administration of the last dose of the maintenance phase. In certain
5 embodiments, the maintenance phase lasts 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39
10 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks, 51 weeks, or 52 weeks as measured from administration of the last dose of the loading phase to administration of the last dose of the maintenance phase. In certain embodiments, the maintenance phase lasts 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10
15 months, 11 months, or 12 months as measured from administration of the last dose of the loading phase to administration of the last dose of the maintenance phase. In certain embodiments, the maintenance phase lasts 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 21 years, 22 years, 23 years, 24 years, 25
20 years, 26 years, 27 years, 28 years, 29 years, 30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36 years, 37 years, 38 years, 39 years, 40 years, 41 years, 42 years, 43 years, 44 years, 45 years, 46 years, 47 years, 48 years, 49 years, or 50 years as measured from administration of the last dose of the loading phase to administration of the last dose of the maintenance phase. In certain embodiments, the maintenance phase lasts as long as
25 the dose continues to be needed, effective, and tolerated.

In certain embodiments where the maintenance phase includes more than one dose, the doses administered during the maintenance phase are all the same as one another. In certain embodiments, the doses administered during the maintenance phase are not all the same. In certain embodiments, the doses increase over time. In certain embodiments, the
30 doses decrease over time.

In certain embodiments, a maintenance dose is administered by parenteral administration. In certain embodiments, the parenteral administration is subcutaneous administration. In certain embodiments, the parenteral administration is intravenous

infusion.

In certain embodiments, the doses during the maintenance phase are about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.1 mg, about 3.2 mg, about 3.3 mg, about 3.4 mg, or about 3.5 mg of the antisense compound per kilogram of the subject's body weight. In certain embodiments, the dose is 2.0 milligrams of the antisense compound per kilogram of the subject's body weight per week (2.0 mg/kg/wk). In certain embodiments, the subject's body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, the doses during the maintenance phase are about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, or about 250 mg. It will be understood that the aforementioned doses of antisense oligonucleotide can be readily represented as milligrams of the antisense compound per kilogram of the subject's body weight per week (mg/kg/wk) by simply dividing the amount by the subject's body weight per week. For example, dividing the aforementioned amounts by an average adult body weight of 70 kg, in certain embodiments the doses can be represented as any of about 15 mg/70 kg (0.2 mg/kg/wk), about 20 mg/70 kg (0.3 mg/kg/wk), about 30 mg/70 kg (0.4 mg/kg/wk), about 40 mg/70 kg (0.6 mg/kg/wk), about 50 mg/70 kg (0.7 mg/kg/wk), about 75 mg/70 kg (1.1 mg/kg/wk), about 100 mg/70 kg (1.4 mg/kg/wk), about 125 mg/70 kg (1.8 mg/kg/wk), about 150 mg/70 kg (2.1 mg/kg/wk), about 175 mg/70 kg (2.5 mg/kg/wk), about 200 mg/70 kg (2.9 mg/kg/wk), about 225 mg/70 kg (3.2 mg/kg/wk), or about 250 mg/70 kg (3.6 mg/kg/wk). In certain embodiments, body weight is calculated as the ideal body weight using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch over } 5 \text{ feet}$; for women (in kg) = $45.5 + 2.3 \text{ kg/inch over } 5 \text{ feet}$.

In certain embodiments, doses, dose frequency, and duration of the maintenance phase may be selected to achieve a desired effect. In certain embodiments, those variables are adjusted to result in a desired concentration of pharmaceutical agent in a subject. For example, in certain embodiments, dose and dose frequency are adjusted to provide plasma concentration of a pharmaceutical agent described herein at an amount sufficient to achieve a desired effect. In certain embodiments, the plasma concentration is maintained above the minimal effective concentration (MEC). In certain embodiments, pharmaceutical compositions described herein are administered with a dosage regimen designed to maintain a concentration above the MEC for 10-90% of the time, between 30-90% of the time, or between 50-90% of the time.

In certain embodiments, doses, dose frequency, and duration of the maintenance phase may be selected to achieve a desired plasma trough concentration of a pharmaceutical composition. In certain embodiments, the pharmaceutical composition is an antisense oligonucleotide. In certain embodiments, the desired plasma trough concentration is from 5-100 ng/mL. In certain embodiments, the desired plasma trough concentration is from 5-50 ng/mL. In certain embodiments, the desired plasma trough concentration is from 10-40 ng/mL. In certain embodiments, the desired plasma trough concentration is from 15-35 ng/mL. In certain embodiments, the desired plasma trough concentration is from 20-30 ng/mL.

In certain embodiments, doses, dose frequency, and duration of the maintenance phase may be selected to achieve a desired safety profile. For example, in certain embodiments, such variables may be selected to mitigate toxicity of the pharmaceutical composition. In certain embodiments, such variables are selected to mitigate liver toxicity. In certain embodiments, such variables are selected to mitigate renal toxicity. In certain embodiments, such variables are selected to mitigate thrombocytopenia or neutropenia.

In certain embodiments, doses, dose frequency, and duration of the maintenance phase may be adjusted from time to time to achieve a desired effect. In certain embodiments, subjects are monitored for effects (therapeutic and/or toxic effects) and doses, dose frequency, and/or duration of the maintenance phase may be adjusted based on the results of such monitoring.

In certain embodiments, pharmaceutical compositions are administered according to a dosing regimen comprising a first phase and a second phase. In certain embodiments,

the pharmaceutical composition comprises an antisense oligonucleotide. In certain embodiments, the antisense oligonucleotide has the nucleobase sequence of SEQ ID NO: 12. In certain embodiments, the antisense oligonucleotide is ISIS 481464.

5 In certain embodiments, the first phase includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or more than 20 doses.

In certain embodiments, the first phase lasts from 1 day to 6 months. In certain embodiments a first phase lasts 1 day, 2 days, 3, days, 4, days, 5 days, 6 days, or 7 days as measured from administration of the first dose of the first phase to administration of the first dose of the second phase. In certain embodiments a first phase lasts 1 week, 2 weeks, 10 3, weeks, 4, weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, or 26 weeks as measured from administration of the first dose of the first phase to administration of the first dose of the second phase. In certain embodiments, the first phase lasts 1 month, 2 months, 3 months, 4 15 months, 5 months, or 6 months as measured from administration of the first dose of the first phase to administration of the first dose of the second phase.

In certain embodiments, the dose administered during the first phase is lower than the dose administered during the second phase. In certain embodiments, the dose administered during the first phase is lower than the dose administered during the second 20 phase to avoid undesired side effects. In certain embodiments, the undesired side effect is increased liver markers. In certain embodiments, the undesired side effect is increased ALT. In certain embodiments, the undesired side effect is increased AST. In certain embodiments, the undesired side effect is thrombocytopenia or neutropenia.

In certain embodiments, the dose administered during the first phase is higher than 25 the dose administered during the second phase. In certain embodiments, the dose administered during the first phase is higher than the dose administered during the second phase to quickly achieve steady state reduction of STAT3 mRNA expression, STAT3 protein expression, and/or STAT3 activity. In certain embodiments, the dose administered during the first phase is higher than the dose administered during the second phase to avoid 30 undesired side effects in the second phase. In certain embodiments, the undesired side effect is increased liver markers. In certain embodiments, the undesired side effect is increased ALT. In certain embodiments, the undesired side effect is increased AST. In

Jr., J.E., et al., Science, 1994, 264, 1415-1421). In addition, STAT3 has been found to have an important role in signal transduction by interferons (Yang, C.-H., et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 5568-5572). Evidence exists suggesting that STAT3 may be regulated by the MAPK pathway. ERK2 induces serine phosphorylation and also
5 associates with STAT3 (Jain, N., et al., Oncogene, 1998, 17, 3157-3167).

STAT3 is expressed in most cell types (Zhong, Z., et al., Proc. Natl. Acad. Sci. USA, 1994, 91, 4806-4810). It induces the expression of genes involved in response to tissue injury and inflammation. STAT3 has also been shown to prevent apoptosis through the expression of bcl-2 (Fukada, T., et al., Immunity, 1996, 5, 449-460).

10 Recently, STAT3 was detected in the mitochondria of transformed cells, and was shown to facilitate glycolytic and oxidative phosphorylation activities similar to that of cancer cells (Gough, D.J., et al., Science, 2009, 324, 1713-1716). The inhibition of STAT3 in the mitochondria impaired malignant transformation by activated Ras. The data confirms a Ras-mediated transformation function for STAT3 in the mitochondria in
15 addition to its nuclear roles.

Aberrant expression of or constitutive expression of STAT3 is associated with a number of disease processes.

Summary

B-cell lymphoma is a B-lymphocyte blood cell cancer that is clinically classified as
20 either Hodgkin's lymphoma or non-Hodgkin's lymphoma. There are several types of non-Hodgkin's lymphoma, of which diffuse large B-cell lymphoma (DLBCL) is the most common type, accounting for approximately 30 percent of all lymphomas. In the United States, DLBCL affects about 7 out of 100,000 people each year.

Several embodiments provided herein relate to the discovery that inhibiting the
25 JAK-STAT signaling pathway can be useful for treating B-cell lymphoma. In certain embodiments, antisense compounds targeting STAT3 are useful for treating B-cell lymphoma, such as DLBCL, at unexpectedly low doses for an antisense compound as a cancer therapeutic. In several embodiments, antisense compounds targeting STAT3 provided herein are administered to a subject having B-cell lymphoma at a fixed total
30 weekly dose in the range of about 15-750 mg. In certain embodiments, antisense compounds targeting STAT3 provided herein are administered to a subject having B-cell lymphoma in the range of about 0.2 to 3.5 milligrams of the antisense compound per

certain embodiments, the undesired side effect is thrombocytopenia or neutropenia.

5 In certain embodiments where the first phase includes more than one dose, the doses administered during the first phase are all the same amount as one another. In certain embodiments, the doses administered during the first phase are not all the same amount. In certain embodiments, the doses given during the first phase increase over time. In certain embodiments, the doses given during the first phase decrease over time.

In certain embodiments, a first dose is administered by parenteral administration. In certain embodiments, the parenteral administration is subcutaneous administration. In certain embodiments, the parenteral administration is intravenous infusion.

10 The range of dosages capable of being administered during the "first phase" and/or "second phase" are the same as can be used for the "loading phase" and "maintenance phase" referred to above. In certain embodiments, dose, dose frequency, and duration of the first phase and/or second phase may be selected to achieve a desired effect. In certain embodiments, those variables are adjusted to result in a desired concentration of
15 pharmaceutical agent in a subject. For example, in certain embodiments, dose and dose frequency are adjusted to provide plasma concentration of a pharmaceutical agent at an amount sufficient to achieve a desired effect. In certain embodiments, the plasma concentration is maintained above the minimal effective concentration (MEC). In certain embodiments, pharmaceutical compositions described herein are administered with a
20 dosage regimen designed to maintain a concentration above the MEC for 10-90% of the time, between 30-90% of the time, or between 50-90% of the time. In certain embodiments, the pharmaceutical composition comprises an antisense oligonucleotide. In certain embodiments, the antisense oligonucleotide has the nucleobase sequence of SEQ ID NO: 12. In certain embodiments, the antisense oligonucleotide is ISIS 481464. In
25 certain embodiments, doses, dose frequency, and duration of the first phase and/or second phase may be selected to achieve a desired plasma trough concentration of a pharmaceutical composition. In certain embodiments, the pharmaceutical composition comprises an antisense oligonucleotide. In certain embodiments, the antisense oligonucleotide has the nucleobase sequence of SEQ ID NO: 12. In certain embodiments,
30 the antisense oligonucleotide is ISIS 481464. In certain embodiments, the desired plasma trough concentration is from 5-100 ng/mL. In certain embodiments, the desired plasma trough concentration is from 5-50 ng/mL. In certain embodiments, the desired plasma trough concentration is from 10-40 ng/mL. In certain embodiments, the desired plasma

trough concentration is from 15-35 ng/mL. In certain embodiments, the desired plasma trough concentration is from 20-30 ng/mL.

In certain embodiments, dose, dose frequency, and duration of the first phase and/or second phase may be selected to achieve a desired effect within 1 to 26 weeks. In certain embodiments, the dose is the same and the dose frequency is varied to achieve the desired effect within 1 to 26 weeks. In certain embodiments, the dose increases over time and the dose frequency remains constant. In certain embodiments, one or more doses of the first phase are greater than one or more doses of the second phase. In certain embodiments, each of the first doses is greater than each of the second doses. In certain embodiments, it is desirable to achieve a desired effect as quickly as possible. In certain embodiments, a first phase with a high dose and/or high dose frequency may be desirable.

In certain embodiments, doses, dose frequency, and duration of the first phase and/or second phase may be selected to achieve an acceptable safety profile. For example, in certain embodiments, such variables may be selected to mitigate toxicity of the pharmaceutical composition. In certain embodiments, such variables are selected to mitigate liver toxicity. In certain embodiments, such variables are selected to mitigate renal toxicity. In certain embodiments, such variables are selected to mitigate thrombocytopenia or neutropenia.

In certain embodiments, doses increase over time. In certain embodiments, one or more doses of the first phase are lower than one or more doses of the second phase. In certain embodiments, a safety profile is not acceptable when ALT is 5-10 times the upper limit of normal. In certain embodiments, a safety profile is not acceptable when ALT is 5-10 times the upper limit of normal, and bilirubin is elevated two or more times the upper limit of normal. In certain embodiments, an acceptable safety profile comprises ALT elevations that are above three times the upper limit of normal, but do not exceed five times the upper limit of normal. In certain embodiments, an acceptable safety profile comprises ALT elevations that are above three times the upper limit of normal, but do not exceed five times the upper limit of normal, and bilirubin elevations that do not exceed two times the upper limit of normal. In certain embodiments, when administration of a pharmaceutical composition of the invention results in ALT elevations that are above three times the upper limit of normal, the dose and/or dose frequency is adjusted to mitigate the ALT elevation. In certain embodiments, the second phase includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more than 20 doses. In certain

embodiments, the second phase lasts from one day to the lifetime of the subject. In certain embodiments, the second phase lasts 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days as measured from administration of the last dose of the first phase to administration of the last dose of the second phase. In certain embodiments, the second phase lasts 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 weeks, 49 weeks, 50 weeks, 51 weeks, or 52 weeks as measured from administration of the last dose of the first phase to administration of the last dose of the second phase. In certain embodiments, the second phase lasts 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months as measured from administration of the last dose of the first phase to administration of the last dose of the second phase. In certain embodiments, the second phase lasts 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 21 years, 22 years, 23 years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years, 30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36 years, 37 years, 38 years, 39 years, 40 years, 41 years, 42 years, 43 years, 44 years, 45 years, 46 years, 47 years, 48 years, 49 years, or 50 years as measured from administration of the last dose of the first phase to administration of the last dose of the second phase. In certain embodiments, the second phase lasts as long as the dose continues to be needed, effective, and tolerated.

In certain embodiments where the second phase includes more than one dose, the doses administered during the second phase are all the same as one another. In certain embodiments, the doses administered during the second phase are not all the same. In certain embodiments, the doses increase over time. In certain embodiments, the doses decrease over time.

In certain embodiments, a second dose is administered by parenteral administration. In certain embodiments, the parenteral administration is subcutaneous administration. In certain embodiments, the parenteral administration is intravenous infusion.

Antisense compounds

Oligomeric compounds include, but are not limited to, oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide mimetics, antisense compounds, antisense oligonucleotides, and siRNAs. An oligomeric compound may be "antisense" to a target nucleic acid, meaning that it is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding.

In certain embodiments, an antisense compound has a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted. In certain such embodiments, an antisense oligonucleotide has a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted.

In certain embodiments, an antisense compound targeted to a STAT3 nucleic acid is 12 to 30 subunits in length. In certain embodiments, an antisense compound targeted to a STAT3 nucleic acid is 14 to 30 subunits in length. In certain embodiments, an antisense compound targeted to a STAT3 nucleic acid is 12 to 22 subunits in length. In other words, such antisense compounds are from 12 to 30 linked subunits, 14 to 30 linked subunits, or 12 to 22 linked subunits, respectively. In other embodiments, the antisense compound is 8 to 80, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to 30, 16 to 50, 17 to 30, 17 to 50, 18 to 22, 18 to 24, 18 to 30, 18 to 50, 19 to 22, 19 to 30, 19 to 50, or 20 to 30 linked subunits. In certain such embodiments, the antisense compounds are 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 linked subunits in length, or a range defined by any two of the above values. In some embodiments, the antisense compound is an antisense oligonucleotide, and the linked subunits are nucleotides.

In certain embodiments, antisense oligonucleotides targeted to a STAT3 nucleic acid may be shortened or truncated. For example, a single subunit may be deleted from the 5' end (5' truncation), or alternatively from the 3' end (3' truncation). A shortened or truncated antisense compound targeted to a STAT3 nucleic acid may have two subunits deleted from the 5' end, or alternatively may have two subunits deleted from the 3' end, of the antisense compound. Alternatively, the deleted nucleosides may be dispersed

throughout the antisense compound, for example, in an antisense compound having one nucleoside deleted from the 5' end and one nucleoside deleted from the 3' end.

When a single additional subunit is present in a lengthened antisense compound, the additional subunit may be located at the 5' or 3' end of the antisense compound. When
5 two or more additional subunits are present, the added subunits may be adjacent to each other, for example, in an antisense compound having two subunits added to the 5' end (5' addition), or alternatively to the 3' end (3' addition), of the antisense compound. Alternatively, the added subunits may be dispersed throughout the antisense compound, for example, in an antisense compound having one subunit added to the 5' end and one subunit
10 added to the 3' end.

It is possible to increase or decrease the length of an antisense compound, such as an antisense oligonucleotide, and/or introduce mismatch bases without eliminating activity. For example, in Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of antisense oligonucleotides 13-25 nucleobases in length were tested for their ability to
15 induce cleavage of a target RNA in an oocyte injection model. Antisense oligonucleotides 25 nucleobases in length with 8 or 11 mismatch bases near the ends of the antisense oligonucleotides were able to direct specific cleavage of the target mRNA, albeit to a lesser extent than the antisense oligonucleotides that contained no mismatches. Similarly, target specific cleavage was achieved using 13 nucleobase antisense oligonucleotides, including
20 those with 1 or 3 mismatches.

Gautschi et al. (*J. Natl. Cancer Inst.* 93:463-471, March 2001) demonstrated the ability of an oligonucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-xL mRNA to reduce the expression of both bcl-2 and bcl-xL *in vitro* and *in vivo*. Furthermore, this oligonucleotide demonstrated potent anti-tumor
25 activity *in vivo*.

Maher and Dolnick (*Nuc. Acid. Res.* 16:3341-3358, 1988) tested a series of tandem 14 nucleobase antisense oligonucleotides, and a 28 and 42 nucleobase antisense oligonucleotides comprised of the sequence of two or three of the tandem antisense oligonucleotides, respectively, for their ability to arrest translation of human DHFR in a
30 rabbit reticulocyte assay. Each of the three 14 nucleobase antisense oligonucleotides alone was able to inhibit translation, albeit at a more modest level than the 28 or 42 nucleobase antisense oligonucleotides.

throughout the antisense compound, for example, in an antisense compound having one nucleoside deleted from the 5' end and one nucleoside deleted from the 3' end.

When a single additional subunit is present in a lengthened antisense compound, the additional subunit may be located at the 5' or 3' end of the antisense compound. When
5 two or more additional subunits are present, the added subunits may be adjacent to each other, for example, in an antisense compound having two subunits added to the 5' end (5' addition), or alternatively to the 3' end (3' addition), of the antisense compound. Alternatively, the added subunits may be dispersed throughout the antisense compound, for example, in an antisense compound having one subunit added to the 5' end and one subunit
10 added to the 3' end.

It is possible to increase or decrease the length of an antisense compound, such as an antisense oligonucleotide, and/or introduce mismatch bases without eliminating activity. For example, in Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of antisense oligonucleotides 13-25 nucleobases in length were tested for their ability to
15 induce cleavage of a target RNA in an oocyte injection model. Antisense oligonucleotides 25 nucleobases in length with 8 or 11 mismatch bases near the ends of the antisense oligonucleotides were able to direct specific cleavage of the target mRNA, albeit to a lesser extent than the antisense oligonucleotides that contained no mismatches. Similarly, target specific cleavage was achieved using 13 nucleobase antisense oligonucleotides, including
20 those with 1 or 3 mismatches.

Gautschi et al. (*J. Natl. Cancer Inst.* 93:463-471, March 2001) demonstrated the ability of an oligonucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-xL mRNA to reduce the expression of both bcl-2 and bcl-xL *in vitro* and *in vivo*. Furthermore, this oligonucleotide demonstrated potent anti-tumor
25 activity *in vivo*.

Maher and Dolnick (*Nuc. Acid. Res.* 16:3341-3358, 1988) tested a series of tandem 14 nucleobase antisense oligonucleotides, and a 28 and 42 nucleobase antisense oligonucleotides comprised of the sequence of two or three of the tandem antisense oligonucleotides, respectively, for their ability to arrest translation of human DHFR in a
30 rabbit reticulocyte assay. Each of the three 14 nucleobase antisense oligonucleotides alone was able to inhibit translation, albeit at a more modest level than the 28 or 42 nucleobase antisense oligonucleotides.

Antisense Compound Motifs

In certain embodiments, antisense compounds targeted to a STAT3 nucleic acid have chemically modified subunits arranged in patterns, or motifs, to confer to the antisense compounds properties such as enhanced inhibitory activity, increased binding affinity for a target nucleic acid, or resistance to degradation by *in vivo* nucleases.

Chimeric antisense compounds typically contain at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, increased binding affinity for the target nucleic acid, and/or increased inhibitory activity. A second region of a chimeric antisense compound may optionally serve as a substrate for the cellular endonuclease RNase H, which cleaves the RNA strand of an RNA:DNA duplex.

Antisense compounds having a gapmer motif are considered chimeric antisense compounds. In a gapmer an internal region having a plurality of nucleotides that supports RNaseH cleavage is positioned between external regions having a plurality of nucleotides that are chemically distinct from the nucleosides of the internal region. In the case of an antisense oligonucleotide having a gapmer motif, the gap segment generally serves as the substrate for endonuclease cleavage, while the wing segments comprise modified nucleosides. In certain embodiments, the regions of a gapmer are differentiated by the types of sugar moieties comprising each distinct region. The types of sugar moieties that are used to differentiate the regions of a gapmer may in some embodiments include β -D-ribonucleosides, β -D-deoxyribonucleosides, 2'-modified nucleosides (such 2'-modified nucleosides may include 2'-MOE and 2'-O-CH₃, among others), and bicyclic sugar modified nucleosides (such bicyclic sugar modified nucleosides may include those having a constrained ethyl). In certain embodiments, wings may include several modified sugar moieties, including, for example 2'-MOE and constrained ethyl. In certain embodiments, wings may include several modified and unmodified sugar moieties. In certain embodiments, wings may include various combinations of 2'-MOE nucleosides, constrained ethyl nucleosides, and 2'-deoxynucleosides.

Each distinct region may comprise uniform sugar moieties, variants, or alternating sugar moieties. The wing-gap-wing motif is frequently described as "X-Y-Z", where "X" represents the length of the 5'-wing, "Y" represents the length of the gap, and "Z" represents the length of the 3'-wing. "X" and "Z" may comprise uniform, variant, or

alternating sugar moieties. In certain embodiments, "X" and "Y" may include one or more 2'-deoxynucleosides. "Y" may comprise 2'-deoxynucleosides. As used herein, a gapmer described as "X-Y-Z" has a configuration such that the gap is positioned immediately adjacent to each of the 5'-wing and the 3' wing. Thus, no intervening nucleotides exist
5 between the 5'-wing and gap, or the gap and the 3'-wing. Any of the antisense compounds described herein can have a gapmer motif. In certain embodiments, "X" and "Z" are the same, in other embodiments they are different. In certain embodiments, "Y" is between 8 and 15 nucleosides. X, Y, or Z can be any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more nucleosides.

10 In certain embodiments, gapmers provided herein include, for example, 11-mers having a motif of 1-9-1.

In certain embodiments, gapmers provided herein include, for example, 12-mers having a motif of 1-9-2, 2-9-1, or 1-10-1.

15 In certain embodiments, gapmers provided herein include, for example, 13-mers having a motif of 1-9-3, 2-9-2, 3-9-1, 1-10-2, or 2-10-1.

In certain embodiments, gapmers provided herein include, for example, 14-mers having a motif of 1-9-4, 2-9-3, 3-9-2, 4-9-1, 1-10-3, 2-10-2, or 3-10-1.

In certain embodiments, gapmers provided herein include, for example, 15-mers having a motif of 1-9-5, 2-9-4, 3-9-3, 4-9-2, 5-9-1, 1-10-4, 2-10-3, 3-10-2, or 4-10-1.

20 In certain embodiments, gapmers provided herein include, for example, 16-mers having a motif of 2-9-5, 3-9-4, 4-9-3, 5-9-2, 1-10-5, 2-10-4, 3-10-3, 4-10-2, or 5-10-1.

In certain embodiments, gapmers provided herein include, for example, 17-mers having a motif of 3-9-5, 4-9-4, 5-9-3, 2-10-5, 3-10-4, 4-10-3, or 5-10-2.

25 In certain embodiments, gapmers provided herein include, for example, 18-mers having a motif of 4-9-5, 5-9-4, 3-10-5, 4-10-4, or 5-10-3.

In certain embodiments, gapmers provided herein include, for example, 19-mers having a motif of 5-9-5, 4-10-5, or 5-10-4.

In certain embodiments, gapmers provided herein include, for example, 20-mers having a motif of 5-10-5.

In certain embodiments, the antisense compound has a "wingmer" motif, having a wing-gap or gap-wing configuration, i.e. an X-Y or Y-Z configuration as described above for the gapmer configuration. Thus, wingmer configurations provided herein include, but are not limited to, for example 5-10, 8-4, 4-12, 12-4, 3-14, 16-2, 18-1, 10-3, 2-10, 1-10, 8-
5 2, 2-13, 5-13, 5-8, or 6-8.

In certain embodiments, antisense compound targeted to a STAT3 nucleic acid has a 2-10-2 gapmer motif.

In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 3-10-3 gapmer motif.

10 In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 5-10-5 gapmer motif.

In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 1-10-5 gapmer motif.

15 In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 3-10-4 gapmer motif.

In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 2-10-4 gapmer motif.

In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a 4-9-3 gapmer motif.

20 In certain embodiments, the antisense compound targeted to a STAT3 nucleic acid has a gap-widened motif.

In certain embodiments, the antisense compounds targeted to a STAT3 nucleic acid has any of the following sugar motifs:

25 k-d(10)-k
c-d(10)-k
k-d(10)-e
k-k-d(10)-k-k
k-k-d(10)-e-e
e-e-d(10)-k-k

k-k-k-d(10)-k-k-k
 e-e-e-d(10)-k-k-k
 k-k-k-d(10)-e-e-e
 k-k-k-d(10)-k-k-k
 5 e-k-k-d(10)-k-k-e
 e-e-k-d(10)-k-k-e
 e-d-k-d(10)-k-k-e
 e-k-d(10)-k-e-k-e
 k-d(10)-k-e-k-e-e
 10 e-e-k-d(10)-k-e-k-e
 e-d-d-k-d(9)-k-k-e
 e-e-e-e-d(9)-k-k-e

wherein, k is a constrained ethyl nucleoside, e is a 2'-MOE substituted nucleoside, and d is a 2'-deoxynucleoside.

15 In certain embodiments, the antisense oligonucleotide has a sugar motif described by Formula A as follows: $(J)_m-(B)_n-(J)_p-(B)_r-(A)_t-(D)_g-(A)_v-(B)_w-(J)_x-(B)_y-(J)_z$

wherein:

each A is independently a 2'-substituted nucleoside;

each B is independently a bicyclic nucleoside;

20 each J is independently either a 2'-substituted nucleoside or a 2'-deoxynucleoside;

each D is a 2'-deoxynucleoside;

m is 0-4; n is 0-2; p is 0-2; r is 0-2; t is 0-2; v is 0-2; w is 0-4; x is 0-2; y is 0-2; z is 0-4; g is 6-14;

provided that:

25 at least one of m, n, and r is other than 0;

at least one of w and y is other than 0;

the sum of m, n, p, r, and t is from 2 to 5; and

kilogram of the subject's body weight per week (0.2-3.5 mg/kg/wk). Such dose ranges are unexpectedly low for treating cancer. By comparison, a Phase 1 study of LY2275796, an antisense oligonucleotide targeted to cap-binding protein eukaryotic initiation factor 4E (eIF-4E), concluded that the maximum tolerable dose (MTD) and biologically effective dose (BED) of LY2275796 is 1,000 mg under a loading and maintenance dose regimen, but even at a 1,000 mg dose, no tumor response was observed. (Hong D.S. et al., Clin Cancer Res. 2011 17(20):6582-91).

Detailed Description

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of the term "or" means "and/or", unless stated otherwise. Furthermore, the use of the term "including" as well as other forms, such as "includes" and "included", is not limiting. Also, terms such as "element" or "component" encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference for the portions of the document discussed herein, as well as in their entirety.

Definitions

Unless specific definitions are provided, the nomenclature utilized in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques may be used for chemical synthesis, and chemical analysis. Where permitted, all patents, applications, published applications and other publications, GENBANK Accession Numbers and associated sequence information obtainable through databases such as National Center for Biotechnology Information (NCBI) and other data referred to throughout in the disclosure herein are incorporated by reference for the portions of the document discussed herein, as well as in their entirety.

the sum of v, w, x, y, and z is from 2 to 5.

Target Nucleic Acids, Target Regions and Nucleotide Sequences

Nucleotide sequences that encode STAT3 include, without limitation, the
5 following: GENBANK Accession No. NM_139276.2 (incorporated herein as SEQ ID NO:
1) and the complement of GENBANK Accession No. NT_010755.14 truncated from
nucleotides 4185000 to 4264000 (incorporated herein as SEQ ID NO: 2).

It is understood that the sequence set forth in each SEQ ID NO contained herein is
independent of any modification to a sugar moiety, an internucleoside linkage, or a
10 nucleobase. As such, antisense compounds defined by a SEQ ID NO may comprise,
independently, one or more modifications to a sugar moiety, an internucleoside linkage, or
a nucleobase. Antisense compounds described by Isis Number (Isis No) indicate a
combination of nucleobase sequence and motif.

In certain embodiments, a target region is a structurally defined region of the target
15 nucleic acid. For example, a target region may encompass a 3' UTR, a 5' UTR, an exon,
an intron, an exon/intron junction, a coding region, a translation initiation region,
translation termination region, or other defined nucleic acid region. The structurally
defined regions for STAT3 can be obtained by accession number from sequence databases
such as NCBI and such information is incorporated herein by reference. In certain
20 embodiments, a target region may encompass the sequence from a 5' target site of one
target segment within the target region to a 3' target site of another target segment within
the same target region.

Targeting includes determination of at least one target segment to which an
antisense compound hybridizes, such that a desired effect occurs. In certain embodiments,
25 the desired effect is a reduction in mRNA target nucleic acid levels. In certain
embodiments, the desired effect is reduction of levels of protein encoded by the target
nucleic acid or a phenotypic change associated with the target nucleic acid.

A target region may contain one or more target segments. Multiple target segments
within a target region may be overlapping. Alternatively, they may be non-overlapping.
30 In certain embodiments, target segments within a target region are separated by no more
than about 300 nucleotides. In certain embodiments, target segments within a target region
are separated by a number of nucleotides that is, is about, is no more than, is no more than

about, 250, 200, 150, 100, 90, 80, 70, 60, 50, 40, 30, 20, or 10 nucleotides on the target nucleic acid, or is a range defined by any two of the preceeding values. In certain embodiments, target segments within a target region are separated by no more than, or no more than about, 5 nucleotides on the target nucleic acid. In certain embodiments, target segments are contiguous. Contemplated are target regions defined by a range having a starting nucleic acid that is any of the 5' target sites or 3' target sites listed herein.

Suitable target segments may be found within a 5' UTR, a coding region, a 3' UTR, an intron, an exon, or an exon/intron junction. Target segments containing a start codon or a stop codon are also suitable target segments. A suitable target segment may specifically exclude a certain structurally defined region such as the start codon or stop codon.

The determination of suitable target segments may include a comparison of the sequence of a target nucleic acid to other sequences throughout the genome. For example, the BLAST algorithm may be used to identify regions of similarity amongst different nucleic acids. This comparison can prevent the selection of antisense compound sequences that may hybridize in a non-specific manner to sequences other than a selected target nucleic acid (i.e., non-target or off-target sequences).

There may be variation in activity (e.g., as defined by percent reduction of target nucleic acid levels) of the antisense compounds within an active target region. In certain embodiments, reductions in STAT3 mRNA levels are indicative of inhibition of STAT3 expression. Reductions in levels of a STAT3 protein are also indicative of inhibition of target mRNA expression. Further, phenotypic changes are indicative of inhibition of STAT3 expression. In certain embodiments, reduced cellular growth, reduced tumor growth, and reduced tumor volume can be indicative of inhibition of STAT3 expression. In certain embodiments, amelioration of symptoms associated with cancer can be indicative of inhibition of STAT3 expression. In certain embodiments, reduction of cachexia is indicative of inhibition of STAT3 expression. In certain embodiments, reduction of cancer markers can be indicative of inhibition of STAT3 expression.

Hybridization

In some embodiments, hybridization occurs between an antisense compound disclosed herein and a STAT3 nucleic acid. The most common mechanism of hybridization involves hydrogen bonding (e.g., Watson-Crick, Hoogsteen or reversed

Hoogsteen hydrogen bonding) between complementary nucleobases of the nucleic acid molecules.

Hybridization can occur under varying conditions. Stringent conditions are sequence-dependent and are determined by the nature and composition of the nucleic acid molecules to be hybridized.

Methods of determining whether a sequence is specifically hybridizable to a target nucleic acid are well known in the art. In certain embodiments, the antisense compounds provided herein are specifically hybridizable with a STAT3 nucleic acid.

10 *Complementarity*

An antisense compound and a target nucleic acid are complementary to each other when a sufficient number of nucleobases of the antisense compound can hydrogen bond with the corresponding nucleobases of the target nucleic acid, such that a desired effect will occur (e.g., antisense inhibition of a target nucleic acid, such as a STAT3 nucleic acid).

Non-complementary nucleobases between an antisense compound and a STAT3 nucleic acid may be tolerated provided that the antisense compound remains able to specifically hybridize to a target nucleic acid. Moreover, an antisense compound may hybridize over one or more segments of a STAT3 nucleic acid such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure).

In certain embodiments, the antisense compounds provided herein, or a specified portion thereof, are, or are at least, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to a STAT3 nucleic acid, a target region, target segment, or specified portion thereof. Percent complementarity of an antisense compound with a target nucleic acid can be determined using routine methods.

For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary

nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an antisense compound which is 18 nucleobases in length having four noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul *et al.*, *J. Mol. Biol.*, 1990, 215, 403 410; Zhang and Madden, *Genome Res.*, 1997, 7, 649 656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (*Adv. Appl. Math.*, 1981, 2, 482 489).

In certain embodiments, the antisense compounds provided herein, or specified portions thereof, are fully complementary (i.e. 100% complementary) to a target nucleic acid, or specified portion thereof. For example, an antisense compound may be fully complementary to a STAT3 nucleic acid, or a target region, or a target segment or target sequence thereof. As used herein, "fully complementary" means each nucleobase of an antisense compound is capable of precise base pairing with the corresponding nucleobases of a target nucleic acid. For example, a 20 nucleobase antisense compound is fully complementary to a target sequence that is 400 nucleobases long, so long as there is a corresponding 20 nucleobase portion of the target nucleic acid that is fully complementary to the antisense compound. Fully complementary can also be used in reference to a specified portion of the first and /or the second nucleic acid. For example, a 20 nucleobase portion of a 30 nucleobase antisense compound can be "fully complementary" to a target sequence that is 400 nucleobases long. The 20 nucleobase portion of the 30 nucleobase oligonucleotide is fully complementary to the target sequence if the target sequence has a corresponding 20 nucleobase portion wherein each nucleobase is complementary to the 20 nucleobase portion of the antisense compound. At the same time, the entire 30 nucleobase antisense compound may or may not be fully complementary to the target sequence, depending on whether the remaining 10 nucleobases of the antisense compound are also complementary to the target sequence.

The location of a non-complementary nucleobase may be at the 5' end or 3' end of the antisense compound. Alternatively, the non-complementary nucleobase or nucleobases may be at an internal position of the antisense compound. When two or more non-complementary nucleobases are present, they may be contiguous (i.e. linked) or non-contiguous. In one embodiment, a non-complementary nucleobase is located in the wing segment of a gapmer antisense oligonucleotide.

In certain embodiments, antisense compounds that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleobases in length comprise no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a STAT3 nucleic acid, or specified portion thereof.

In certain embodiments, antisense compounds that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a STAT3 nucleic acid, or specified portion thereof.

The antisense compounds provided herein also include those which are complementary to a portion of a target nucleic acid. As used herein, "portion" refers to a defined number of contiguous (i.e. linked) nucleobases within a region or segment of a target nucleic acid. A "portion" can also refer to a defined number of contiguous nucleobases of an antisense compound. In certain embodiments, the antisense compounds, are complementary to at least an 8 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 9 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 10 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least an 11 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 12 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 13 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 14 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 15 nucleobase portion of a target segment. Also contemplated are antisense compounds that are

complementary to at least a 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleobase portion of a target segment, or a range defined by any two of these values.

Identity

The antisense compounds provided herein may also have a defined percent identity
5 to a particular nucleotide sequence, SEQ ID NO, or compound represented by a specific
Isis number, or portion thereof. As used herein, an antisense compound is identical to the
sequence disclosed herein if it has the same nucleobase pairing ability. For example, a
RNA which contains uracil in place of thymidine in a disclosed DNA sequence would be
considered identical to the DNA sequence since both uracil and thymidine pair with
10 adenine. Shortened and lengthened versions of the antisense compounds described herein
as well as compounds having non-identical bases relative to the antisense compounds
provided herein also are contemplated. The non-identical bases may be adjacent to each
other or dispersed throughout the antisense compound. Percent identity of an antisense
compound is calculated according to the number of bases that have identical base pairing
15 relative to the sequence to which it is being compared.

In certain embodiments, the antisense compounds, or portions thereof, are at least
70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to one or more
of the antisense compounds or SEQ ID NOs, or a portion thereof, disclosed herein.

In certain embodiments, a portion of the antisense compound is compared to an
20 equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an
equal length portion of the target nucleic acid.

In certain embodiments, a portion of the antisense oligonucleotide is compared to
an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11,
25 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to
an equal length portion of the target nucleic acid.

Modifications

A nucleoside is a base-sugar combination. The nucleobase (also known as base)
portion of the nucleoside is normally a heterocyclic base moiety. Nucleotides are
30 nucleosides that further include a phosphate group covalently linked to the sugar portion of
the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate
group can be linked to the 2', 3' or 5' hydroxyl moiety of the sugar. Oligonucleotides are

formed through the covalent linkage of adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.

5 Modifications to antisense compounds encompass substitutions or changes to internucleoside linkages, sugar moieties, or nucleobases. Modified antisense compounds are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target, increased stability in the presence of nucleases, or increased inhibitory activity.

10 Chemically modified nucleosides may also be employed to increase the binding affinity of a shortened or truncated antisense oligonucleotide for its target nucleic acid. Consequently, comparable results can often be obtained with shorter antisense compounds that have such chemically modified nucleosides.

Modified Internucleoside Linkages

15 The naturally occurring internucleoside linkage of RNA and DNA is a 3' to 5' phosphodiester linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, internucleoside linkages are often selected over antisense compounds having naturally occurring internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and
20 increased stability in the presence of nucleases.

 Oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom as well as internucleoside linkages that do not have a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates. Methods of preparation of
25 phosphorous-containing and non-phosphorous-containing linkages are well known.

 In certain embodiments, antisense compounds targeted to a STAT3 nucleic acid comprise one or more modified internucleoside linkages. In certain embodiments, the modified internucleoside linkages are phosphorothioate linkages. In certain embodiments,
30 each internucleoside linkage of an antisense compound is a phosphorothioate internucleoside linkage.

Modified Sugar Moieties

Antisense compounds provided herein can optionally contain one or more nucleosides wherein the sugar group has been modified. Such sugar modified nucleosides may impart enhanced nuclease stability, increased binding affinity, or some other beneficial biological property to the antisense compounds. In certain embodiments, nucleosides comprise a chemically modified ribofuranose ring moiety. Examples of chemically modified ribofuranose rings include, without limitation, addition of substituent groups (including 5' and 2' substituent groups); bridging of non-geminal ring atoms to form bicyclic nucleic acids (BNA); replacement of the ribosyl ring oxygen atom with S, N(R), or C(R1)(R2) (R = H, C₁-C₁₂ alkyl or a protecting group); and combinations thereof. Examples of chemically modified sugars include, 2'-F-5'-methyl substituted nucleoside (see, PCT International Application WO 2008/101157, published on 8/21/08 for other disclosed 5', 2'-bis substituted nucleosides), replacement of the ribosyl ring oxygen atom with S with further substitution at the 2'-position (see, published U.S. Patent Application US2005/0130923, published on June 16, 2005), or, alternatively, 5'-substitution of a BNA (see, PCT International Application WO 2007/134181, published on 11/22/07, wherein LNA is substituted with, for example, a 5'-methyl or a 5'-vinyl group).

Examples of nucleosides having modified sugar moieties include, without limitation, nucleosides comprising 5'-vinyl, 5'-methyl (R or S), 4'-S, 2'-F, 2'-OCH₃, and 2'-O(CH₂)₂OCH₃ substituent groups. The substituent at the 2' position can also be selected from allyl, amino, azido, thio, O-allyl, O-C₁-C₁₀ alkyl, OCF₃, O(CH₂)₂SCH₃, O(CH₂)₂-O-N(Rm)(Rn), and O-CH₂-C(=O)-N(Rm)(Rn), where each Rm and Rn is, independently, H or substituted or unsubstituted C₁-C₁₀ alkyl.

As used herein, "bicyclic nucleosides" refer to modified nucleosides comprising a bicyclic sugar moiety. Examples of bicyclic nucleosides include, without limitation, nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, antisense compounds provided herein include one or more bicyclic nucleosides wherein the bridge comprises a 4' to 2' bicyclic nucleoside. Examples of such 4' to 2' bicyclic nucleosides, include, but are not limited to, one of the formulae: 4'-(CH₂)-O-2' (LNA); 4'-(CH₂)-S-2'; 4'-(CH₂)₂-O-2' (ENA); 4'-CH(CH₃)-O-2' and 4'-C-H(CH₂OCH₃)-O-2', and analogs thereof (see, U.S. Patent 7,399,845, issued on July 15, 2008); 4'-C(CH₃)(CH₃)-O-2', and analogs thereof (see, published PCT International Application WO2009/006478, published January 8, 2009); 4'-CH₂-N(OCH₃)-2', and analogs thereof (see, published PCT International Application WO2008/150729, published

December 11, 2008); 4'-CH₂-O-N(CH₃)-2' (see, published U.S. Patent Application US2004/0171570, published September 2, 2004); 4'-CH₂-N(R)-O-2', wherein R is H, C₁-C₁₂ alkyl, or a protecting group (see, U.S. Patent 7,427,672, issued on September 23, 2008); 4'-CH₂-C(H)(CH₃)-2' (see, Chattopadhyaya, *et al.*, *J. Org. Chem.*, 2009, 74, 118-134); and 4'-CH₂-C(=CH₂)-2', and analogs thereof (see, published PCT International Application WO 2008/154401, published on December 8, 2008). Also see, for example: Singh *et al.*, *Chem. Commun.*, 1998, 4, 455-456; Koshkin *et al.*, *Tetrahedron*, 1998, 54, 3607-3630; Wahlestedt *et al.*, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, 97, 5633-5638; Kumar *et al.*, *Bioorg. Med. Chem. Lett.*, 1998, 8, 2219-2222; Singh *et al.*, *J. Org. Chem.*, 1998, 63, 10035-10039; Srivastava *et al.*, *J. Am. Chem. Soc.*, 129(26) 8362-8379 (Jul. 4, 2007); Elayadi *et al.*, *Curr. Opinion Invens. Drugs*, 2001, 2, 558-561; Braasch *et al.*, *Chem. Biol.*, 2001, 8, 1-7; Orum *et al.*, *Curr. Opinion Mol. Ther.*, 2001, 3, 239-243; U.S. Patent Nos. U.S. 6,670,461, 7,053,207, 6,268,490, 6,770,748, 6,794,499, 7,034,133, 6,525,191, 7,399,845; published PCT International applications WO 2004/106356, WO 94/14226, WO 2005/021570, and WO 2007/134181; U.S. Patent Publication Nos. US2004/0171570, US2007/0287831, and US2008/0039618; and U.S. Patent Serial Nos. 12/129,154, 60/989,574, 61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787, and 61/099,844; and PCT International Application Nos. PCT/US2008/064591, PCT/US2008/066154, and PCT/US2008/068922. Each of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α -L-ribofuranose and β -D-ribofuranose (see PCT international application PCT/DK98/00393, published on March 25, 1999 as WO 99/14226).

In certain embodiments, bicyclic sugar moieties of BNA nucleosides include, but are not limited to, compounds having at least one bridge between the 4' and the 2' position of the pentofuranosyl sugar moiety wherein such bridges independently comprises 1 or from 2 to 4 linked groups independently selected from -[C(R_a)(R_b)]_n-, -C(R_a)=C(R_b)-, -C(R_a)=N-, -C(=NR_a)-, -C(=O)-, -C(=S)-, -O-, -Si(R_a)₂-, -S(=O)_x-, and -N(R_a)-

wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_a and R_b is, independently, H, a protecting group, hydroxyl, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl,

substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical, substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃, COOJ₁, acyl (C(=O)-H), substituted acyl, CN, sulfonyl (S(=O)₂-J₁), or sulfoxyl (S(=O)-J₁); and

5 each J₁ and J₂ is, independently, H, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, acyl (C(=O)-H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C₁-C₁₂ aminoalkyl, substituted C₁-C₁₂ aminoalkyl, or a protecting group.

10 In certain embodiments, the bridge of a bicyclic sugar moiety is, -[C(R_a)(R_b)]_n-, -[C(R_a)(R_b)]_n-O-, -C(R_aR_b)-N(R)-O- or, -C(R_aR_b)-O-N(R)-. In certain embodiments, the bridge is 4'-CH₂-2', 4'-(CH₂)₂-2', 4'-(CH₂)₃-2', 4'-CH₂-O-2', 4'-(CH₂)₂-O-2', 4'-CH₂-O-N(R)-2', and 4'-CH₂-N(R)-O-2', wherein each R is, independently, H, a protecting group, or C₁-C₁₂ alkyl.

15 In certain embodiments, bicyclic nucleosides are further defined by isomeric configuration. For example, a nucleoside comprising a 4'-2' methylene-oxy bridge, may be in the α-L configuration or in the β-D configuration. Previously, α-L-methyleneoxy (4'-CH₂-O-2') BNA's have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden *et al.*, *Nucleic Acids Research*, 2003, 21, 6365-6372).

20 In certain embodiments, bicyclic nucleosides include, but are not limited to, (A) α-L-Methyleneoxy (4'-CH₂-O-2') BNA, (B) β-D-Methyleneoxy (4'-CH₂-O-2') BNA, (C) Ethyleneoxy (4'-(CH₂)₂-O-2') BNA, (D) Aminooxy (4'-CH₂-O-N(R)-2') BNA, (E) Oxyamino (4'-CH₂-N(R)-O-2') BNA, (F) Methyl(methyleneoxy) (4'-CH(CH₃)-O-2') BNA, (G) methylene-thio (4'-CH₂-S-2') BNA, (H) methylene-amino (4'-CH₂-N(R)-2') BNA, (I) methyl carbocyclic (4'-CH₂-CH(CH₃)-2') BNA, and (J) propylene carbocyclic (4'-(CH₂)₃-2') BNA as depicted below.

25

Unless otherwise indicated, the following terms have the following meanings:

“2'-deoxynucleoside” means a nucleoside comprising 2'-H furanosyl sugar moiety, as found naturally occurring in deoxyribonucleosides (DNA). In certain embodiments, a 2'-deoxynucleoside may comprise a modified nucleobase or may comprise an RNA nucleobase (e.g., uracil).

“2'-O-methoxyethyl” (also 2'-MOE and 2'-O(CH₂)₂-OCH₃) refers to an O-methoxy-ethyl modification of the 2' position of a furanosyl ring. A 2'-O-methoxyethyl modified sugar is a modified sugar.

“2'-MOE nucleoside” (also 2'-O-methoxyethyl nucleoside) means a nucleoside comprising a 2'-MOE modified sugar moiety.

“2'-substituted nucleoside” means a nucleoside comprising a substituent at the 2'-position other than H or OH. Unless otherwise indicated, a 2'-substituted nucleoside is not a bicyclic nucleoside.


“5'-methylcytosine” means a cytosine modified with a methyl group attached to the 5' position. A 5-methylcytosine is a modified nucleobase.

“About” as applied to dosing amounts means within $\pm 12\%$ of a value. For example, if it is stated, “the dose is an amount in the range of about 15-750 mg,” it is implied that the dose is an amount in the range of 13-840 mg. In another example, if it is stated that the dose is an amount of “about 50 mg,” it is implied that the dose can be from 44 mg to 56 mg. “About” as applied to activity levels means within $\pm 10\%$ of a value. For example, if it is stated, “the compounds affected at least about 70% inhibition of STAT3”, it is implied that the STAT3 levels are inhibited within a range of 63% and 77%.

“Active pharmaceutical agent” means the substance or substances in a pharmaceutical composition that provide a therapeutic benefit when administered to an individual. For example, in certain embodiments an antisense oligonucleotide targeted to STAT3 is an active pharmaceutical agent.


“Active target region” or “target region” means a region to which one or more active antisense compounds is targeted. “Active antisense compounds” means antisense compounds that reduce target nucleic acid levels or protein levels.

“Administered concomitantly” refers to the co-administration of two agents in any manner in which the pharmacological effects of both are manifest in the patient at the same



wherein Bx is the base moiety and R is, independently, H, a protecting group or C₁-C₁₂ alkyl.

In certain embodiments, bicyclic nucleoside having Formula I:



wherein:


Bx is a heterocyclic base moiety;

-Q_a-Q_b-Q_c- is -CH₂-N(R_c)-CH₂-, -C(=O)-N(R_c)-CH₂-, -CH₂-O-N(R_c)-, -CH₂-N(R_c)-O-, or -N(R_c)-O-CH₂;

R_c is C₁-C₁₂ alkyl or an amino protecting group; and

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium.

In certain embodiments, bicyclic nucleoside having Formula II:



5

wherein:

Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;


10

Z_a is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, substituted C_1 - C_6 alkyl, substituted C_2 - C_6 alkenyl, substituted C_2 - C_6 alkynyl, acyl, substituted acyl, substituted amide, thiol, or substituted thio.

In one embodiment, each of the substituted groups is, independently, mono or poly substituted with substituent groups independently selected from halogen, oxo, hydroxyl, OJ_c , NJ_eJ_d , SJ_c , N_3 , $OC(=X)J_c$, and $NJ_eC(=X)NJ_eJ_d$, wherein each J_c , J_d , and J_e is, independently, H, C_1 - C_6 alkyl, or substituted C_1 - C_6 alkyl and X is O or NJ_c .

15

In certain embodiments, bicyclic nucleoside having Formula III:




20 wherein:

Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;

- Z_b is C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, substituted C_1 - C_6 alkyl, substituted C_2 - C_6 alkenyl, substituted C_2 - C_6 alkynyl, or substituted acyl ($C(=O)-$).

In certain embodiments, bicyclic nucleoside having Formula IV:



wherein:


Bx is a heterocyclic base moiety;

- T_a and T_b are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;

R_d is C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, substituted C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, or substituted C_2 - C_6 alkynyl;

- each q_a , q_b , q_c and q_d is, independently, H, halogen, C_1 - C_6 alkyl, substituted C_1 - C_6 alkyl, C_2 - C_6 alkenyl, substituted C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, or substituted C_2 - C_6 alkynyl, C_1 - C_6 alkoxy, substituted C_1 - C_6 alkoxy, acyl, substituted acyl, C_1 - C_6 aminoalkyl, or substituted C_1 - C_6 aminoalkyl;

In certain embodiments, bicyclic nucleoside having Formula V:



wherein:

Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;

q_a , q_b , q_e and q_f are each, independently, hydrogen, halogen, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_1 - C_{12} alkoxy, substituted C_1 - C_{12} alkoxy, OJ_j , SJ_j , SOJ_j , SO_2J_j , NJ_jJ_k , N_3 , CN , $C(=O)OJ_j$, $C(=O)NJ_jJ_k$, $C(=O)J_j$, $O-C(=O)NJ_jJ_k$, $N(H)C(=NH)NJ_jJ_k$, $N(H)C(=O)NJ_jJ_k$ or $N(H)C(=S)NJ_jJ_k$;


or q_e and q_f together are $=C(q_g)(q_h)$;

q_g and q_h are each, independently, H, halogen, C_1 - C_{12} alkyl, or substituted C_1 - C_{12} alkyl.

The synthesis and preparation of the methyleneoxy (4'- CH_2 -O-2') BNA monomers adenine, cytosine, guanine, 5-methyl-cytosine, thymine, and uracil, along with their oligomerization, and nucleic acid recognition properties have been described (*see, e.g.*, Koshkin et al., *Tetrahedron*, 1998, 54, 3607-3630). BNAs and preparation thereof are also described in WO 98/39352 and WO 99/14226.

Analogues of methyleneoxy (4'- CH_2 -O-2') BNA, methyleneoxy (4'- CH_2 -O-2') BNA, and 2'-thio-BNAs, have also been prepared (*see, e.g.*, Kumar et al., *Bioorg. Med. Chem. Lett.*, 1998, 8, 2219-2222). Preparation of locked nucleoside analogs comprising oligodeoxyribonucleotide duplexes as substrates for nucleic acid polymerases has also been described (*see, e.g.*, Wengel et al., WO 99/14226). Furthermore, synthesis of 2'-amino-BNA, a novel conformationally restricted high-affinity oligonucleotide analog, has been described in the art (*see, e.g.*, Singh et al., *J. Org. Chem.*, 1998, 63, 10035-10039). In addition, 2'-amino- and 2'-methyamino-BNA's have been prepared and the thermal stability of their duplexes with complementary RNA and DNA strands has been previously reported.

In certain embodiments, bicyclic nucleoside having Formula VI:



wherein:

Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety, or a covalent attachment to a support medium;

each q_i, q_j, q_k and q_l is, independently, H, halogen, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₁-C₁₂ alkoxy, substituted C₁-C₁₂ alkoxy, OJ_j, SJ_j, SOJ_j, SO₂J_j, NJ_jJ_k, N₃, CN, C(=O)OJ_j, C(=O)NJ_jJ_k, C(=O)J_j, O-C(=O)NJ_jJ_k, N(H)C(=NH)NJ_jJ_k, N(H)C(=O)NJ_jJ_k, or N(H)C(=S)NJ_jJ_k; and

q_i and q_j or q_i and q_k together are =C(q_g)(q_h), wherein q_g and q_h are each, independently, H, halogen, C₁-C₁₂ alkyl, or substituted C₁-C₁₂ alkyl.

One carbocyclic bicyclic nucleoside having a 4'-(CH₂)₃-2' bridge and the alkenyl analog, bridge 4'-CH=CH-CH₂-2', have been described (*see, e.g., Freier et al., Nucleic Acids Research*, 1997, 25(22), 4429-4443 and *Albaek et al., J. Org. Chem.*, 2006, 71, 7731-7740). The synthesis and preparation of carbocyclic bicyclic nucleosides along with their oligomerization and biochemical studies have also been described (*see, e.g., Srivastava et al., J. Am. Chem. Soc.* 2007, 129(26), 8362-8379).

As used herein, "4'-2' bicyclic nucleoside" or "4' to 2' bicyclic nucleoside" refers to a bicyclic nucleoside comprising a furanose ring comprising a bridge connecting the 2' carbon atom and the 4' carbon atom.


As used herein, "monocyclic nucleosides" refer to nucleosides comprising modified sugar moieties that are not bicyclic sugar moieties. In certain embodiments, the sugar moiety, or sugar moiety analogue, of a nucleoside may be modified or substituted at any position.

As used herein, "2'-modified sugar" means a furanosyl sugar modified at the 2' position. In certain embodiments, such modifications include substituents selected from: a halide, including, but not limited to substituted and unsubstituted alkoxy, substituted and unsubstituted thioalkyl, substituted and unsubstituted amino alkyl, substituted and unsubstituted alkyl, substituted and unsubstituted allyl, and substituted and unsubstituted alkynyl. In certain embodiments, 2' modifications are selected from substituents

including, but not limited to: $O[(CH_2)_nO]_mCH_3$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, $O(CH_2)_nONH_2$, $OCH_2C(=O)N(H)CH_3$, and $O(CH_2)_nON[(CH_2)_nCH_3]_2$, where n and m are from 1 to about 10. Other 2'- substituent groups can also be selected from: C_1 - C_{12} alkyl; substituted alkyl; alkenyl; alkynyl; alkaryl; aralkyl; O-alkaryl or O-aralkyl; SH; SCH₃;
 5 OCN; Cl; Br; CN; CF₃; OCF₃; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving pharmacokinetic properties; and a group for improving the pharmacodynamic properties of an antisense compound, and other substituents having similar properties. In certain embodiments, modified nucleosides
 10 comprise a 2'-MOE side chain (*see, e.g.*, Baker et al., J. Biol. Chem., 1997, 272, 11944-12000). Such 2'-MOE substitution have been described as having improved binding affinity compared to unmodified nucleosides and to other modified nucleosides, such as 2'-*O*-methyl, *O*-propyl, and *O*-aminopropyl. Oligonucleotides having the 2'-MOE substituent also have been shown to be antisense inhibitors of gene expression with promising features
 15 for *in vivo* use (*see, e.g.*, Martin, P., *Helv. Chim. Acta*, 1995, 78, 486-504; Altmann et al., *Chimia*, 1996, 50, 168-176; Altmann et al., *Biochem. Soc. Trans.*, 1996, 24, 630-637; and Altmann et al., *Nucleosides Nucleotides*, 1997, 16, 917-926).

As used herein, a "modified tetrahydropyran nucleoside" or "modified THP nucleoside" means a nucleoside having a six-membered tetrahydropyran "sugar" substituted in for the pentofuranosyl residue in normal nucleosides (a sugar surrogate).
 20 Modified THP nucleosides include, but are not limited to, what is referred to in the art as hexitol nucleic acid (HNA), anitol nucleic acid (ANA), manitol nucleic acid (MNA) (*see* Leumann, C.J. *Bioorg. & Med. Chem.* (2002) 10:841-854), fluoro HNA (F-HNA), or those compounds having Formula X:

25 Formula X:



X

wherein independently for each of said at least one tetrahydropyran nucleoside analog of Formula X:

Bx is a heterocyclic base moiety;

T₃ and T₄ are each, independently, an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound or one of T₃ and T₄ is an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound and the other of T₃ and T₄ is H, a hydroxyl protecting group, a linked
5 conjugate group, or a 5' or 3'-terminal group;

q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each, independently, H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl; and

one of R₁ and R₂ is hydrogen and the other is selected from halogen, substituted or
10 unsubstituted alkoxy, NJ₁J₂, SJ₁, N₃, OC(=X)J₁, OC(=X)NJ₁J₂, NJ₃C(=X)NJ₁J₂, and CN, wherein X is O, S, or NJ₁, and each J₁, J₂, and J₃ is, independently, H or C₁-C₆ alkyl.

In certain embodiments, the modified THP nucleosides of Formula X are provided wherein q_m, q_n, q_p, q_r, q_s, q_t, and q_u are each H. In certain embodiments, at least one of q_m, q_n, q_p, q_r, q_s, q_t, and q_u is other than H. In certain embodiments, at least one of q_m, q_n, q_p, q_r,
15 q_s, q_t and q_u is methyl. In certain embodiments, THP nucleosides of Formula X are provided wherein one of R₁ and R₂ is F. In certain embodiments, R₁ is fluoro and R₂ is H, R₁ is methoxy and R₂ is H, and R₁ is methoxyethoxy and R₂ is H.

As used herein, "2'-modified" or "2'-substituted" refers to a nucleoside comprising a sugar comprising a substituent at the 2' position other than H or OH. 2'-modified
20 nucleosides, include, but are not limited to, bicyclic nucleosides wherein the bridge connecting two carbon atoms of the sugar ring connects the 2' carbon and another carbon of the sugar ring and nucleosides with non-bridging 2' substituents, such as allyl, amino, azido, thio, O-allyl, O-C₁-C₁₀ alkyl, -OCF₃, O-(CH₂)₂-O-CH₃, 2'-O(CH₂)₂SCH₃, O-(CH₂)₂-O-N(R_m)(R_n), or O-CH₂-C(=O)-N(R_m)(R_n), where each R_m and R_n is, independently, H or
25 substituted or unsubstituted C₁-C₁₀ alkyl. 2'-modified nucleosides may further comprise other modifications, for example, at other positions of the sugar and/or at the nucleobase.

As used herein, "2'-F" refers to a sugar comprising a fluoro group at the 2' position.

As used herein, "2'-OMe" or "2'-OCH₃" or "2'-O-methyl" each refers to a
30 nucleoside comprising a sugar comprising an -OCH₃ group at the 2' position of the sugar ring.

As used herein, "oligonucleotide" refers to a compound comprising a plurality of linked nucleosides. In certain embodiments, one or more of the plurality of nucleosides is modified. In certain embodiments, an oligonucleotide comprises one or more ribonucleosides (RNA) and/or deoxyribonucleosides (DNA).

5 Many other bicyclo and tricyclo sugar surrogate ring systems are also known in the art that can be used to modify nucleosides for incorporation into antisense compounds (*see, e.g., review article: Leumann, J. C, Bioorganic & Medicinal Chemistry, 2002, 10, 841-854*).

Such ring systems can undergo various additional substitutions to enhance activity.

10 Methods for the preparations of modified sugars are well known to those skilled in the art.

In nucleotides having modified sugar moieties, the nucleobase moieties (natural, modified, or a combination thereof) are maintained for hybridization with an appropriate nucleic acid target.

15 In certain embodiments, antisense compounds comprise one or more nucleotides having modified sugar moieties. In certain embodiments, the modified sugar moiety is 2'-MOE. In certain embodiments, the 2'-MOE modified nucleotides are arranged in a gapmer motif. In certain embodiments, the modified sugar moiety is a cEt. In certain
20 embodiments, the cEt modified nucleotides are arranged throughout the wings of a gapmer motif.

Compositions and Methods for Formulating Pharmaceutical Compositions

Antisense oligonucleotides may be admixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical
25 compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

An antisense compound targeted to a STAT3 nucleic acid can be utilized in pharmaceutical compositions by combining the antisense compound with a suitable pharmaceutically acceptable diluent or carrier. A pharmaceutically acceptable diluent
30 includes phosphate-buffered saline (PBS). PBS is a diluent suitable for use in compositions to be delivered parenterally. Accordingly, in one embodiment, employed in

the methods described herein is a pharmaceutical composition comprising an antisense compound targeted to a STAT3 nucleic acid and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is PBS. In certain embodiments, the antisense compound is an antisense oligonucleotide.

5 Pharmaceutical compositions comprising antisense compounds encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts
10 of antisense compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

 A prodrug can include the incorporation of additional nucleosides at one or both ends of an antisense compound which are cleaved by endogenous nucleases within the
15 body, to form the active antisense compound.

Conjugated Antisense compounds

 Antisense compounds may be covalently linked to one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the resulting antisense oligonucleotides. Typical conjugate groups include cholesterol
20 moieties and lipid moieties. Additional conjugate groups include carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.

 Antisense compounds can also be modified to have one or more stabilizing groups that are generally attached to one or both termini of antisense compounds to enhance
25 properties such as, for example, nuclease stability. Included in stabilizing groups are cap structures. These terminal modifications protect the antisense compound having terminal nucleic acid from exonuclease degradation, and can help in delivery and/or localization within a cell. The cap can be present at the 5'-terminus (5'-cap), or at the 3'-terminus (3'-cap), or can be present on both termini. Cap structures are well known in the art and
30 include, for example, inverted deoxy abasic caps. Further 3' and 5'-stabilizing groups that can be used to cap one or both ends of an antisense compound to impart nuclease stability include those disclosed in WO 03/004602 published on January 16, 2003.

Certain Antisense Compounds

In certain embodiments, antisense compounds useful for treating B-cell lymphoma at the doses and dosing regimens described above include any of the antisense oligonucleotides described in WO 2012/135736, which is incorporated by reference in its entirety herein. Examples of antisense compounds described in WO 2012/135736 suitable for treating B-cell lymphoma include, but are not limited to, those described in Tables 1 & 2 below:

Table 1

cEt and MOE chimeric antisense oligonucleotides targeted to STAT3 (SEQ ID NO: 1)

ISIS NO	Human Start Site	Human Stop Site	Sequence	Motif	Wing Chem	SEQ ID NO
481355	322	337	ACTGCCGCAGCTCCAT	3-10-3	cEt	3
481597	731	744	GAGATTCTCTACCA	2-10-2	cEt	4
481374	788	803	AGATCTTGCATGTCTC	3-10-3	cEt	5
481390	1305	1320	ATAATTCAACTCAGGG	3-10-3	cEt	6
481420	1948	1963	ACTTTTTCACAAGGTC	3-10-3	cEt	7
481431	2206	2221	CCATGATCTTATAGCC	3-10-3	cEt	8
481453	2681	2696	GATAGCAGAAGTAGGA	3-10-3	cEt	9
481463	3001	3016	CAAGGTTAAAAAGTGC	3-10-3	cEt	10
481688	3002	3015	AAGGTTAAAAAGTG	2-10-2	cEt	11
481464	3016	3031	CTATTGGATGTCAGC	3-10-3	cEt	12
481689	3017	3030	TATTGGATGTCAG	2-10-2	cEt	13
481465	3032	3047	TAGATAGTCCTATCTT	3-10-3	cEt	14

time. Concomitant administration does not require that both agents be administered in a single pharmaceutical composition, in the same dosage form, or by the same route of administration. The effects of both agents need not manifest themselves at the same time. The effects need only be overlapping for a period of time and need not be coextensive.

5 “Administering” means providing a pharmaceutical agent to an individual, and includes, but is not limited to administering by a medical professional and self-administering.

10 “Amelioration” refers to a lessening of at least one indicator, sign, or symptom of an associated disease, disorder, or condition. The severity of indicators may be determined by subjective or objective measures, which are known to those skilled in the art.

 “Animal” refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees.

15 “Antisense activity” means any detectable or measurable activity attributable to the hybridization of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity is a decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic acid.

20 “Antisense compound” means an oligomeric compound that is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding. Examples of antisense compounds include single-stranded and double-stranded compounds, such as, antisense oligonucleotides, siRNAs, and shRNAs.

25 “Antisense inhibition” means reduction of target nucleic acid levels or target protein levels in the presence of an antisense compound complementary to a target nucleic acid as compared to target nucleic acid levels or target protein levels in the absence of the antisense compound.

 “Antisense oligonucleotide” means a single-stranded oligonucleotide having a nucleobase sequence that permits hybridization to a corresponding region or segment of a target nucleic acid.

30 “Bicyclic sugar” means a furosyl ring modified by the bridging of two atoms. A bicyclic sugar is a modified sugar.

481690	3033	3046	AGATAGTCCTATCT	2-10-2	cEt	15
481466	3047	3062	AAGAAACCTAGGGCTT	3-10-3	cEt	16
481691	3048	3061	AGAAACCTAGGGCT	2-10-2	cEt	17
481467	3097	3112	GCTGATACAGTGTTTT	3-10-3	cEt	18
481692	3098	3111	CTGATACAGTGTTT	2-10-2	cEt	19
481468	3112	3127	ATACAGAAAGGCTATG	3-10-3	cEt	20
481693	3113	3126	TACAGAAAGGCTAT	2-10-2	cEt	21
481469	3127	3142	GCTTAAGTTTCTTAAA	3-10-3	cEt	22
481694	3128	3141	CTTAAGTTTCTTAA	2-10-2	cEt	23
481470	3461	3476	AGCACCAAGGAGGCTG	3-10-3	cEt	24
481695	3462	3475	GCACCAAGGAGGCT	2-10-2	cEt	25
481471	3476	3491	AAGCTGAATGCTTAAA	3-10-3	cEt	26
481696	3477	3490	AGCTGAATGCTTAA	2-10-2	cEt	27
481472	3491	3506	TTACCAGCCTGAAGGA	3-10-3	cEt	28
481697	3492	3505	TACCAGCCTGAAGG	2-10-2	cEt	29
481473	3506	3521	CAGGGATTATATAAAT	3-10-3	cEt	30
481698	3507	3520	AGGGATTATATAAA	2-10-2	cEt	31
481474	3521	3536	ACCTGAAGCCCGTTTC	3-10-3	cEt	32
481699	3522	3535	CCTGAAGCCCGTTT	2-10-2	cEt	33
481475	3536	3551	TGTCTTAAGGGTTTGA	3-10-3	cEt	34
481700	3537	3550	GTCTTAAGGGTTTG	2-10-2	cEt	35

481476	3551	3566	GGTTGCAGCTTCAGAT	3-10-3	cEt	36
481701	3552	3565	GTTGCAGCTTCAGA	2-10-2	cEt	37
481477	3567	3582	TCAACACCAAAGGCCA	3-10-3	cEt	38
481702	3568	3581	CAACACCAAAGGCC	2-10-2	cEt	39
481478	3585	3600	TCCTTAAACCTTCCTA	3-10-3	cEt	40
481703	3586	3599	CCTTAAACCTTCCT	2-10-2	cEt	41
481479	3600	3615	AAAATGCTTAGATTCT	3-10-3	cEt	42
481704	3601	3614	AAATGCTTAGATTC	2-10-2	cEt	43
481480	3628	3643	AAATAAGTCTATTTAT	3-10-3	cEt	44
481705	3629	3642	AATAAGTCTATTTA	2-10-2	cEt	45
481481	3648	3663	GGCCAATACATTACAA	3-10-3	cEt	46
481706	3649	3662	GCCAATACATTACA	2-10-2	cEt	47
481482	3670	3685	TGCCCAGCCTTACTCA	3-10-3	cEt	48
481707	3671	3684	GCCCAGCCTTACTC	2-10-2	cEt	49
481483	3685	3700	GTTGTAAGCACCTCT	3-10-3	cEt	50
481708	3686	3699	TTGTAAGCACCTC	2-10-2	cEt	51
481484	3700	3715	AGAAAGGGAGTCAAGG	3-10-3	cEt	52
481709	3701	3714	GAAAGGGAGTCAAG	2-10-2	cEt	53
481485	3717	3732	GCAGATCAAGTCCAGG	3-10-3	cEt	54
481710	3718	3731	CAGATCAAGTCCAG	2-10-2	cEt	55
481486	3730	3745	AGCCTCTGAAACAGCA	3-10-3	cEt	56

481711	3731	3744	GCCTCTGAAACAGC	2-10-2	cEt	57
481487	3746	3761	CCCACAGAAACAACCT	3-10-3	cEt	58
481712	3747	3760	CCACAGAAACAACC	2-10-2	cEt	59
481488	3761	3776	AGCCCTGATAAGGCAC	3-10-3	cEt	60
481713	3762	3775	GCCCTGATAAGGCA	2-10-2	cEt	61
481489	3776	3791	AATCAGAAGTATCCCA	3-10-3	cEt	62
481714	3777	3790	ATCAGAAGTATCCC	2-10-2	cEt	63
481490	3833	3848	GCCTCTAGCAGGATCA	3-10-3	cEt	64
481715	3834	3847	CCTCTAGCAGGATC	2-10-2	cEt	65
481491	3848	3863	CACGCAAGGAGACATG	3-10-3	cEt	66
481716	3849	3862	ACGCAAGGAGACAT	2-10-2	cEt	67
481492	3863	3878	TGAGGGACCTTTAGAC	3-10-3	cEt	68
481717	3864	3877	GAGGGACCTTTAGA	2-10-2	cEt	69
481493	3886	3901	CAGGATTCCTAAAACA	3-10-3	cEt	70
481718	3887	3900	AGGATTCCTAAAAC	2-10-2	cEt	71
481494	3901	3916	ATGAGGTCCTGAGACC	3-10-3	cEt	72
481719	3902	3915	TGAGGTCCTGAGAC	2-10-2	cEt	73
481495	3940	3955	CATCATGTCCAACCTG	3-10-3	cEt	74
481720	3941	3954	ATCATGTCCAACCT	2-10-2	cEt	75
481496	3955	3970	GGGCCCCATAGTGTGC	3-10-3	cEt	76
481721	3956	3969	GGCCCCATAGTGTG	2-10-2	cEt	77

481497	3977	3992	AGCTCAACCAGACACG	3-10-3	cEt	78
481722	3978	3991	GCTCAACCAGACAC	2-10-2	cEt	79
481498	3992	4007	GAACCATATTCCCTGA	3-10-3	cEt	80
481723	3993	4006	AACCATATTCCCTG	2-10-2	cEt	81
481499	4007	4022	CAAGAAACTGGCTAAG	3-10-3	cEt	82
481724	4008	4021	AAGAAACTGGCTAA	2-10-2	cEt	83
481500	4022	4037	GCCACTGGATATCACC	3-10-3	cEt	84
481501	4048	4063	AACTGAATGAAGACGC	3-10-3	cEt	85
481523	4489	4504	GCTTATTATGTACTGA	3-10-3	cEt	86
481748	4490	4503	CTTATTATGTACTG	2-10-2	cEt	87
481524	4530	4545	GCCCAAGTCTCACCTT	3-10-3	cEt	88
481749	4531	4544	CCCAAGTCTCACCT	2-10-2	cEt	89
481525	4541	4556	CCCAATGGTAAGCCCA	3-10-3	cEt	90
481750	4542	4555	CCAATGGTAAGCCC	2-10-2	cEt	91
481526	4543	4558	AACCCAATGGTAAGCC	3-10-3	cEt	92
481751	4544	4557	ACCCAATGGTAAGC	2-10-2	cEt	93
481527	4560	4575	TAGGTCCCTATGATTT	3-10-3	cEt	94
481752	4561	4574	AGGTCCCTATGATT	2-10-2	cEt	95
481528	4579	4594	AAGCCCTGAACCCTCG	3-10-3	cEt	96
481753	4580	4593	AGCCCTGAACCCTC	2-10-2	cEt	97
481529	4615	4630	CCTAAGGCCATGAACT	3-10-3	cEt	98

481754	4616	4629	CTAAGGCCATGAAC	2-10-2	cEt	99
481530	4630	4645	ACCAGATACATGCTAC	3-10-3	cEt	100
481755	4631	4644	CCAGATACATGCTA	2-10-2	cEt	101
481531	4646	4661	TACAATCAGAGTTAAG	3-10-3	cEt	102
481756	4647	4660	ACAATCAGAGTTAA	2-10-2	cEt	103
481532	4664	4679	TCCTCTCAGAACTTTT	3-10-3	cEt	104
481757	4665	4678	CCTCTCAGAACTTT	2-10-2	cEt	105
481533	4666	4681	GCTCCTCTCAGAACTT	3-10-3	cEt	106
481758	4667	4680	CTCCTCTCAGAACT	2-10-2	cEt	107
481534	4693	4708	TTCTTTAATGGGCCAC	3-10-3	cEt	108
481759	4694	4707	TCTTTAATGGGCCA	2-10-2	cEt	109
481535	4767	4782	ACGGGATTCCCTCGGC	3-10-3	cEt	110
481760	4768	4781	CGGGATTCCCTCGG	2-10-2	cEt	111
481536	4782	4797	GTAGGTAAGCAACCCA	3-10-3	cEt	112
481761	4783	4796	TAGGTAAGCAACCC	2-10-2	cEt	113
481537	4830	4845	GAATTTGAATGCAGTG	3-10-3	cEt	114
481762	4831	4844	AATTTGAATGCAGT	2-10-2	cEt	115
481538	4844	4859	TGAAGTACACATTGGA	3-10-3	cEt	116
481763	4845	4858	GAAGTACACATTGG	2-10-2	cEt	117
481539	4860	4875	ATAAATTTTACACTA	3-10-3	cEt	118
481764	4861	4874	TAAATTTTACACT	2-10-2	cEt	119

481765	4869	4882	CAATAATATAAATT	2-10-2	cEt	120
481541	4934	4949	CTGGAAGTTAAAGTAG	3-10-3	cEt	121
481766	4935	4948	TGGAAGTTAAAGTA	2-10-2	cEt	122

Table 2

Chimeric antisense oligonucleotides targeted to STAT3 (SEQ ID NO: 2)

Human Start Site	Human Stop Site	ISIS No	Sequence	Chemistry	SEQ ID NO
5701	5716	GTACTCTTTCAGTGGT	529962	e-e-e-d(10)-k-k-k	123
74784	74799	ATGCTTAGATTCTCCT	529979	k-k-k-d(10)-e-e-e	124
74905	74920	AGCAGATCAAGTCCAG	529982	k-k-k-d(10)-c-e-c	125
75423	75438	AGGTGTTCCCATACGC	529983	k-k-k-d(10)-c-e-c	126
75424	75439	TAGGTGTTCCCATACG	529984	k-k-k-d(10)-e-e-e	127
5701	5716	GTACTCTTTCAGTGGT	529999	k-k-k-d(10)-e-e-e	123
9878	9893	GGTTCCTCCTGTTGGC	530006	k-k-k-d(10)-e-e-e	128
12361	12376	GGTTCCTCCTGTTGGC	530006	k-k-k-d(10)-e-e-e	128
74783	74799	ATGCTTAGATTCTCCTT	530020	e-e-k-d(10)-k-e-k- e	129

5 Certain Combination Therapies

In certain embodiments, one or more pharmaceutical compositions provided herein are co-administered with one or more other pharmaceutical agents. In certain embodiments, such one or more other pharmaceutical agents are designed to treat the same

disease, disorder, or condition as the one or more pharmaceutical compositions provided herein. In certain embodiments, such one or more other pharmaceutical agents are designed to treat a different disease, disorder, or condition as the one or more pharmaceutical compositions provided herein. In certain embodiments, such one or more
5 other pharmaceutical agents are designed to treat an undesired side effect of one or more pharmaceutical compositions provided herein. In certain embodiments, one or more pharmaceutical compositions provided herein are co-administered with another pharmaceutical agent to treat an undesired effect of that other pharmaceutical agent. In certain embodiments, one or more pharmaceutical compositions provided herein are co-
10 administered with another pharmaceutical agent to produce a combinational effect. In certain embodiments, one or more pharmaceutical compositions provided herein are co-administered with another pharmaceutical agent to produce a synergistic effect.

In certain embodiments, one or more pharmaceutical compositions provided herein and one or more other pharmaceutical agents are administered at the same time. In certain
15 embodiments, one or more pharmaceutical compositions provided herein and one or more other pharmaceutical agents are administered at different times. In certain embodiments, one or more pharmaceutical compositions provided herein and one or more other pharmaceutical agents are prepared together in a single formulation. In certain embodiments, one or more pharmaceutical compositions provided herein and one or more
20 other pharmaceutical agents are prepared separately. In certain embodiments, one or more other pharmaceutical agents include all-trans retinoic acid, azacitidine, azathioprine, bleomycin, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, mechlorethamine,
25 mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, teniposide, tioguanine, valrubicin, vinblastine, vincristine, vindesine, or vinorelbine. In certain embodiments, one or more other pharmaceutical agents include a combination of cyclophosphamide, hydroxydanorubicin, oncovin (vincristine), prednisone or prednisolone (CHOP). In certain embodiments, one or more other pharmaceutical agents
30 include a combination of rituximab and CHOP (R-CHOP). In certain embodiments, one or more other pharmaceutical agents include another antisense oligonucleotide. In certain embodiments, another antisense oligonucleotide is a second STAT3 antisense oligonucleotide.

In certain embodiments, one or more other pharmaceutical agents include molecular targeted therapies. In certain embodiments, the molecular targeted therapy is an EGFR inhibitor, a mTOR inhibitor, a HER2 inhibitor, or a VEGF/VEGFR inhibitor. In certain embodiments, EGFR inhibitors include gefitinib, erlotinib, lapatinib, cetuximab, panitumumab. In certain embodiments, mTOR inhibitors include everolimus and temsirolimus. In certain embodiments, HER2 inhibitors include trastuzumab and lapatinib. In certain embodiments, VEGF/VEGFR inhibitors include pazopanib, bevacizumab, sunitinib, and sorafenib.

In certain embodiments, one or more pharmaceutical compositions provided herein are administered with radiation therapy. In certain embodiments, one or more pharmaceutical compositions are administered at the same time as radiation therapy. In certain embodiments, one or more pharmaceutical compositions are administered before radiation therapy. In certain embodiments, one or more pharmaceutical compositions are administered after radiation therapy. In certain embodiments, one or more pharmaceutical compositions are administered at various time points throughout a radiation therapy regimen.

In certain embodiments, radiation therapy is useful for inhibiting tumor growth. In certain embodiments, radiation therapy is useful for increasing overall survival. In certain embodiments, radiation therapy used in conjunction with administration of one or more pharmaceuticals provided herein is advantageous over using either therapy alone because both radiation therapy and administration with one or more pharmaceuticals can be limited to achieve effective antiproliferative response with limited toxicity.

In certain embodiments, a physician designs a therapy regimen including both radiation therapy and administration of one or more pharmaceutical compositions provided herein. In certain embodiments, a physician designs a therapy regimen including radiation therapy, administration of one or more pharmaceutical compositions provided herein, and administration of one or more other chemotherapeutic agents.

EXAMPLES

Non-limiting disclosure and incorporation by reference

While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate certain embodiments described herein and are not intended to limit

the same. Each of the references recited in the present application is incorporated herein by reference in its entirety.

Example 1: Phase 1, open-label, study for treating a patient having advanced B cell lymphoma with a STAT3 antisense oligonucleotide

The effect of intravenous infusion of the STAT3 antisense oligonucleotide, ISIS 481464, in patients with advanced B cell lymphomas was studied. Patients with diffuse large B-cell lymphomas (DLBCL) were recruited for this study.

The criteria for patient inclusion with respect to their tumor status was that the tumors should be relapsed or refractory to at least one prior anti-cancer systemic therapy, and/or for which no standard therapy exists; that their disease should be measurable or evaluable, according to RECIST version 1.1 for solid tumors, or according to the International Workshop Response Criteria for Non-Hodgkin's Lymphoma for NHL tumors (Cheson, B.D. et al., J. Clin. Oncol. 1999, 17: 1244; Cheson, B.D. et al., J. Clin. Oncol. 2007, 25(5):579-86), or according to appropriate criteria for other advanced cancers. RECIST (Response Evaluation Criteria in Solid Tumors) is an internationally accepted set of guidelines used in clinical trials for solid tumor disease.

One patient fitting the criteria above is a 63 year old female with DLBCL designated herein as Patient #1001. Prior to commencing therapy, Patient #1001 showed multiple areas of hypermetabolic adenopathy, both above and below the diaphragm, including the supraclavicular, left paratracheal, right internal mammary, pericardial, left intra-mammary, pre-hepatic, retroperitoneal, and mesenteric regions. In addition, the patient suffered from fatigue, nausea, night sweats, shortness of breath on exertion, and peripheral neuropathy. The patient also noted 5-6 days of right-sided abdominal fullness and associated pain. Patient therapy was commenced with a treatment period comprising administration during a first phase of 3 loading doses of ISIS 481464: a 3-hr intravenous infusion of 2 mg/kg ideal body weight of ISIS 481464 administered on days 1, 3, and 5 of cycle 0. The ideal body weight was determined using the Devine formula (Pai, M.P. and Paloucek, F.P. Ann. Pharmacol. 2000. 34: 1066-1069): for men (in kg) = $50 + 2.3 \text{ kg/inch}$ over 5 feet; for women (in kg) = $45.5 + 2.3 \text{ kg/inch}$ over 5 feet. Treatment was then continued in a second phase by once-weekly administrations (Cycle 1 and beyond) of 2 mg/kg ideal body weight of ISIS 481464 until disease progression, unacceptable toxicity,

or patient discontinuation for any other reason occurred. Disease assessments were performed at the end of even cycles.

Tumor lesions were evaluated on each even-numbered cycle, starting with Cycle 2, day 15, by positron emission tomography (PET) scan. According to RECIST guidelines, a complete tumor response is achieved when all target lesions have disappeared. Partial response is achieved when the sum of the diameters of all tumor lesions is reduced at least 30% compared to the sum of the tumor lesion diameters at pre-dose. The sum of the lesion diameters, if any, was calculated, per RECIST guidelines (Eisenhauer, E.A. et al., Eur. J. Cancer 45: 228-247, 2009).

After 28 days of treatment with ISIS 481464, the patient reported reduced fatigue and night sweats, and was tolerating the treatment well.

After 49 days of treatment with ISIS 481464, a PET scan was performed and revealed a 55% reduction in tumor size. Tumors were reduced in all compartments, but most notably, in the supraclavicular, paratracheal, pericardial, and mesenteric regions.

After 91 days of treatment with ISIS 481464, Patient #1001 had a second PET scan and the partial response observed in the first scan was found to be maintained at a 55% reduction in tumor size.

After 133 days of treatment with ISIS 481464, Patient #1001 had a third PET scan and the partial response was found to be maintained at a 55% reduction in tumor size.

After 162 days of treatment with ISIS 481464, further treatment was paused for a month during which Patient #1001 had a fourth PET scan, and the partial response was maintained at a 55% reduction in tumor size. Patient #1001 is scheduled for further scans.

Example 2: Phase 1, open-label, study for treating a patient having advanced/metastatic hepatocellular carcinoma with a STAT3 antisense oligonucleotide

The effect of intravenous infusion of the STAT3 antisense oligonucleotide, ISIS 481464, in patients with advanced/metastatic hepatocellular carcinoma is being studied in an on-going clinical trial.

In the study described in this protocol, AZD9150 will be administered to patients with advanced/metastatic hepatocellular carcinoma at a starting dose of 1 mg/kg

"Bicyclic nucleoside" (also BNA) means a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4'-carbon and the 2'-carbon of the sugar ring.

- 5 "Cap structure" or "terminal cap moiety" means chemical modifications, which have been incorporated at either terminus of an antisense compound.

"cEt" or "constrained ethyl" means a bicyclic nucleoside having a sugar moiety comprising a bridge connecting the 4'-carbon and the 2'-carbon, wherein the bridge has the formula: 4'-CH(CH₃)-O-2'.

- 10 "Constrained ethyl nucleoside" (also cEt nucleoside) means a nucleoside comprising a bicyclic sugar moiety comprising a 4'-CH(CH₃)-O-2' bridge.

- "Chemically distinct region" refers to a region of an antisense compound that is in some way chemically different than another region of the same antisense compound. For example, a region having 2'-O-methoxyethyl nucleotides is chemically distinct from a
15 region having nucleotides without 2'-O-methoxyethyl modifications.

"Chimeric antisense compound" means an antisense compound that has at least two chemically distinct regions.

- "Co-administration" means administration of two or more pharmaceutical agents to an individual. The two or more pharmaceutical agents may be in a single pharmaceutical
20 composition, or may be in separate pharmaceutical compositions. Each of the two or more pharmaceutical agents may be administered through the same or different routes of administration. Co-administration encompasses parallel or sequential administration.

"Complementarity" means the capacity for pairing between nucleobases of a first nucleic acid and a second nucleic acid.

- 25 "Contiguous nucleobases" means nucleobases immediately adjacent to each other.

"Diluent" means an ingredient in a composition that lacks pharmacological activity, but is pharmaceutically necessary or desirable. For example, the diluent in an injected composition may be a liquid, e.g. saline solution.

- "Dose" means a specified quantity of a pharmaceutical agent provided in a single
30 administration, or in a specified time period. In certain embodiments, a dose may be administered in one, two, or more boluses, tablets, or injections. For example, in certain

intravenously 3x during week 1 followed by 1x weekly and dose intensity will be escalated or de-escalated in subsequent cohorts through modification of unit dose administered and/or interval of administration to determine a maximum tolerated dose and recommended phase II dose in patients with advanced/metastatic hepatocellular carcinoma (HCC).

5 Following the dose escalation phase of the study additional patients will be enrolled to a dose expansion phase to explore further the safety, tolerability, pharmacokinetics and biological activity at selected dose(s)/schedules. Patients included in the study are relapsed, refractory, intolerant or unlikely to benefit from first-line systemic therapy (sorafenib).

10 To date, the 1 mg/kg and 1.5 mg/kg cohorts have completed. From the 1 mg/kg cohort 4 patients remain on study with stable disease in excess of 3 months. Stable disease has also been seen in 1.5 mg/kg cohort. These patients and future patients will be monitored further for clinical activity as the trial progresses.

200159 PCT SEQ.txt

SEQUENCE LISTING

<110> ISIS Pharmaceuticals Inc.

<120> CANCER TREATMENT

<130> BIOL0216US.L2

<160> 129

<170> FastSEQ for windows Version 4.0

<210> 1

<211> 4978

<212> DNA

<213> Homo sapiens

<400> 1

ggtttccgga	gctgcggcgg	cgagactg	gagggggagc	cgggggttcc	gacgtcgag	60
ccgagggaa	aagccccaac	cgatcctg	acaggcacc	cggcttggcg	ctgtctctcc	120
ccctcggctc	ggagaggccc	ttcggcctga	gggagcctcg	ccgcccgctc	ccggcacacg	180
cgcagccccg	gcctctcggc	ctctgccgga	gaaacagttg	ggaccctga	ttttagcagg	240
atggcccaat	gaagaatcaa	acagcagctt	gacacacggg	acctggagca	gctccatcag	300
ctctacagt	acagcttccc	aatggagctg	cggcagtttc	tggcccttg	gattgagagt	360
caagattggg	catatgcggc	cagcaaagaa	tcacatgcc	ctttggtgtt	tcataatctc	420
ctgggagaga	ttgaccagca	gtatagccgc	ttcctgcaag	agtcgaatgt	tctctatcag	480
cacaatctac	gaagaatcaa	gcagtttctt	cagagcaggt	atcttgagaa	gccaatggag	540
attgcccggg	ttgtggcccc	gtgcctgtgg	gaagaatcac	gccttctaca	gactgcagcc	600
actgcccggc	agcaaggggg	ccaggccaac	cacccacag	cagccgtggg	gacggagaag	660
cagcagatgc	tggagcagca	ccttcaggat	gtccggaaga	gagtcgagga	tctagaacag	720
aaaatgaaag	tggtagagaa	tctccaggat	gactttgatt	tcaactataa	aaccctcaag	780
agtcaaggag	acatgcaaga	tctgaatgga	aacaaccagt	cagtgaccag	gcagaagatg	840
cagcagctgg	aacagatgct	cactgcgctg	gaccagatgc	ggagaagcat	cgtgagttag	900
ctggcggggc	ttttgtcagc	gatggagtac	gtgcagaaaa	ctctcacgga	cgaggagctg	960
gctgactgga	agaggcgcca	acagattgcc	tgacttggag	gcccggccaa	catctgcca	1020
gatcggctag	aaaactggat	aacgtcatta	gcagaatctc	aacttcagac	ccgtcaacaa	1080
attaagaaac	tggaggagtt	gcagcaaaaa	gtttcctaca	aaggggaccc	cattgtacag	1140
caccggccga	tgctggagga	gagaatcgtg	gagctgttta	gaaactta	gaaaagtgcc	1200
tttgtggtgg	ctgcagccc	atgcattcctg	tgacttggag	accggccctc	cgcatcaag	1260
accggcgtcc	agttcactac	ttaaagtcagg	ttgctggtca	aattccctga	gttgaattat	1320
cagcttaaaa	ttaaagtgtg	cattgacaaa	gactctgggg	acgttcagac	tctcagagga	1380
tcccggaaat	ttaacattct	gggcacaaac	acaaaagtga	tgaacatgga	agaatccaac	1440
aacggcagcc	cctctgcaga	attcaaacac	tgaccctga	gggagcagag	atgtgggaat	1500
gggggcccag	ccaattgtga	tgcttccctg	attgtgactg	aggagctgca	cctgatcacc	1560
tttgagaccg	aggtgtatca	ccaaggcctc	aagattgacc	tagagaccca	ctccttgcca	1620
gttgtggtga	tctccaacat	ctgtcagatg	cctaatgcct	gggcttccat	cctgtggtac	1680
aacattgctg	ccaacaatcc	caagaatgta	aactttttta	ccaagccccc	aattggaacc	1740
tgggatcaag	tggccgaggt	cctgagctgg	cagttctcct	ccaccaccaa	gagaggactg	1800
agcatcgagc	agctgactac	actggcagag	aaactcttgg	gacctggtgt	gaattattca	1860
gggtgtcaga	tcacatgggc	ttaaattttgc	aaagaaaaca	tggctggcaa	gggcttctcc	1920
ttctgggtct	ggctggacaa	tatcattgac	cttgtgaaaa	agtacatcct	ggcccttggg	1980
aacgaagggt	acatcatggg	ctttatcagt	aaggagcggg	agcgggccat	cttgagcact	2040
aagcctccag	gcaccttctt	gctaagattc	agtgaagca	gcaaagaagg	aggcgtcact	2100
ttcacttggg	tggagaagga	catcagcggg	aagaccaga	tccagtccgt	ggaaccatac	2160
acaaagcagc	agctgaacaa	catgtcattt	gtgaaatca	tcatgggcta	taagatcatg	2220
gatgtacc	atatcctggt	gtctccactg	gtctatctct	atcctgacat	tccaaggag	2280
gaggcattcg	gaaagtattg	tcggccagag	agccaggagc	atcctgaagc	tgaccagggt	2340
agcgctgccc	catacctgaa	gaccaagttt	atctgtgtga	caccaacgac	ctgcagcaat	2400
accattgacc	tgccgatgtc	ccccgcact	ttagattcat	tgatgcagtt	tgaaaataat	2460
ggtgaagggt	tgaaaccctc	agcaggaggg	cagtttgagt	ccctcacctt	tgacatggag	2520
ttgacctcgg	agtgcgttac	ctccccatg	tgaggagctg	agaacggaag	ctgcagaaag	2580
atacgactga	ggcgcctacc	tgattcttgc	caccctcac	acagccaaac	cccagatcat	2640
ctgaactac	taacttttgg	gttccagatt	ttttttaatc	tcctacttct	gctatctttg	2700
agcaatctgg	gcacttttta	aaatagagaa	atgagtgaat	gtgggtgatc	tgcttttatc	2760
taaagtcaaa	taaggatgtg	ttctctgaga	cccatgatca	ggggatgtgg	cggggggtgg	2820
ctagagggag	aaaaaggaaa	tgtcttgtgt	tgttttgttc	ccctgccctc	ctttctcagc	2880
agctttttgt	tattgtttgt	gttgttctta	gacaagtgcc	tcctggtgac	tgccgcatcc	2940

INTELLECTUAL PROPERTY OFFICE
RECEIVED

2018 JUL -5 PM 12:13

10018 10:52 00371

200159 PCT SEQ.txt

ttctgcctgt	ttctgtaagc	aaatgccaca	ggccacctat	agctacatac	tcctggcatt	3000
gcacttttta	accttgctga	catccaaata	gaagatagga	ctatctaagc	cctaggtttc	3060
tttttaaat	aagaaataat	aacaattaaa	gggcaaaaa	cactgtatca	gcatagcctt	3120
tctgtattta	agaaacttaa	gcagccgggc	atggtggctc	acgcctgtaa	tcccagcact	3180
ttgggaggcc	gagggcgatc	ataaggctcag	gagatcaaga	ccatcctggc	taacacgggtg	3240
aaaccccgtc	tctactaaaa	gtacaaaaaa	ttagctgggt	gtggtgggtg	gcgcctgtag	3300
ttccagctac	tggggaggct	gaggcaggag	aatcgcttga	acctgagagg	cggagggtgc	3360
agtgaagcaa	aattgcacca	ctgcacactg	cactccatcc	tgggcgacag	tctgagactc	3420
tgtctcaaaa	aaaaaaaaaa	aaaaaagaaa	cttcagttaa	cagcctcctt	ggtgctttaa	3480
gcattcagct	tccttcaggc	tggtaattta	tataatccct	gaaacgggct	tcaggtaaaa	3540
cccttaagac	atctgaagct	gcaacctggc	ctttggtggt	gaaataggaa	ggtttaagga	3600
gaatctaagc	atttttagact	tttttttata	aatagactta	ttttcctttg	taatgtattg	3660
gccttttagt	gagtaaggct	gggcagaggg	tgcttacaac	cttgactccc	tttctcctcg	3720
gacttgatct	gctgtttcag	aggctagggt	gtttctgtgg	gtgccttatc	agggtgggga	3780
tacttctgat	tctggcttcc	ttcctgcccc	acctccccga	ccccagctcc	cctgatcctg	3840
ctagaggcat	gtctccttgc	gtgtctaaag	gtccctcatc	ctggttgttt	taggaatcct	3900
ggtcttcagg	cctcatggaa	gaagaggggg	agagagttac	aggttggaca	tgatgcacac	3960
tatggggccc	cagcgacgtg	tctggttgag	ctcagggaat	atggttctta	gccagtttct	4020
tggtgatata	cagtggcact	tgtaatggcg	tcttcattca	gttcatgcag	ggcaaaggct	4080
tactgataaa	cttgagtctg	ccctcgtagt	aggggtgata	cctggcctcc	ctctgaggct	4140
ggtgctcctt	gctgctggg	gccccacagg	tgaggcagaa	cagctagagg	gcctccccgc	4200
ctgccccgct	tggttggtg	gctcgctctt	cctgtgcgta	tggaacacc	tagcacgtgc	4260
tggttggtg	gcctctgact	cagaggcatg	gccggatttg	gcaactcaaa	accaccttgc	4320
ctcagctgat	cagagtttct	gtggaattct	gtttgttaaa	tcaaattagc	tggtctctga	4380
attaaggggg	agacgttcta	ctctaagatg	aacagggttc	gccccagctc	tcctgctctg	4440
agacagttga	tggtgcatgc	agagctctta	cttctccagc	aacactcttc	agtacataat	4500
aagcttaact	gataaacaga	atatttagaa	aggtgagact	tggtcttacc	attgggttta	4560
aatcataggg	acctagggcg	aggggttcagg	gcttctctgg	agcagatatt	gtcaagttca	4620
tggtccttag	tagcatgtat	ctggtcttaa	ctctgattgt	agcaaaagtt	ctgagaggag	4680
ctgagccctg	ttgtggccca	ttaaagaaca	gggtcctcag	gccccgccc	cttctctgct	4740
actgccccct	ccccatcccc	agcccagccg	agggaaatccc	gtgggttgct	tacctaccta	4800
taaggtgggt	tataagctgc	tgtcctggcc	actgcattca	aattccaatg	tgtacttcat	4860
agtgtaaaaa	tttatattat	tgtgagggtt	tttgtctttt	tttttttttt	tttttttttg	4920
tatatgtctg	tatctacttt	aacttccaga	aataaacggt	atataggaa	cgtaaaaa	4978

<210> 2
 <211> 79001
 <212> DNA
 <213> Homo sapiens

<400> 2						
ataaaaaatta	aaaaccctga	tagtatcagc	acatacacag	aaatcactcc	attatgcaaa	60
gttcatcctc	tattatgaaa	ggcaaatgt	ctacatttcc	tatcaaccac	tggttcaat	120
tcagtaaaac	ttgcatacca	agtaggcaag	gtggaaga	aaaaggcaga	acatttcattg	180
tattttcaatt	cagacgcata	aaaaatgtcaa	gccctacacg	ttatcagctt	tcgtatacac	240
cggtattctgc	attcgcctgt	acgggccaat	gggctagctg	gtcggcggtt	gatgcttgaa	300
gtgatggaac	ggagtagcgg	gttaaatcca	ctaccctctc	cccacgcact	ctagtaatta	360
ctctatttcc	acgtcatgtt	tccgggtgtg	tgtgtccctg	ctcacgcaga	aactgaagtt	420
caaaagcaggc	ggagtcaccc	atgttctttt	tgtgtccccc	agaacccaat	tcaggagtgt	480
ggtccccaga	ggatctggag	atacctgggg	actatctaac	tagctgattc	ccgcgtggtg	540
agaggctctc	aaacctcgcca	ccacgtgggtg	ccaagggccg	ggaaaaggga	gagcgggcag	600
gagggagctg	tatcaggggc	atttaaagtg	ccttgacgtc	acgcactgcc	aggaactcag	660
ctgagttttc	agcaggacat	tccggtcatc	ttccctccct	ccccccgggc	ttctgtgccc	720
aagtccctcg	ctcttccctc	gctgtggcgg	agggaggagc	accgaactgt	cggaaacagcc	780
agcacagggg	cgtatcagtc	tcctcttggc	tccgcctttt	ctcctagctg	ctctcctcat	840
tggtcagtg	gcggggcttc	ggctgtaccg	cacacgcact	gggacctctg	ggtggccgaa	900
cgagctggcc	tttcatgaat	tatgcatgac	ggcgtgcctc	ggccaggctg	gggctgggcg	960
aggattggct	gaaggggctg	taattcagcg	gtttccggag	ctgcggcggc	gcagactggg	1020
agggggagcc	gggggttccg	acgtcgacgc	cgagggaaca	agccccaacc	ggatcctgga	1080
caggcacccc	ggcttggcgc	tgtctctccc	cctcggtcgc	gagaggccct	tcggcctgag	1140
ggagcctcgc	cgcccgctcc	cggcacacgc	gcagccccgc	cctctcggcc	tctgcccggag	1200
aaacaggtga	agggggtgca	gggtggggcc	gttggggagg	cctggggacc	cgggggctcc	1260
gcagcggcag	ggggcctctg	ggacctggg	gatgttgtga	tggaagctgc	agtggggccg	1320
ggagagatga	agagacgcgg	agggtcgccc	tgagggaaga	ctcttcggga	tgacaggagc	1380
gggcctcgga	agggactcgg	ggcgtggag	ggaagtctcg	ttcttcggag	aaacagaacg	1440
cgctcgaggg	ggcaccgtgg	ggcgagggcg	cactcggttg	cggcggcagg	agtgaaggac	1500
agtccccgca	tttctgtctc	cctggggccc	tggggacgtt	ccggccaccg	gagcagactgt	1560
cacgcccagc	gggatcaccg	gcgcgagtg	ggggtcgga	agcgctcct	ccccgcccg	1620

200159 PCT SEQ.txt

tcggcggtctc	ccgctgagcc	acttcctccg	cttgccctgt	tcccgtcctc	tcaggagaca	1680
gctgtgcctc	tttggaggca	ggaataggtg	tgtctgtcgc	ctgcagcctt	acgggctggc	1740
tggctcgtggg	taggctttat	tgcataagaa	tcaagtttcc	tgtagggaaa	ttgacagacc	1800
ggtagctttt	ctaaattccc	tcgcatcttt	ttctaggtta	aattatgctc	ccccacgctc	1860
cccgctttgt	aaaaaagaga	aaaaaagaca	aaataaaatc	cccatcaacc	cgtaagacca	1920
gctctagaga	gagaaataaa	cctcttgaca	ttgtcctttt	ccaaatacct	ggtaaagtcg	1980
gccagaagat	aaataattga	gccattgcat	ttactggatt	gtggtgttgc	ttaattgcat	2040
aggacggaat	gaaccaattg	agagtgggag	ttttctgtct	cagagccaag	atcttgggta	2100
aatgcagagg	agaggggaaac	aaagacaggc	tggccttgaa	aaaaccatgt	gtgcaaacct	2160
tacatgcatt	tggggggtgt	ggttgcactg	aagttaacaa	gattcaaacc	gtcgcccaag	2220
ttgggtatttc	catgttttgg	acacatcact	ctgtgccata	tcaggtcggt	gttaagtgtg	2280
gtgacaaaat	cagtggtttag	tcattttttt	aattaaaaat	gtgtatagt	tgtacctgct	2340
ggcttacttg	tatgtgcaac	taaagggtta	catagtctgt	gtatgggttg	taaatttttg	2400
gctggctgtg	ctgataaagc	attgggcttg	aataaagcaa	agcagaaaat	catctcaatc	2460
ttttatatgt	ggatttagac	tgtgttatga	cttgggttcag	ccagttttct	atcttatttt	2520
atattaaata	tgtctgtggt	ctctgagtca	gcacatttat	ttccttatta	catgttccag	2580
cagggaattg	tagcccaggt	ttgttcagt	cttcacagtg	ggatggggaa	acaagtctgg	2640
aatttaaaaa	aaaatgtttt	agaggttgga	gccttgattt	tagtctctat	attagcacat	2700
ccatcacaaa	gaaccattag	taaattcatg	aatcttttgt	tttttatgta	gttcatattga	2760
gaagaataat	cacttagaaa	tatccacagt	gccaggcatg	gtggtgcaca	cctctgatcc	2820
caggaatgtg	aaggctgagg	tgggaggatt	ccttgagctc	aggagtgtag	tctgggtctg	2880
gcaacatggt	gagaggccag	gaattgggtc	tagagtctag	tctaagcacc	ataatgagaa	2940
cccatcttta	agaaagaaag	aaaggaaagg	aggaagaaag	gaaagaaaaa	gaaataccca	3000
cagcacagtt	atgaattaac	ccacaaagga	cttgtgaggt	gggtagttca	cataacaatt	3060
accctaattg	cgtagataag	aaaattgagg	ccaaaggatc	aagacacttg	gccaacgcag	3120
cagagtgcga	tagtgggtga	atttgtgcct	ccttctgtat	attttgtgaa	aagtatcagt	3180
gaaattcttt	tttttttttt	ttttgagtca	gagcttgcct	ctgttgccca	ggctagagtg	3240
cagtggcgca	atcttggctc	actgcaacct	ctgcctcctg	ggttcaagcg	attctcctgc	3300
ctcagcctcc	caagtagctg	ggactacagg	cgtgcgccac	cacgcccagc	taatttttgg	3360
tttttttagta	gagacggggg	ttttaccata	tgtgccaggc	tggctctgaa	ctcctgacct	3420
tgtgatttgc	ccacctctat	ctcccaaagt	gctgggatta	caggtgtgag	ccaccgcgcc	3480
cagtaagtta	cagtgaattt	ctaaccatata	tctgaacagt	aaaataccac	caataggctg	3540
aaagacttca	tgggaggtaa	atattcaata	aacagggtgaa	aaaagaaata	caaatggagc	3600
ttgcttagat	tatttttcta	attgctatgt	ctaacttggg	aagttaggaa	ctgttttttg	3660
tcagcataat	ttaccatcag	aatttagcta	tttactaatg	aaaagaaata	ctaattctagg	3720
tttgtttttag	attaaggaca	gtcatgacct	aaatgtcatt	ttaaccagag	tgcattgtgg	3780
cttgatcagt	ggtcattttc	gtctctagaa	agttgcttta	acttctctgc	ctctacgtgt	3840
ctcttgacct	tcagatttct	ggtggggtag	aggtgggtgac	caactttcca	gacgctgag	3900
tccaaacctt	cttagcttat	ggtttttcta	ggtgatgtgc	aaatcaacaa	atatatactt	3960
tttttttttt	ttttttgagt	tggagttgca	ctctatcacc	caggctggag	tgcagtggca	4020
tgatcgtggc	tcactgcaac	ctcctctccc	cgggttcaag	tgattctcgc	acctcagcct	4080
cctgagatag	tgggattaca	ggtgcccgcg	actacgcccg	gctaattttt	gtatttttag	4140
tagagataag	gtttcactat	attgaccagg	ctgggtctcaa	actcctgacc	tcaagagatc	4200
tgcccacctc	agcctcccaa	agtgtctgga	ttacaggcgt	gaaccacctt	gcctggccaa	4260
catatatata	ccttttgcaa	ctttgtcaga	gttgctatga	agaataagtt	gtatcttgtt	4320
cacagataat	gcagcttact	gggggagctg	ataaatgttt	taaccatcca	atgtaacatg	4380
ttgtcatcaa	agagatgggt	agactttaca	cttgtgctaa	caaggtagct	gttctacata	4440
aaagaacata	cagtacagat	gtagaacttt	tctgttatca	tagaacgttc	tattggacag	4500
tgttaggctg	aatgctacag	atcttcagag	aaaggagagg	ttatgaggcc	tggagttgtc	4560
tagaaaagtct	ttttgccaaa	gagggatttc	aactgggtcc	caaataatgg	gtggaatttg	4620
ataggtgtaa	agaatttgcg	gtgggtttatg	cctgtaatcc	cagcactttg	ggaggctgag	4680
gcaggaggat	tgtctgagcc	caggagtttg	agaccagctt	gggcaacgtg	gtaaaaactc	4740
ctctccccta	aaaataaaaa	aaattagcca	ggcctgggtg	cgtggacctg	tagtcccagc	4800
tactggtgag	actaagggtg	gaggatcacc	caagccccgg	gggttaaggc	tgcagtgagc	4860
cgtgatcccc	ccaccgcact	ccagcctggg	tgacagagtg	agaccctgtc	tccaaaaaaa	4920
aaaaaaattc	ctggtagccc	ggtagactag	gagggtaagt	aggggagaag	tgattactta	4980
caaaagacat	tgaatacagg	accaaggaat	ttcagttctg	ttcttttgta	ggggaagctt	5040
ttaaaacttt	cggggcgccg	ggcgcggtg	ctcacgcctg	taatcccagc	actttgggag	5100
gcccagacgc	gcggatcacg	aggccaggag	atcgagacca	tcctggctaa	cacggtgaaa	5160
ccccatctct	actaaaaata	caaaaaaaag	tagccgggcg	ttgtggcggg	cgtctgtagt	5220
cccagctact	cgggaggctg	aggcaggaga	agagcgtgaa	ctcgggaggc	ggagcttgca	5280
gtgagccgat	atcgaccac	tgcactccag	cctgggcgac	agagcgagac	tccgtctcaa	5340
aaaaaaaaaa	aataaataaa	taaaataata	caataaaactt	tggagccgaa	gcactgtatg	5400
ttaatcatag	agtgttact	atgtgttagg	cacaggcctg	attgcctgat	gctgggtaat	5460
ttgtacaaag	taaatcagtg	catatgccct	ctgccctagg	ggagttatta	actggagtct	5520
gacattgtac	aaaggtaggt	atcctgacta	gtttgatttg	gtactttggg	tgaaaaaagt	5580
atagtgtgct	taagtgcaga	agtgtttttt	gaggattttt	gattggatac	aaaccaccac	5640
tcataattta	tgtctttggc	acttaaaaaat	ttcaccataa	cttttgagtc	atttataaaa	5700

200159 PCT SEQ.txt

accactgaaa	gagtacttga	gggacatccc	cgaatcctga	agaacttctg	gtgttctgga	5760
gcagcctcag	tgagatccag	gaggatggca	ttgctgggct	ggcccagccc	ttattgatta	5820
tggtgtaaaag	aattaatatg	gtggttatat	actctttgtt	agacaccttg	gcttacaaga	5880
cgtaagcgta	aagtgtagt	cgcttttagtc	agtatggcca	catggctcctt	tggtggtaaa	5940
ttgtttgaga	tgccctccagt	ttttaaaagg	agtagcatat	cgggccagga	gcagtggctc	6000
atgcctataa	tcccagcact	ttggaaggcc	gaggcaagag	gattgcttga	gcccaggagt	6060
tcaagaccag	cctgggcaac	atagtgaagc	cactttgttt	ctttaaaaaa	aaaaaaaagg	6120
caaaaacagg	ctgggcctgg	tggctgatgc	ctgtaatccc	agcgctttgt	gaggcagagg	6180
tgagcggatc	acttgaggct	aggagtttga	gaccagcctg	gccaacatgg	taaaaccccc	6240
tctctactaa	aaatacaaaa	attagccagg	tgtgggtggca	cacgcctgta	gttccagcta	6300
ctctggaggc	tgagccagga	gaattgcttg	aacctgggag	gtggaggctg	cagtgcagca	6360
agatcctgcc	actgcactcc	agactggggg	acagagtga	acattctgac	agtgcctacac	6420
tgaatgctac	atgtcttcag	aggaaggaga	ggttatgagg	cctgggaata	acatatggaa	6480
gaatgaat	ctgttatggt	cagttctcat	ttgtcatggt	aggattactg	caactcttac	6540
ccagccgggt	gtgggtggctc	atgcctgtaa	ttccagcact	ttggggaggct	gtgggcggat	6600
cagagggtca	gggagctcag	accatcctgg	ctaaccgggt	gaaactccgc	ctctactaaa	6660
aatacaaaaa	attagcccag	cggtgtggca	gacgcctgta	gtcccagcta	ctcaggaggc	6720
tgaggcagga	gaatggcatg	agtccctggag	gcggagcttg	cagtgcagctg	agatcgtgcc	6780
actgcactcc	agcctgggca	acagagtggg	actccatctc	aaaaaaaaaa	gaaaaaaaag	6840
aggattaccg	caactcttta	attcagatca	gcaaacatgt	tgagagccag	gtattgcgtc	6900
aggcaggatc	caaggataat	gaaatattgt	ccgttttcat	gaaactggag	atgttgcagg	6960
gaccgcagg	tgtgtcatgc	cagtatggaa	gtaggacagg	ggagacgaca	gggcagtgag	7020
tggttcaagt	ctctggctct	gaagtcaaac	agatctggga	ctgaatcctg	gatctgccac	7080
ttcctagtca	gaatcttgagc	ctctattttc	ttatctgtaa	aagaagatta	taacagtgtc	7140
tatctttag	gtactgttga	cgattcaata	agataatgtg	gataaaatgc	ttagcatagt	7200
gcctggcaca	tagtaagagc	tcggtaaatc	taagttctta	ctaaatatcc	aagaaaagag	7260
accaattctt	ttcaggagtg	agagaaagtc	atcattattg	aggggcttta	tcagatggga	7320
atcattgaat	agggttttat	aggatgaata	ggaattcttt	ccacgaagtt	gcgttacaaa	7380
aagttgcatt	caaggctgaa	ggaacatgag	ggtgcagagg	cttaaaacag	ccttgtgtgt	7440
tcaggggagct	ataagtagaa	gttccttaatt	tagggagaact	aaaccaaggg	gaaaggaggc	7500
caagggaacca	cagttcttat	cccttttctg	ttaataattg	ggtttaaatg	tcattaaaaa	7560
aagttatttt	gtccttttta	gaaaagtaat	aacatgctat	tataaaaaaa	aagacttgta	7620
ggaatataaa	atgtgtgttt	tacatgtatc	ctgttaattg	acttgctttt	attcagattt	7680
tttgagcccc	tttctgttta	ccagggttatc	ttggagacat	atttattcca	aattcctttt	7740
tttttttttt	tttgagatgg	agtctcgctc	tgctgcccag	gctggagtgc	agtggcgcta	7800
tcttggtcca	ttgcaagctc	cgcttcccgg	ctctcacgca	ctctcctgcc	tcagcctccc	7860
gagtagctgg	gactacaggc	gcccggcacc	acgcccagct	aatgtttttt	tttttatatt	7920
tttagtagcg	acagggtttc	accgtgttag	ccaggatggt	ctcaatctcc	tcacattgtg	7980
atccgcccgtc	ctcggccttc	caaagtgtg	ggattacagg	cgtaggccag	cacgcctggc	8040
cttccaaatt	ccttttaaca	gcctagcaaa	agaataataa	ggaaggtaaa	ctcgccctta	8100
caagaaaata	atgcttcgac	gatccggctt	tccttctctg	tacccccagc	cataagaata	8160
aatgaccttg	ctcatcactg	aaattttacc	tgacctttga	atttttaact	gcgtcagcca	8220
agaactttat	atttttagta	ttcctaagg	gattgtctat	gtagttttga	aacacttggt	8280
tggtatgttt	gaggggttca	tggtccaaag	ttactatagc	agttaaaaga	gtggactatc	8340
aggtcagacc	tattgggctt	taatcccagt	tctgccttct	cttagacctt	gggcctgttg	8400
ttttcacttc	tctggttttc	agtttctctg	tccacaattg	tggaacagag	gtccacttgt	8460
agagtaattg	agaggatgaa	gcaagatgat	gcatatcaag	tactttgcat	agtgcggggc	8520
agacaggtaa	cattcaagtg	ctaataatta	ctattattac	tatttatttt	ttgagacagg	8580
ttctcactct	gtcacctagg	ctggagtgc	gcggtgagat	cacagctcat	gacagccttg	8640
acctcctagg	ctcaagtgat	cctcctgcct	cagccttcgg	ggtagctggg	gctacagggtg	8700
tgtgtctacca	ccctcagcta	attttcta	ttttttgagt	caggatctcg	tcacgttgcc	8760
taggctgaat	tactcttatt	aaaaactata	atatcaggcc	gagtgcggtg	gctcacgcct	8820
gtaatcccg	cactttggga	ggccaaggcg	ggtggatcac	ctgaggctcag	gagttcaaga	8880
ccagcctgcc	caacagagtg	agaccccccc	cgctcttact	aaaaatataa	aaattagcca	8940
gttggtggtg	tgggcacctg	taatcccagc	tactcgggag	gctgaggcag	gataatcgct	9000
tgaacccggg	aggcggagg	tgcggtgaac	cgagatcggtg	ccactgcact	acagcctggg	9060
tgacagagtg	agactctgtc	tcaaaaaaac	cgaaaaacaa	aaagcataat	tagggtggta	9120
acgcttatac	ataggggcag	gtggaataaa	acataattag	gaggtcgggc	atggtggctc	9180
acgcctgtaa	ttccagcact	ttgggaggcc	gaggcgggtc	aggagtcaa	gaccagcctg	9240
cccaacatag	tgagaccccg	tctctactaa	aaatataaaa	tttagcctgt	tgtgggtggc	9300
ggtgcctgta	gtcccagcta	cccgggaggc	tgaggcagga	gaattgcttt	tgaacccagg	9360
agggtgggggt	tgagatcgag	tgagatcgcg	ccgctgcact	ccagcctggg	agacagagca	9420
agactccgtc	acaaaaacaa	aaaacaaaaa	actgtcatat	caaaaactaa	actaaaatgg	9480
taatatctgt	tagatattac	aaagttaggc	aaattatgat	tcatggcagc	cactaatgac	9540
caaaggaga	gaaagaataa	ttagcagatt	ctaaccataa	gggaaaaaaa	ctaaatgaat	9600
agggatgggg	gacttacatt	ctgttagagg	aaattgaggc	tgcatataaa	aagggaatagg	9660
taaggcaaac	tgtaaattcc	tgtttacaca	aatgcccttc	tgataaatct	ctgcattgcc	9720
cacagtcct	gattacctct	cccttatttt	aagtaatat	taacacatta	aaaatggatt	9780

embodiments where subcutaneous administration is desired, the desired dose requires a volume not easily accommodated by a single injection, therefore, two or more injections may be used to achieve the desired dose. In certain embodiments, the pharmaceutical agent is administered by infusion over an extended period of time or continuously. Doses may be stated as the amount of pharmaceutical agent per hour, day, week, or month. In certain embodiments, single dose means administration of one dose, and only one dose, to a subject.

"Dosage unit" means a form in which a pharmaceutical agent is provided. In certain embodiments, a dosage unit is a vial containing lyophilized ISIS 481464. In certain embodiments, a dosage unit is a vial containing reconstituted ISIS 481464.

"Dosing regimen" is a combination of doses designed to achieve one or more desired effects. In certain embodiments, a dose regimen is designed to provide a therapeutic effect quickly.

"Duration" means the period of time during which an activity or event continues. For example, the duration of a loading phase is the period of time during which loading doses are administered. For example, the duration of the maintenance phase is the period of time during which maintenance doses are administered.

"Effective amount" means the amount of active pharmaceutical agent sufficient to effectuate a desired physiological outcome in an individual in need of the agent. The effective amount may vary among individuals depending on the health and physical condition of the individual to be treated, the taxonomic group of the individuals to be treated, the formulation of the composition, assessment of the individual's medical condition, and other relevant factors.

"First phase" means a dosing phase during which administration is initiated and steady state concentrations of pharmaceutical agents can be, but is not necessarily, achieved in a target tissue. "Second phase" means a dosing phase after the "first phase." In certain embodiments, the dose or total weekly dose of the first phase and the second phase are different.

"Fully complementary" or "100% complementary" means each nucleobase of a first nucleic acid has a complementary nucleobase in a second nucleic acid. In certain embodiments, a first nucleic acid is an antisense compound and a target nucleic acid is a second nucleic acid.

200159 PCT SEQ.txt

```

accaccaag gaattgctcc cgaccagaa agtgcaggta gtgttgaagg tttgagggga 9840
agaggaatga ttagagttgg ttgtgtctca ggaagaagcc aacaggagga accttatttt 9900
gagtcaggta aagaaggtgg gtagtgaggag gcatcccggt ggccagggtat gaagctggga 9960
gctgattgct gcacattact cagctgaatt aaatgtgccc tcacatctgt gtgtgtgcgt 10020
acatgcaaat gtacatgtgt atgagttagt tggaggggta gacctttatt ttcctgtcct 10080
gtaactttcc ttgcaaact ctctcaccct atctccccc gtatgcgggg caggaagaag 10140
gcttgctccat gaaacaggtt tttcctggcc gtatgcgggg caggaagaag 10200
aaaaggcagt gcttttcttt tctgggaaat aaacggcttg gcttccctat tgtggaggag 10260
ttgaaagaga aagtaaacct tctgggaaat aaacggcttg gcttccctat tgtggaggag 10320
gagtgc aaat tattaggggg atgtttgggt agtttttga gaagccattt ctgaaaactg 10380
cctgtttccc gtgaaggtaa gcccatttta ggaaaaccct gccagtgctg gtgtcagcca 10440
tattacaaga gctttgtttg attgatttga tttagttgtg gtattctgag ctctcatttt 10500
taaaatgcat gtttgggaagt ttgagctga acttgagcac ctgtctcggt gaaagcttcc 10560
actttttctg gttttttcac attttttctc atgtttcattt tgttttgctt tttagcaaac 10620
aatgttaact acagaatcca aaagcattag acttttcttg ttttccctgt ctctccccc 10680
aagtgc aatgttagct atgttaatta ctctccctgt aaaccaaaca 10740
aagtgc aatgttagct atgttaatta ctctccctgt aaaccaaaca 10800
gtgtgtttaga cattaataat atttcatctc agactgactt tctcgacaaa tcagttttgc 10860
aatgtgtgtc gtttttcatc gtatgtttag ggaaagcaca ttatttgaa cattaaccaa 10920
aatgtgtgtc gtttttcatc gtatgtttag ggaaagcaca ttatttgaa cattaaccaa 10980
gagaccaagg catgtggatt gcttgaggtc aggagtcaa gaccatcctt gccgacttgg 11040
tgaaatcctg ttttctactg aaatacaaaa aactagctgg gtgtgtgtgac gcgtgcctgt 11100
aatcccagct actctggagg cactgcactc cagcctgggc aacagagact ggaacctggga ggcagaggtt 11160
gcagtgagtc gactgagctg agcataatta ggggtgtaac gcttatacat aggggcaggt 11220
caacaaaaaa aacaaaaaca agcatttctg gagccagaaa taatcaactg attaagaata atctggctgg 11280
ggaataattg aagcatttctg gagccagaaa taatcaactg attaagaata atctggctgg 11340
gtgagggtgg tcacgcctgt aatcccagct actcaggagg ctgaggcagg agaattcgctt 11400
gaacctggga ggtggaggtc gcagtgcgcg cattgcactc cagcctgggc 11460
tatggagcaa gactccatct caaaaaaaa aaaaaaaa atcctgtttc tgcagaaata 11520
tcccaggtgt cctgggtcag cagtgcacca tagattccac ggacgtttac cctaagtttt 11580
ccaatgggag ttcatacctc ataccaggtt gagaatattt tctgagtaat gggaatgaga 11640
ttggagatgt agatccatac agtctttggg ttaaactttt tcctctttgc 11700
ctaggaaaga ttaattgtaa tcttaaccac agattttag taagaatgta tcagttttgt 11760
cattcagttc tagactccag ttttctttat tgtaatacca atattttaga gtaaattttg 11820
aaatgaatca gtacaaaaga tatgtagtaa gtggaaagtt agtccgcacc ttatccttgg 11880
gactcttttc caggggacag tagttaccta ctcttgagtt ctcttgagtt acttcattg 11940
tatgcatgca aacatgttat tctctgggtg ttgttccttc catatatagc agcaaatata 12000
ccaaactctg tattttgctt tttgtcactt tatcttagag aataactcaat gcaaatacat 12060
gtgtatatac cctcagttaa aaaaatctac atagtaaaat tagccaggca tggtagtgtg 12120
tgctgttaac ccagctact cgggaggtcg tgggtggaga atcacttgaa ccctgagatc 12180
acaccactgg actccagcct gggccacaga gcaagattct gtctcaaaaa acaaaaaaca 12240
aaacaaaaaa actacagagt agtattctag gctatgcata tcataaattt gatttcctaa 12300
tgataggcat agatgatttt cctgggcggc aaattagcgt tggctgtgtc tcaggaagaa 12360
gccaacagga ggaacattat tttgagtcag ttcccaaaga cagaacattt gtctgacatt 12420
tgtttttggg cttatatgaa taaatctgta cacatatatt tttaattgtt taatcgtaat 12480
atgtatacta tttggaaatg tggcttttta gttaacagag tgcattgttt accccattgc 12540
acttaaacat taacttgggg ataattaaat gagtctgtca cttggacagg caggaattgt 12600
acccccacaa aaccataaaa cgcgaattt ttttttttg agacagagcc tcattctgtt 12660
gcccaggctg gagtgcagtg gtgcgactct ggcccactgt aagctcagcc tcccggttc 12720
atgccattct cctgcctcag cctccaagt agctgggact acaggcggcc gtcacaatgc 12780
ccggctaatt ttttgtattt ttagtagagt cggggtttca ccatgttagc caggatggtc 12840
tctatctcct gacctgtgga tccgccgtt ttggcctccc aaagtgtgtg aattacagtt 12900
gtgagccacc gcacctggcc ggtttttttt ttttttttg agatggagtc ttgctctgtt 12960
gccaggctgg agtgcaatgg catgatctcc gctcactgca acctccacct cccgggttca 13020
agtgtattct ctgcctcagc ctcttgagta gctgggacta caggcgtgtg ccaccacgca 13080
cagctaattt ttgcaatttt agtagagat gggtttcatt aataatcatt aatattagac 13140
aactgtcaga ctcacagtgg ttgatacaaa ctttctcaaa ttctgatttt tactctaaag 13200
ctcaaatttt atcattggca acaaatattg tcagttgctt tccctgaaca gacagcttcc 13260
cttctttcat ttttgagaaa atatctgcca gtatccaggt tggtttatca atcattcttt 13320
cttctttttt ttttgagacc gagtctcact gtgtcaccca ggctggagtg cagtggcatg 13380
atctcggctc acttgaaact ccacctcca ggtccagca attctcctgc ctcagcctcc 13440
cgagtagctg ggattacagg ggctagcagc cacacctggc taatttttgc attttttagta 13500
gagacagggt tttaccatgt tggccaggct gatcttgaac tcctgacctc atgatatgcc 13560
caccttggcc tcccaaagtg ctgggattac aggtgtgagc cattgcgccc ggctctatta 13620
tttcttttct tttttttttt ttcttttttt tttttgagat ggagtttcgc tctgtgtgcc 13680
caggctggag tgcaatggcg cgatctcgcc tcaccacaac ctccgcctcc cgaattcaag 13740
tgattctctt gcctaagcct cccgagtagc tgggattaca ggcattgtgc accacaccgc 13800
tctagttttg tatttttatt agagatgggg gtttctccat gttggtcagg ctggtctcga 13860

```

200159 PCT SEQ.txt

actcccaacc	tcaggagatc	tgccctgcctc	agcctcccaa	agtactggga	ttacagtttt	13920
gagccacctg	acccgggtttg	cttattatttt	cttttaaat	taaaaaataa	taaataaagg	13980
ggccatgaga	cggaagaggtt	tgagaaaggt	tggtctaaag	gttttaacat	aagaatccct	14040
gggttattttg	cttaaaaaga	agaaagaatc	tatggatctg	cctgagaggg	tctgatgtag	14100
tttatctggg	gtcatcctca	caggcatagc	agatattctg	attcagatgg	tccttggttc	14160
ttagtttgag	aatgtggct	ttacaaggcc	catagaatat	aaagtcttct	ttggattag	14220
gaagtcattgt	ccacaggggt	tagaaaatgt	ttttgtttta	gagataaagg	taagtgggaag	14280
agtagacatg	tagtgaatga	gggaaaatgt	tttagagatt	tctttttatt	ctgtttactc	14340
ttcttggtat	gcacgtacct	gaatattaag	gatattttat	gaagtcatga	cattaccaga	14400
ttaatgttgg	ttttgtttta	agggtactttc	tgactgctgg	ggttaattcc	tacagacgat	14460
tctggtaaaag	aatagcctttt	aagtttttaa	agtgttgact	tatttcagat	gtcttaataa	14520
agttaacttc	cagtattattac	atgtaacgta	tataaagctc	tcattttcct	ttattctcgt	14580
taattgtttg	cataacaaat	tcaaaggga	atttgcttgg	cagagatcag	atagcagaga	14640
tgagatttaa	aaacaggtaa	tttggctact	agcctgggag	tttgaagatt	ccaagttgc	14700
atcctatgta	atgcactta	catttctgtc	cttatctgta	aatgggaata	acacctactt	14760
gatagggttg	ttcatttatc	ttggccacct	caggttctct	ttggctgagt	gattgactgg	14820
aaaacgcaat	gtgaattcat	gcttcagact	gggttctttt	tttttttttt	ttttgagatg	14880
gagtttctact	cttattgccc	aggctggagt	gcaatggcac	gatctcagct	cactgcaacc	14940
tctggctccc	aggttccc	gattctctcg	cctcaggctc	ccgagtacgt	gggattacag	15000
gcatgcacca	ccatgcctgg	ctaatttttt	tgtattttta	gtagagacgg	ggtttctactg	15060
tgttggtcag	actggtttca	aactcctgac	ctcaggtgat	ccacctgctt	cagtctccca	15120
aagtgtctgg	attacaggca	tgagccaccg	caccagccc	aggctagggt	ctatatgggt	15180
gtgctttttta	gaattgtttt	catgggctat	ccccaacaca	aactggataa	tgtttctttc	15240
tagattctct	ctaagcgtgt	attctctttc	tttccctaggc	acagccacca	cttcacttat	15300
attgtgggat	tataatttca	tgagtagtgg	aatttccctt	accttctctt	gtgtgggagc	15360
tgaaggacaa	aatgagatat	tctctgaaga	gtggttacat	catgcaaaac	tatgatgtgt	15420
aatgaggtca	cttagttttt	taagtacatt	atacattttg	ataagatttt	catagaaaag	15480
cttgtctcct	ttggggagatc	actcatcttc	cactttgact	attattttaa	ctttatgggt	15540
cagattttatc	tttttaaaaa	cttaaccata	aagctcaatt	aatttttttt	tttttttttt	15600
gagacggagt	ctcgctctgt	tgccagggt	ggagtgtagt	ggcgcgatct	cggctcactg	15660
caagctctgc	ctcccagggt	catgccattc	tcctgcctca	gcctcctgac	tagatgggag	15720
tacagcgcc	cggcacgatg	cccggctaat	ttttgtatt	tttagtagag	acgggggttc	15780
accgtgttag	gatggctctg	atctcctgac	ctcgtgatcc	acccgcctcg	gcctcccaaa	15840
gtgctgggat	tacaagcgtg	agccaccgcg	cccggctcaa	ttaatatatt	ttaaaaatta	15900
atagacttta	ttatttttat	tttattttat	ttttgaggca	gagtctcgct	ctgtcaccca	15960
ggctgagtgc	agtgggtgta	tcttggtcca	ctgcaaaactc	cacctcccg	gctcaagtga	16020
ttctcctgcc	tcagcctcct	aagtagctag	gattacaggt	gcctgccacc	ataccggct	16080
agtttttgta	atttttagtag	atacgtgttt	tctttctttt	cttttctttt	ttttgagatg	16140
gagtttctact	ctttttgccc	aggctggagt	gcaatggcat	gatctcggt	cactgcaacc	16200
ttcgcctccc	agttttcagg	gattctcctg	cctcagcctc	ccaagtagct	gagattatag	16260
ttgtctgcc	ccacgcctgg	ctaatttttt	gtatgtttga	tagagacagg	gtttcactat	16320
gttagccagg	atgtctcgat	ctcttgacct	cgtagatccg	ctgccttggc	ctcccaaagt	16380
gctgggatta	caggcgtgag	ccactgcggc	cagtctagac	tttatttttt	aaagcagtgt	16440
tagtttttaca	gaaaaattat	gtggaaagta	cagagagttt	ccataatacc	cttactttct	16500
cccacaactt	ctattattaa	catcttgcac	tagtatagta	cgccctttac	aactaatgaa	16560
ccaactcgat	acattattat	taaccaaatt	cctgagttta	ttttatttct	attttttatt	16620
tattattatt	atttttttaga	ggtagggtct	cactgtgttg	tccaggccag	gttgacagtgt	16680
catcttcata	gcttgctata	gcctgaaact	cctgggctca	agcaatcctc	ctgcctcagt	16740
ctcccaaagt	gttggaatta	cagggtgtgag	ccactctgtc	cagcctgaag	tccatagttt	16800
acattacatt	tcactctgtt	gagcattcta	tggattttga	caaatgtgtg	atgatgtata	16860
tttgccagta	cacaattata	taaaatagtt	ttactgccct	agaaaccccc	tgtgtccac	16920
ctatttcattc	ctctgctgaa	ccactggcaa	ccactgatct	tttataatat	ctccatagtt	16980
ttgtcttttc	cagaatgtca	tatagttgga	catacagtgt	gtagcctttt	cagattggct	17040
tctttcagta	aatgatatgc	atttcagggt	tcttcatgtt	tttttggtgg	ttgatagggt	17100
gtttcttttc	attggtgagt	aatactctat	tgtatggata	taccacatgt	tgttttacaa	17160
acattcacct	gaaggataga	catcttggtt	gcttccaagt	ttgagcagtt	atgaataaag	17220
ctgctataaa	cattccagtg	caggactttt	cacctcctct	ggataaatat	caaggagtgc	17280
aattgctaga	tcatatggta	agagtatgtt	tagttttgta	agaagctatc	aaactatatt	17340
caaagtgact	gtaccattat	acattcccat	cagcagtgtg	tgagagttcc	tgttactcca	17400
catcttcacc	agcatttagt	ggtgtcagtg	ttttggattt	tagccatttt	aatgggtgta	17460
taatggtata	cctattaaaa	ttggtttttt	ttggagacag	agtttcacag	tttactcttt	17520
gttgccctgg	ctggagtgca	atggcgcaat	ctcggctcac	tgacgcctcc	gcctccaggt	17580
ttcaagtgat	tctcctgcct	cagcctccca	agtagctggg	attacaggtg	cagccacca	17640
tgttctgcta	atttttttgt	atttttagtg	agatgggggt	tcactgtgtt	acccaggtcg	17700
gtcttgaact	cctgagctca	ggtaatccac	ctgctcagc	ttcccaaagt	gttaggatta	17760
caggcatgag	ccaccgcacc	tggcctcaat	tttttttttt	ttttttttga	gacagagttt	17820
tgctcctgtt	gaccaggctg	gagtgcagtg	gcacaatctc	ggctcactgc	aacctccgcc	17880
tcctgagttc	aagcgattct	cctgccacag	cctcctgagt	agctgggatt	ataggcgccc	17940

200159 PCT SEQ.txt

```

gccactacgc ctggctaatt tttttttttt ttttaattag agacgaggtt tctccatggt 18000
ggtcaggctg gtcttgaact ccccgttctc aggtgatccg cctgcctcag cctcccaaag 18060
tgcttagatt acaggtgtga gccaccgtgc cccgctgtgt ttggctttta ctgtgaagac 18120
gtgttagccg ctgtgatgac tagcaagtgt ggccctccac ccagtcgctc tgggctccca 18180
gctcctgcat cctgctgcaa acttgacatc ttccctcaag taactgttag ttgtctcctg 18240
tctacttgcc caaaatataa ctcttaaact tttctctctg caagtttgtg cctctctccc 18300
tgtctgactt ccccatctaa ataaatggta gaccaccatc tactcctttg tgcaagccag 18360
aaatctagga atcatcctta aattccctgt tctgtcttat ctctgctttc attcaaagca 18420
tcagcaaatc ctgttggttc tacctctgaa gttttctcaa atactgttac ttgactcatc 18480
ctgacttttg tttctgcttt atgttaggct aaatgccctg aaaactcttt tgtacaaaac 18540
acctagaaat actggtataa ctgggcttaa cagggaggcc cgggtgtggt gctcacgcct 18600
gtaataccag aactttggga ggccaagggt ctgaggtcag ctgaggtcag gagtccaga 18660
ccagcctggc caatacgtag tgaaacccca cctctactaa aaaaaaaaaa aaaaattagc 18720
tgggtgttgt ggtgcacacc tgtaggttgt gcatgcttga acttgggagg cggaggttgc 18780
agcgagctga gatcgcgcca ctgcacttca gcctgggtga cagagcagga ttctgtctct 18840
tgaataaaaa aacataaaaa gaataccttc aaagcaaaaa ccaaacatc 18900
tcaccaaaag aatgagaaga tggctgggct cggtggctca cgctgtaat cccagcactt 18960
tgggaggtcg aggcgggcag atcacccgag atgggcagat caccggaggt caggaattcg 19020
agacagctgt ggccaatag gtgaaacccc gtctctgcta aaaatacaaa aattagccag 19080
gtgtgtgtgt agccgcctgt aaatccagct ctgaggcagg ctgaggcagg agaattcgct 19140
gaacctggga ggcgagggtt gcagtgagcc gagatcatgc cactgtactc tagcctggac 19200
gacagagcaa gactctgtct caaaaaaaaaa aaaggctggg tgtgtgtggt catgcctata 19260
atcttagcac tttgggaggc caaggtgggc ggatcacttg aggccagggt aacatggcga 19320
aacccccctc tgtctcttag tactaaagtt agtgggcat ggtgtgtggt gcctgtaatc 19380
ccagctactc gggaggcgag gcaggagaat cgctgaacc aggaggtgga ggttacagt 19440
aaccgagatc tcgccaccgc actctagtct gggcgacaga gcaagactcc gtctcaaaaa 19500
acaacaacaa aaaaccaaca catggccaaa gtgcagtgc ttacatctgt ataatcccaa 19560
tgaattggga gctgaggtg ggaggatcgc ttgagtcagg gaatttgaga ccagcctggg 19620
caacatagac ctcatcacca aaaaaaaaaa attttttaat tagctgggtt tggcagcatg 19680
tacctgtagt cctagctact caggaggctg aggtgggagg atcacttagg cccaggaggt 19740
tgatagtctg aggttatagt gagctatgat cctgccactg cactccagcc tgggccacag 19800
agttagaccc tgtctcttag aaacaaaaaa aagaaactga attaaaaaca 19860
acaagaacaa aaatgtctgt tttgtttatt gagttgtagc ccaagtttct tgagggtaaa 19920
gcattgaaaa gcaggcagta atagatttgc tgtttaaaga gatttacttg cagcactatt 19980
cacaatagca aagacatgga atcaacctaa atgcccataa gtgacaaatt ggataaagaa 20040
aatgtgtgac atactagtgt gaatactatg accacataaa aaacaacgag atcatgtttt 20100
tgtttgtttg tttgtttgtt tgtttttgag atggagtctt gctctattgc ccaggctgga 20160
atgcaggtgg cacgatttca gctcactgca acctccgctt cccaggttca agcaattctc 20220
tgctcagccc tcccagtag ctgggattac aggtgccctc caccatgcct ggctaatttt 20280
tgtatttcta gttgaggtg ggtttcaccc tgttgggcag gctgttcttg aactcctgt 20340
ctcatgatcc tcccactctg gcctcccaaa gtgccgggat tacgtgtgag ccaccgtgct 20400
cggctgagat catgtttttg caggaacatg gatggagctg gaggctatta tccttagcaa 20460
agtaatgcag gaacagaaaa ccgaagacca cgtgttctca cttataagtg ggagctaaat 20520
gtaaatgact tgtgaacaca ccacagatac tgggggttac ttgaggtggg tgaggtggg 20580
agagtgggag gagggagagg aacagaaaag ataactattg ggtattgggc ttaataactt 20640
atattttatc aaaataagct gtacaacaaa cccctctgac atgagtttac ctatataaca 20700
aacttgcacg tgtaacccca aacctaaaat aaaagttaaa aaaaaaaaaa aaggctgggt 20760
gcattgggag gctgaggtg gcagagcact ctgagccagg aattcgagac cagcttggct 20820
aacgtggaga aaccctgtct tctactaaaa ttcaaaaatt agccagggtg ggtgggtgat 20880
gcctgcagtc ccagctacca gggaggctga ggcaggagaa ttgcttgaac tcaggaggca 20940
gagggtgcag tgagctgaga ttgcaccact gcattccagc ctgggcgaca gggcgagacc 21000
ttgtctcaaa aaacaaaaaa aaaacctgtc actttgggaa tatctcaaac 21060
ctagtcatcc aagtgttgtt acgattttag tgtctgcata tcaatattta gtgtgatcta 21120
ctttcttaga ttctcaaata ctgccaatgg gcacatgtca tgaaataatg tcttttagag 21180
gacaagagag tgctaaagtc tcattattgc agtttaagaa aaacaattct gtaacagttt 21240
aactttatag gaaatgcctt ttgttttttc ttttgaggct tagattttta 21300
tttttatgtt tttagagatg gggcttctct atgttaccce ggctggcctt gaattcctgg 21360
gctcaagtga tcttcctgct tcagcctcct gagtagctgg gactagacgt ccactactgc 21420
tcctggctgg aagtttagat ttttaattta actcttctat tgggaaactt tgtatgtttg 21480
ctttaccact taacatttgc atgcattatt gtacctattg tctcctactt aagggaaggc 21540
agtttatgct gttatatgaa gtgaattaac ctctatgtgt acttcagttt tctctatgct 21600
aaaagtgtgt tctagatttt tgaaaaactt acttaatttt cattcattta ttcaaatatt 21660
tgagcattct gtgattgtct gggaaatagc agtgaactga agaattgtct tgttcttatg 21720
gggtctaaag tcctagttag tcatattgga aggagataca tgaaaaaaga aatatatgaa 21780
cgaatggagg cgatgagtag tgtaaaggag aattcagcag gggagatgtt gctgttttag 21840
atagaggggt gtcaagagac attgtgcaga gacctgaacg aagtgaggga gcaagccatg 21900
gagatatcta gggaaagagc ctatcaggtg gagagaagag tcctagggca gaaacgggca 21960
aggtgtgttc caggagcaga gaggggacag ctgtgagcaa ggggagagtt ttaggggaag 22020

```

200159 PCT SEQ.txt

aggcaagag	agacatctgg	ggcaaaatgg	attgactggg	gggccgtggg	aggactttgg	22080
attttttcct	gagtggtgtt	tgagcagggg	aatgaaatga	tctgactctg	gttttttttt	22140
tttttggaga	caaaatcttg	ctctgttgcc	gaggctgaag	tgcaagtggc	caatctcgcc	22200
tcattgcaac	atctacttcc	tgggttcaag	ctatgctcct	gcctcagcct	cccagtagtc	22260
taggattaca	ggcttggggc	accatgccgg	cgaatttctg	tttttatttt	tattttttat	22320
ttatttttat	gtttatgttt	tttgagacgg	agtctcgctg	tgtcaccag	gctggagtgc	22380
agtggcgcg	tctcagctca	ctgcaacctc	tgccctcccc	gttcaagcaa	cttctcctgc	22440
ctcagcctcc	cgagtagctg	agattacagg	cgcttgccac	tacacctggc	taatttttgt	22500
atttttagta	gaaacgggat	ttcaccttgt	tggccaggct	ggtctcgaac	tcctgacctt	22560
aatttatctg	ctcgccttgg	cctcccaaag	tgctgggatg	acaggtttga	gccaccgtgc	22620
cagccaggac	tctttatgtt	aaaggatctg	taatgtggag	aatagaaggt	agagggacaa	22680
ggatgaaagc	atccaggcca	gttagcctag	tccagctatc	taggtaaagg	atgtgtgtgg	22740
cctggattaa	ggctgctgca	gtgggaggtt	gtgagaaagg	ctcaccttcc	tttttttttt	22800
tttttttttt	ttttgagaca	ggatcttact	ctgtctccca	ggctggagtg	cagtgtgtga	22860
atctcagctt	actacaacct	ccgcctcctg	ggctcaagtg	atacccctcc	ctcagcctcc	22920
caagtacctg	ggatgacagg	cttgccgctac	tgcttccggc	taatttttgt	atatttcgta	22980
gagacagggt	tttgccatgt	tgccctaggct	ggtctcaaac	tcctgagctc	aagtgatcca	23040
cccgcctcag	cctcctaaag	tgctgggatt	ataggcctga	gccattgtgc	ccggtcactt	23100
ccagattttg	aagacagagc	caacaggatt	tgtaaatgga	ttaggtgtgg	caggaggagg	23160
gggaggaagg	gagagagaga	ctggagttag	agttaaggct	catttcaagg	tttttagcct	23220
caacatgtgc	aggaatggag	ttgtcacttg	ctagaatggg	ggagactgga	ggagaagccg	23280
gctgggagag	gttttttaatg	aaaggggttg	ctttggatac	attaagtgtg	acatgcattt	23340
tagacatcca	ggtggagata	ttgaagaggc	aagtggctat	aagtgtctga	tgttcatatt	23400
agcggatgga	ggtgagagaca	taaattttgag	aattgtcagt	gtataaacgt	tgttttgata	23460
gaaagtgggg	ctgaataatt	tagaaaggag	tgcatagaga	aaataagttt	actattaaaa	23520
tagctttaac	aggccgggca	cggtggctca	tgccctgtaat	cccagcactt	tgggaggctg	23580
gggtgggcag	atcaaaaggt	caggagtgtg	agaccagcct	ggccaatatg	gtgaaacctt	23640
gtctctactg	aaaatacaaaa	aattagccag	gcgttgtacc	gggcacctgt	agtcaccagt	23700
acttgggagg	ttgaggcagg	agaatcactt	caaccgggga	gggtggagggt	gcagttagcc	23760
aagatcacgc	cactgcactc	catcctgggc	aacagagcaa	gactccgtct	caaaaaaaaa	23820
aacaaaaaaa	aacaaaaaaa	aaaaacttta	acagcaaaagc	ctcttccttt	aaaattatga	23880
atttttttct	ggactctttc	attattaaagt	attattaaagt	ctacattcaa	tcactatggt	23940
agtaaaaaatg	ttgttctagt	tgccgaatgc	aataaaccag	ctcagactta	gtggcctaaa	24000
gcagcaatca	tttgactatg	ttcgaagatg	ccgtgggcag	gaatttagat	aacagcaggg	24060
atggcttgct	tttgctctgc	gatgtctgag	gtctcactga	gaaaactcaa	gcggctgggg	24120
gtctactactg	aaaatacaaaa	tccttactcc	gcttctgcat	gtctgggctg	cgatgacctg	24180
aaggctgatt	tcagctgaga	ctgtagacca	cgctgcctact	tgtggcctcc	ccttttgcct	24240
tgggtttctc	acagaatgtg	gctgggtctg	gagaatgaga	cttccaatga	aatcagggtg	24300
aaatgacatc	tcgccgcttt	cagcatgctc	tattgggttg	aacagttatg	gacttagcta	24360
gattcaaaag	aagggacaac	agacccctcc	ctctcagaga	gtggggcata	atgagagcat	24420
ttaggggccat	gttatccaac	caccacaaat	gccttctgaa	tttgaggttc	tgccctcaaaa	24480
gttcatagtt	cctttgactg	aaggacttct	atataccaa	gcacgtcgag	cccaggtat	24540
attgtttccat	gtaagtgacc	aggactacct	tagtatttctg	tatagggaaa	gtgacctgaa	24600
taaattttgag	aaaagaatct	tccttctctc	cagttaagcac	tgaggtaagc	attgagcatt	24660
attataggtt	tatgactttg	agactcagaa	atttaaattc	ttggccaggc	gcagtggctc	24720
acgcctgtaa	ccccaacact	ttgggaggcc	aaggcaggca	gatcacttga	ggtcaggagt	24780
ttgagaccaa	cctggccaaa	atgggtgaaac	tccatctcta	cgaaaaatac	aaaaatttagc	24840
caggttgacc	ggcgggcacc	tgtaattcca	gctacttggg	aggctgaggt	aagagaattg	24900
cttaagtgtct	ctttatctgc	tttatttcag	ttgcctctct	tagatgaata	ttaatgactt	24960
acatagcatt	ttagatcagt	ggatgttttt	gtgattcttt	tatttgagct	ttggccaaag	25020
ataacagtac	ccacagggtt	tttccagcta	ctcgcctctc	tccttccagt	ggccctcgag	25080
cctggaaaaat	ctgacatgac	aatgtgcttg	ctcaacctac	cactgttttt	cttttgaaaa	25140
gtttggcagc	ctgtttctga	ctcctatgaa	ggtgaattcc	tcagcattca	cagtttatta	25200
gaaaaatact	ttgcttctct	ccaaactcga	aattcaagat	aaccacacct	atatataggc	25260
tgatctttca	ggatgcagtt	gtcatgttga	tgccatgctt	ttcagtatcg	tggccatcat	25320
ctgtttcagta	ggggagggtg	acttctgtaa	tgggagggtg	tggttatgtg	tgtgtgcaag	25380
tgtttatttg	gtgtcttaag	ttagcctgtg	ggaagttcta	aatcaggatg	gtacgtgggt	25440
gccagcagag	agctgtctct	caagtgaagg	aggtagaatc	aaagccaata	ggaaagagcc	25500
tcagatgctt	atatatgtac	cgctggggatt	cagagtgaac	gcagtcatcg	gactaggggt	25560
ggggtttagg	agagcctgtc	tgacagacac	aagaaaggga	tgataaacgc	caccagaga	25620
aaaaagcatt	ttaggcaaga	acaaatatga	aaaaaggaca	aagtctgtgg	gtggggggca	25680
aggaggagat	aagttagactt	gaagggaagc	aacacttatg	aaagtcacct	ggaggctggg	25740
tgccatggct	catgcctata	atcgagcac	tttgaggaggc	cgaggtagga	ggacaacttg	25800
agccccagg	ttcgagacca	tcctgggcaa	catggtgaga	ctgagtctct	accaaaaaaa	25860
aaaaaaaagg	aaatatttcc	agacatggtg	gcatgtgcct	gtaatccag	ttactcagga	25920
ggctgagggt	ggagggttgc	ttgagccag	gaggttgagg	ctgcagttag	ctgtgatcgt	25980
attattgcac	tccagcctgg	gtaacagagc	aagaccctgt	ctcaaaaaat	gaaagtcatt	26040
tgtaggctgg	agagaggaac	tggagggggc	ttaaagttgc	tgagttagta	cagagcctga	26100

200159 PCT SEQ.txt

gataagggtg	aagattttgc	attggacaat	gagatgttag	tgtgtgtttt	tgagctgggg	26160
agtgcgtgta	ttttactctt	attgaagaat	cactgaagga	ttattcttga	atcagtgatt	26220
cttgatcatt	cttgaatttt	tcaaacagca	aaactggaa	agttggccta	ttcctcagaa	26280
tattttctaa	ttgggcgcag	tgctctcact	tgggagaacc	tggtctacaca	ctttagttgt	26340
aattcactcc	agtcgttcat	tcattcaata	cctatttttt	cagcacctat	tatgagccag	26400
acactatgct	ggatgccagg	gttcagggtg	ggacacgcta	gtgagcaaaa	gccaaagactc	26460
ttcttgtctt	catggggcct	tcagtcacgc	atagtgggta	tgagtccaag	ttaatggagt	26520
cacagtactt	gggtgcaagt	catggtgatg	gtgatagaag	gaaggcatgt	gtgagggcca	26580
gtggcaggca	ggagcctggt	gtttttgagg	acctgaagaa	ggagcagagt	gagtgccagg	26640
aacttagcca	ccagctggta	ccagccatac	gagaggggca	gagccagcca	ggatgtcggg	26700
catgctagta	atgagtacaa	acacttacat	gtgcacgcgt	attgggcctc	tgagtgtctac	26760
gtgttcatta	gctcgatgaa	tttgtacagc	aacctgtgtg	ggtaagcact	gttctctccc	26820
ctttctatag	atgaggaaat	taaggcacaa	agaggataaa	taactggcac	cagctacacg	26880
ctaagtgatc	gaagtgggtg	aaccaggatt	caaattccatg	ctattctgcc	ttaagataac	26940
aaatctgtgt	ttttagccta	agaacagagc	agtcctcagg	agggttttta	gtagggggtg	27000
ggcaagatca	agttttgtgt	ttgaaaaggt	ctctctaccc	acagtgtgga	aaatggcctg	27060
gaggcaagca	cacagatggt	gggagacagt	taacagctct	tgccatggcc	ccctatgcat	27120
tttggtcttg	atgtttctgc	ctgatttttc	tcttgccctc	gcctcttttc	ctgaggggat	27180
ggcaggtttt	accattcagc	tgaggtacaa	acctgaacc	ctttttgggt	aaatatctac	27240
ttgtttttcc	tacagtatta	ttttgagttg	ctgtggctgt	aatgtcttga	gggaatcgag	27300
cttgacagta	atttatagaa	caaacagttt	ttagagactg	tgtggcccaa	ttgccctctc	27360
aatgtttgca	ctcctgccat	gacattttacc	atgctgagca	tgtgaccgcc	atctgaatac	27420
caaatgccac	aggaaccctg	gaggttgtca	cttactcctc	cctttctctg	agtcaccttt	27480
gcccttcagt	cagtcaccaa	gtcccacac	atgtagctct	gtaatgtcac	agaagatgga	27540
tgtctgcctc	aaaacactta	caatgctgct	acctaaattg	ggcagccacg	acctcccacc	27600
aggattattg	cagcctgagg	gatctttttg	aaatgtaaat	caaactatca	cttgtctgtt	27660
taaagctttt	caaagactta	ccccattgcc	cttggaaagaa	agtgcagata	tcttgacagg	27720
agagcctctc	ccagcctcct	cttctgccgt	ggctcctctg	tacagtctct	acagtgtgat	27780
gcttcattag	aaccttgagg	attattattt	gctagtctct	ggctaagaac	tggcacctgg	27840
ctttgtagag	ctcctcagga	gattctgagg	cgtattcaga	gttgagccct	gatctctgtc	27900
ctgattctga	ggttctcggt	atattttata	atgatcacga	aaaaatttat	tattattctt	27960
tggcctcact	ttagctcact	ctgaggaatt	tttttttttt	tttgacagag	ttttgtctct	28020
gttgcccagg	ctggagtgca	atggcgtgat	ctcagctcac	tgcaacctcc	gcctcccggg	28080
ttcaagagat	tctcctgcct	cagcctccca	agtagctgaa	attacaggca	tccaccacca	28140
tgctgtctaa	tgtttttgta	tttttttagta	gaggtgggct	ttcacagtgt	tggtcagggt	28200
ggttttgaac	ccctgacgtc	agctgatcca	cccaccagag	ccccccagag	tgctgggatt	28260
acaggtgtga	gccaccgtgc	ccagccgtag	ctttcgaaat	ttgaaacctg	gtcccactgt	28320
cagaggttcc	aattttggc	tggtttgggt	cccaggcatc	tttcttgctg	tatatatttt	28380
ttagtgtcag	ccaggggtga	gacctctgta	ttacttcatg	gggaagaatt	tgggagaaga	28440
tggtgtgagg	agacaggttc	tagctttatc	ctttctcgta	ctttctcgta	cagattttca	28500
ggatattgag	gggccactct	tctgtaattc	atgtttttct	ctcctaacct	cactcctgtt	28560
gcctgcatct	tcttgctgag	caaaatattc	aaggtcttca	actcctcaca	ccctgggtgt	28620
ccctccctgg	atgtgtttgg	ttgttttagt	gttccatttc	aattttgata	cacagaatta	28680
gaattgcatc	cagatgtggg	tctgttacag	ctagactact	agatccctca	aaatccaagt	28740
actagtatgt	ctattaaaat	accataagat	cacattggct	agttacaatg	gttggtttgt	28800
gggttactta	aaaatcaact	aaaattcttt	tttttttttt	gagatggagt	tttgctcttg	28860
ttgcctaggg	tggaatgcaa	tgacacaatc	ttggctcact	gccacctctg	cctcccagggt	28920
tcaagcaatt	cccctgcctt	agcctcctga	gtagctggga	ttacaggcat	gtgccaccat	28980
ggccagctaa	ttctgtattt	ttagtagaga	tgaggttttt	ccatgttggt	caggctgggtc	29040
tcgaactccc	gacctcaggt	gatccacctg	cctcagcctc	ccaaagtgtc	gggattacag	29100
gcgtgagcca	ctgagcctgg	ccaaaattcc	cactttctaa	tactcctgta	gtagctgggt	29160
acggtgggtc	acatctgtaa	tcccagcact	tttgagggtc	gaggtgggag	gatcgcttga	29220
gcctaggagt	tcgagaccag	cctgggcaag	atggccagac	gccatctcta	atttaaaaaa	29280
aagaaaaaac	aagactccta	tagtgggtgaa	gaacagacat	tccgaaaaca	gactgtgcgt	29340
tatgattcca	gctccatgcc	tttactacct	gtgttgtgac	tttggataaa	tcacttaaaa	29400
atcttttttt	tttttttttt	tttttgagac	ggagctcttg	tctgcccggc	aggctggagt	29460
gcagtggcgc	gatctcggct	cactgcaagc	tctgcctccc	agggtcacac	cattctcctg	29520
cctcagcctc	ccaagtagct	gggactgcag	gtgcccgcga	ctacacctgg	ctaatttttt	29580
gtatttttag	tagagacggg	gtttcaccgt	gttagccagg	atggctctga	tctcctgtcc	29640
tcgtgatcca	cccgcctcag	cctctcaaag	tgttgggatt	acaggcgtga	gccaccgcac	29700
ccggccaaat	cacttaaaat	tctgtgcctc	agtttctcct	ctgtaaagtg	ggataaaaaa	29760
agtacattatc	tgatagggtt	gttacaatta	tgaaatgagc	aaataagtat	gtcaagtgtt	29820
taaaacagcg	cctggcttct	tgtaaaaagt	gctatataaa	tcatagttat	aatcattact	29880
tatttcgact	gctctttaac	caaggttctt	atttttctac	tttttctttt	gttttgaata	29940
tcacttagtg	ttttcacctt	ttactctttt	taggacctag	agccatccta	ggtgaaatac	30000
gtatggagat	atttgatcag	gtcaccaccc	agctctcctg	acctcccttc	tctccttaaa	30060
ttaacatgcc	aaatcacagc	atcactgact	ccttccctcc	cgatatgata	agagtgtgca	30120
ttgaaatgca	tgtattttac	ttagcaggga	aagctgatta	gtgattatca	cacttaaccc	30180

200159 PCT SEQ.txt

ctagtgaatc	tgatggatta	acctgctttc	caggacacta	aggaaatggg	tttaagataa	30240
gaaatatctg	gctgggtgcg	gtggctttac	gcctgtaatc	ccagcacctt	gggaggccga	30300
gggtgggcaga	tcacgaggtc	aggtgattga	gatcatctcg	gctaacacga	tgaaaccccc	30360
tctttactaa	aaatacaaaa	aattagccgg	gtgtggtggc	gggcgcctgg	agtcccagct	30420
actcgggagg	ctgaggcaag	agaatggtgt	gaaccacgga	ggcagagctt	gcagtgaagt	30480
gagattgtgc	ccaccgcatt	ccagcctggg	caacagagtg	agactacatc	tcaaaaaaaa	30540
aaaaaaaaaa	agtaagaaat	gtccatgaaa	gggagaccct	gggggaaagg	aacaataact	30600
gcagctctga	ggatctggca	ccagcagcac	cagcacagag	ggatgctgta	caaccattat	30660
tgattttaac	tttacaacag	ttcttcaaag	gagagagagt	tccctgtttt	actgaagaga	30720
aagcccattt	ggtagtgaaa	taccattccc	aaagacaaat	agctaataaa	tgtcaggcag	30780
ggttttgcac	ccaggcccat	ccagctcccg	tctctactgt	cctttccccc	acaccacact	30840
gatacagagg	aatgtgtctg	gttggggaag	tggaagtgtt	cccaagtggg	gaggtcatct	30900
gatgcacaaa	tttggctctg	tttgtgggtt	ttcttgtttt	agttttagtt	ttttagtagc	30960
tcagacctgt	tcttaggcag	ctttaacaat	caactgtgca	ctcagtaatt	gacaaatcat	31020
gtttgttact	tttaatttag	aggggaattag	gtttgttaag	ctcttgctcc	ttcttttagag	31080
atggggctca	gctctgtcac	ccaggctgga	gcgcagtggg	atgatcacag	ctcactgcag	31140
gtcgaactcg	ctagctgcat	cctcctccat	gggactacaa	gcagtggcca	gcagtggcca	31200
ccatgctagg	ctaattttta	aaaaattttt	ttgtagaggc	aaggtctcac	gggtgtgccc	31260
aggctggctt	tgaactcctg	agctcaagca	atccctcttc	caccttgccc	tctcaaagtg	31320
ctagaattat	aggcatgagc	caccatgcct	ggcctttact	tctttcatat	attcaaattt	31380
tgtcataatta	gtagggaact	ataactcaag	ttttcttata	gattgatgtt	cattttttaca	31440
agcttgatcg	tcattgggtt	tttaattttta	agcaaactct	gttatatgta	attgaacatt	31500
acagtaatta	tagtaatttg	tttcagattg	ggcactcaag	tgtaaatatt	ttgtctcttt	31560
aggaaatcaa	aactagattt	atatatagac	ttcttattgc	aagtatctag	tcttaaactt	31620
tacaaaggta	ctatttggac	ttaaaactat	gaaattgtgt	gcttactata	taagtgtact	31680
tattttgagt	tatgttttaa	acttgaattt	ccattcttaa	tgtctagagt	aattatgaat	31740
ggttaaatta	tgaatgactc	taatagttta	aagctacagt	atttatttat	ttattttatt	31800
aaatttattt	ttgagatgga	gtttcgcctt	tgctgcccag	gctggagtgt	agtggcacca	31860
tcttggttca	ctgaaccttc	tgccctcgcg	gttcaagtga	ttctcctgcc	tcagcctccc	31920
aagtggctgg	gattacagg	gtatttcacc	atgcctggct	aatTTTTtga	tttttagtag	31980
agacaggctt	ttgccatgtt	agcctggctg	gtctcgaact	cctgacctca	ggtgacctac	32040
cctcctcagc	ctcccaagga	ttacaagcat	gagccaccac	acctggccta	cagtatttta	32100
aatgtggactc	tctgtcatcc	attatgctgt	ttatcctgtg	gtgaaaattt	tatgaagatt	32160
gaattgtttt	ctctagctg	aattgctttc	tcttactttt	ctcatttttt	tccttcctaa	32220
tctacttgca	gatacttcag	attattttta	gaacgtggta	tggtgagaac	aaataaattg	32280
gggtttccaa	atcttaataa	attatgtggc	cctcagtggg	attagcaggg	ttgtattgaa	32340
aacaccaata	gaaacaaaa	agttctttta	tgcgctttta	ataaaaaatt	cttttcaggc	32400
caggcgagct	ggctcacacc	tgtaatcca	gcaccctggg	aggctgaggc	aggcagatca	32460
cctcaggctca	ggagttttaag	acaagcctgg	ccaacatggg	gaagcgccgt	ctctactaaa	32520
aatacaaaaa	ttagccgggt	atgatggcgc	atgcctgtaa	tcccagctac	tccagaggct	32580
gaggcatgag	aatacattga	actcaggaga	tggaaggtgc	agtgaagtga	gatggtgcca	32640
ctgcaactta	gcctgggcaa	cagagtga	tctgtctca	aacaacaaca	acaacaataa	32700
caaaacatct	cttttcaggc	caggtactgt	ggctcacgcc	tgtaatccca	gcactttggg	32760
aggccaaaac	aggagggtcg	cttgagacca	ggagtttgag	accagcttgg	gcagctgggt	32820
tctatttgaa	caaaacaaca	aacaaacaca	atactctttt	catagaaaaa	tgtttactac	32880
acaaataaat	ttaaaagaat	atgcagctgt	attaatgcta	tgactccaat	gtaaaaaaa	32940
aaaaatatat	atatatatat	acacacacac	aaacacattc	tgaaatagat	ttaaaggaat	33000
tacatcaaca	tgtcaatttt	tattttttcg	gagacagggt	ctcgctgtgt	cacccaagct	33060
ggagtacagt	ggtgcaatca	cagctcactg	cagccttgac	ttcctggcct	caagtgatcc	33120
tccccctcta	gcctcccaaa	gtgctggggg	cacagaccac	cacacctggc	aacatgtcag	33180
ttttgttctt	gcatagtggg	atgggtggat	atggatgttt	ttatctttta	ttttcttttt	33240
tatatttttc	taaattttcc	acattgaaca	ttattttata	atctttcaaa	catatctctt	33300
aaaaggactg	gttcctatag	aattcagtgc	aagaaatctt	ctgtgtttct	ttatactttg	33360
gttgcttga	tcactgggcc	tttcctgaca	gcaaagaaga	ggttagtgta	ggcagcagat	33420
aaaacacagg	tatgtcttat	ttaaaatgca	tgtattttata	ataaaagtat	aggtgggtacc	33480
caaaggaaaa	tgtcatgaca	cattgcaaag	tggaacagaa	gttatcttta	gatcactttc	33540
tgttctggat	tattgtatga	gcctgatttt	cgtctctctt	tccgccttcc	ctcaccctcg	33600
ttgtaaatcc	actagtgc	ggatgtgaag	tacaagtctt	aactttaaaa	agttttatga	33660
agctgtgtag	taaatccctt	ttgtaagtgg	tcttgactgc	gtttctcaat	atatcttttg	33720
gtttcattag	attcaagtat	ataaatgaga	actgtaactt	tggaacagact	ttttcagtca	33780
tctttacggg	aataagttcc	caattagaca	atagttattt	gttttatgac	ttgctgttgg	33840
taggttatcc	ccaagggact	gagaaattcc	tgttttgaaa	agtccaaaaa	gtctttgatg	33900
acttctgtgt	tcattttttt	cttttctctt	cagttataga	aaacaggatt	acaccacctt	33960
tgcttttgta	cagtgcattc	actatctgct	gacttaacct	gagtaaatgc	tttgaattga	34020
gccccatata	atgtcctaag	gcagcctata	tggaagtaag	aattgtcttc	tctcttatgc	34080
acccagagtg	gtagtgtgca	ctcaagttgt	tcctcagata	actttgtgtg	ttctggggct	34140
caatgaagta	gttattaagt	cacaggcttg	gggagaacat	tcattcctatg	gcattgaatg	34200
aagtgttgcc	caattctaga	atgtctaata	aaattttttt	aaaaaccac	aggcttagaa	34260

200159 PCT SEQ.txt

ttattccgta	gatatgaagt	aatgtagtta	gaacttagtg	gagttcttta	gattaacttg	34320
taatttgaaa	aaccaaaatt	gaaattgtga	aataacatgg	gctctttgag	gtcttttcca	34380
gtaaaacagt	tacagtaaag	ctgcttgcca	gtgattttcc	tagacacttt	ggctagtcat	34440
ctcctgtgac	tgctgttaat	ttaaataatgg	ttgtagctaa	gcagcctgta	aggagaagag	34500
tatggaagta	tttgcataatt	ctctccttga	aaatactacc	tggtctttgg	ctttaagtta	34560
tactttttatt	ttccccctgta	gaataactat	taaagtatta	cctatggtga	ttagactaag	34620
aagtaaaaca	tgaaatcagt	cattgttggt	gccctgggtgc	cttctttttt	ttttttttga	34680
gacagatgct	cactctgttg	cccaggctgg	agtgcattgg	cacgatcttg	gtcactgca	34740
acctctgcct	cccaggttca	agcgattctc	ctgcctcagc	ctcccaagta	gctgagacta	34800
caggcgccca	ccaccacgcc	tggtctaattt	ttgaattttt	agtagagaca	gggttttact	34860
atattggcta	ggctggctct	aaactcctga	ccttgtgatc	cgccacactc	agcctcccaa	34920
agtgtcggga	ttataggttg	tagccactgt	gccagcctg	gtgctttaat	tttatggaaa	34980
aatgctagtag	ctggtttctg	ttttaagaaa	taaacacaggc	cgggtgacct	gacttgcgt	35040
tgtactccca	gcagtttggg	aggccgaggc	ggcgcatca	cgaggtcagg	agtttgagac	35100
cagcctggcc	aacatagtag	aaccccgctc	ctactaaaaa	tacaaaaatt	agccgggct	35160
gggtggggcat	gcctgtagtc	ccagctactc	gggaggctga	ggcaggagaa	tcgcttgaac	35220
ctgggagggtg	tgagctgcag	tgagcccaaga	tcgccccact	gcacaccagc	cgggttgaca	35280
gtattttcatc	tcaaaaaaaa	aaaaaaaaaa	aagaacacaa	ttattgtact	acttactagc	35340
cctcctctgt	ccccagctaa	aaataagaac	agcaacaacc	aaaaaatcct	tagttatgta	35400
ctggaaatga	attagataat	tttcaataac	ttacacgttt	ttaggatatg	ttagtttgaa	35460
aatgcaaatga	ttcatgcatg	accccagtg	taacttatga	tgagcagagt	atagtgggt	35520
gctgtttcat	gatttaattt	ggaccttcag	ggagtagact	gtgatgcctc	tgcatttgta	35580
tccaagacaa	ataattaaat	agtctatttt	tggttgggca	tgatgcctca	tgcctgcagt	35640
cccagcactt	tggtgggctg	agggtgggag	atcgcttgag	gccaggaggt	caagatcagt	35700
ctgggcaaca	aaatgagacc	ttgtctctac	aaaaactaca	aaaaattagc	tgaacattgt	35760
ggcttgtgcc	cctagtccca	gctactcagg	tccttgagtt	aggaggattg	cttgagccca	35820
ggagttggag	gttacagtga	tctatatattg	ccactgcact	ccagcctggg	tgacagagag	35880
agaccctgtc	tcaaaaaata	aagtctgttt	ttaaaattaa	ttttaaacac	tgaggtttat	35940
tacaaaaagc	agttggttct	tttttttaaa	tttttttttt	taggagaacc	accgcttttt	36000
ggctacattg	tctagtagtag	cagtgttcaa	taaaaataag	atccaaagta	catatgtaat	36060
gttaagtttt	cttttagttt	ctttttcttt	tcttttcttt	tctcttcttt	ctttctttct	36120
ttcttttttt	tttttttgat	atgcagtctc	actctgttgc	ccaggctgga	gtgcagtggc	36180
acgatctcgg	cccactgcaa	cctccgcctc	cggggttcaa	gcaattctcc	tgccctcagc	36240
tcccagtag	ctgggactac	aggcatgtgc	cccatatacc	agctaatttt	tgtattttta	36300
gtagagatgg	agctttgcc	tggtggccag	tctggtctca	aactcctgac	ctcgggtgat	36360
ccacatgctt	tggtcctcct	aagtgtctgg	attacaggca	tgagccacca	tgccctacca	36420
atgttaagtt	ttctagtagt	catattaaaa	gaagtaaaaa	gaaatgggtg	aagtttaatt	36480
taataatata	ttttatttaa	cccaatatat	cccaaatatt	atcatttcaa	catgaacaag	36540
atactttaca	ttcttttggt	tttactaag	tcctcaaaat	ccagtgtgta	ttttatattg	36600
acagcatagt	tcagtttgaa	gcagccacat	ttcaagtgtc	cagttagccac	atgtggctag	36660
tgactccata	ctggactgtg	taggtttaga	gtttcagtaa	atttgtatgc	aatagaatct	36720
acataaaattg	gcataattatg	cagatttctt	tgatgcaca	tcagttcttg	catagcataa	36780
gtcagggtcat	gatgtctttt	gtctatgagg	cagatttttt	tttttttttt	tttgagacag	36840
agtctcactt	ggtcacccag	gctggagtgt	agatgcacaa	tcttggctca	ctgcaacctc	36900
cattgtgagg	agattttaac	ttggccctaa	tgcaaatatt	gtaagagaga	tctaattggc	36960
tttgatttct	tacagagggc	aatcaatata	tgccatgggt	acaatgcttc	agcatatagt	37020
atgcacgtca	gccactgctt	ttactctggc	tgtgtcttag	tgtacctgta	ccactgcca	37080
ggcagcattt	gtcctgtggc	agggtgaatt	taggttgga	ggttgcaagt	aacattgctt	37140
ttttttgaga	gggagcttg	ctgtattgcc	caggctggag	tgagtggtg	cgatctcggc	37200
tactacaac	ctccacctcc	cgggttcaag	gtattctctt	gcctcagcct	cctgagttag	37260
tggtgattaca	gacggccacc	accatgtctg	gctaattttt	gtatttttag	tagagacggg	37320
gtttcactat	gttggtcagg	ctggtctcga	actcctgacc	tcgtgatcca	cccgcctcgg	37380
cctcccaaag	ttctgggatt	acaggtgtga	gccaccgtgc	ccagcctaca	tttttaatt	37440
aattaattat	aagcaggatc	tcactgtggt	ggccagactg	gtcttgaact	gataagagt	37500
caagaccagc	ctaggcaaca	tggtaaaaac	ctgtctacta	aaaaatacaa	aaaaaaaaat	37560
tagctgggca	tggtggtgcg	tgcttataat	cccagctact	tggtgagctg	aggcaggaaa	37620
atcgcttgaa	ccggggagac	tgaagttgca	gtgaggtgag	attgcaccac	tgactccag	37680
cctaggcgat	tccatctcaa	aaacaataac	aacaaaataa	cattgttga	atatttagtt	37740
aatttataga	agcgatttgg	cctaatttgg	gcaaatacct	tattctgaca	ttctctctat	37800
ttgctttact	gagctttttc	accagtggaa	tttaagccct	tgatacatga	ggagggaaaa	37860
taccttggag	ctgtgctgca	catgtaaagt	acacaggaga	tttagaaaac	ttcgtagcaa	37920
aaaaaagagt	gtaaagtatc	tcattaatag	tttttgggg	ctggacacgg	tggtcaagc	37980
ctatactctt	ggcacatttg	gaggtgaga	tgcatgagtc	taggagtttg	agaccagcct	38040
gggcaacaca	gtaggacccc	gtctctacaa	aaataatcag	ccagatgtgg	tgcgcatctg	38100
tagtcccagt	tacttgagag	gctgaggtgg	gaggtatcgt	tgagctggga	agttgaggct	38160
acagtgaagt	gtgattgaac	cactgcactc	cagcctgggt	gacagagtgc	ctgtctccaa	38220
aaaataaata	aaaataaata	aaatagtttt	gtatgttcac	atgttgcaat	aacatttttg	38280
atatattaaa	tgaaataaaa	tacattaaaa	ttaatttcac	ctgtttcttt	tcttttcttt	38340

200159 PCT SEQ.txt

tttttttttt	tttttgagat	ggagtctcgc	tatgtcatca	ggctggagtg	cagtggcacg	38400
atctcggctc	actgcaacct	cctcctcctg	ggttcaagcg	attcttctgc	ctcagcctcc	38460
ctagtagctg	ggattaaagg	catgtgccac	cacacccagc	taatttttgt	attttttagta	38520
gagacggggt	ttcaccatat	tggccaggat	ggtctcgatc	tcctgacctc	atgatccgcc	38580
tgccttggcc	tcccaaagtt	ctgggattac	aggcgtgagc	cactgcaccc	agcctctttt	38640
aactttttta	gtatggctac	cagaaaaattt	aaaatgcatg	tgtggcctgt	attctattttc	38700
tgttggatgc	tgctgcctta	gattattaat	tattcaatgt	aaagactgct	gggaggtact	38760
acctgcactt	ccctgaatat	atgcttgaga	gtccaccag	ccgtcttcac	agtagcaaga	38820
gggttattct	gagctctgtcc	cccaaagagg	gagggagaag	tgacgccttc	tcaggttctg	38880
tcagaaaacc	tgatcccagg	ccaggcggtg	tagcttacgc	ctgtaatccc	agcacttttg	38940
gaggttgagg	caggaggatt	gcttaagccc	aggagttcga	gaccagcctg	ggcaacacag	39000
tgaagaccct	atctctacaa	aaattttttt	aaaaaaatta	gccaggtgca	gcaatgctgc	39060
ctgtactccc	agctgcttgg	gaggctgagg	taggaggatt	gcctgagccc	aggagttaga	39120
ggttgcagga	gttagagggt	ccacgatcgc	acctttcatt	ccgttacatt	tgctgccttg	39180
agaacagaag	acctgctggt	tttgttgcca	gtttgctcag	tcatttttat	gaaaaagcca	39240
tgtgtaacta	ggtgcttctt	cgtgccttct	ctgagaatca	agaactctag	tatgtttgcg	39300
tgtgtgtact	ctctcattaa	atgttctcac	tatccagag	aaccatctca	ttggaccttg	39360
gtctgtacat	accttcattc	ttggctctga	cttctaatta	tttttagaac	ttctcttttt	39420
tttttttttg	agacagagtt	ttgctctagt	tgccagactg	gaatgcagtg	gcacgatctc	39480
agctcacctc	aacctctgcc	ttccagggttc	aagcaattct	cctgcctcaa	cctcttgagt	39540
agctgttaatt	acaggcattg	gccaccacgc	ctggctaatt	ttgtgttttt	agtagagaca	39600
gggttttctc	aagtgtgtca	ggctgggtct	aaactcccga	cctcaggtga	tctgcccgcc	39660
ttggcctccc	aaagtgtcgg	gattacaggc	gtaagccact	gcgcctggcc	taatttttaga	39720
acttggttaa	acaacttggc	ctctattgat	atttccatga	cccatgctat	tcagaaaagag	39780
gattacatgc	aattagctgg	ctgggtttct	cataccagag	catttcactg	ggatgttctt	39840
gaacctggga	caacttttat	gcctggcatt	ttcttttctt	tctctgttgt	cccagactaa	39900
gcaattttta	aaatagttat	tatttgttga	gtaggagaat	ctcaggcaga	tcttcttgga	39960
tccttcattta	tacttttaaa	cctgtagtct	tggaaattagt	gctctgtccc	ccaaccccaa	40020
acatccaatt	tctacatttt	ggctacagta	caggtttact	gtgtataact	aaaagggctg	40080
tggaggagaa	agaaaggaa	cgacatttgt	tggcatctgt	ttatgtgcca	tgacttgagc	40140
tggatgctgt	aggaatatct	caatacctct	gaggagtggg	aattattatc	tctattttat	40200
agacaaggga	atagaaatct	gggagttaag	taatttttta	atttcacaca	cttctggtag	40260
ataattggatt	ctagaacctg	gcataatagc	cacttgtcat	cccagtgtaa	aagagatgtg	40320
tggccagatg	gggtgcttca	catatgtaat	cccagcactt	tgggaagccg	aggcaggagg	40380
atgacttgag	cccaggagtt	caagaccagc	ctgggcatgt	tttgtttgtc	tcacgaaaca	40440
tttttttaaaa	aatgagtgtg	gcatgggtgt	gtgtgccatt	agtcccagct	cctcgggagg	40500
ctgagggtgg	aggatctctt	gagcccatga	tcatgccatt	gcactctagc	ctgggccaca	40560
gagcaagact	ctgtcttttg	aaaataataa	aaaggagctg	tgattatccc	aagggtggga	40620
ttgtgaatgt	gtttgtattg	ttctaaactg	ggagaaacag	gctgggtgtg	ttggcttatg	40680
cctgtaatct	cagcactttg	ggaggccaag	gtgggaggat	cacttgagtc	caggagtcca	40740
aggccaccct	gggcaacagg	caaaaaatag	agaccccatc	tctatttttt	aaaaataaaa	40800
taaactggga	gggtcctccc	gagcatctct	cagagcatct	ttatccctag	tcacagacct	40860
gacacctgtg	ttgggcaatg	gctacttcta	gattgtttac	ccctactggg	acttgtggtg	40920
aacatatgca	cactttgggt	tacagtgggg	acccctgatt	ttagcaggat	ggcccaatgg	40980
aatcagctac	agcagcttga	cacacggtac	ctggagcagc	tccatcagct	ctacagtga	41040
agcttcccaa	tggagtctgc	gcagtttctg	gcccttgga	ttgagagtca	agattgtgga	41100
gtccttctta	agtgactctc	caaattgtta	gttttcagtt	tgagtcaaga	gacatgaact	41160
cttaatgtca	tgccttgctg	ttccattaaa	aaatgtatgg	gtacagggtg	tggggaaaat	41220
gagatcagga	gataaagggg	cacccttttg	tcttgtaaag	ccttttttat	cttagaaggg	41280
catgtgggca	accttctttg	acacattgaa	accgctgta	tggtgggtga	tgtcttgaag	41340
gttgatttgg	acttcattta	cttgggcaga	tcctctatat	attctgataa	tccagtgtatg	41400
tggtagacat	attttttctc	tgaatgtgaa	ttctgtcata	gctagaactt	tgggttgata	41460
cttgtaattc	cccttttagtt	aaaggaagga	gccacagggg	tgtattagtc	tgttctcaat	41520
ttgtctataa	gaaataacctg	agactgggta	atttataaga	aaagagggtt	aatcggtca	41580
tagttctgga	ggctatatag	gaagcatagc	agcatctgct	gctggggagg	cctcagcaag	41640
cttccaatca	tggcgggaagg	cagagagggg	gcaggcaggt	cacatggcca	cagcaagagc	41700
aagagagcaa	gggggagggtg	ccacacactt	ttaaactatc	agatctcaca	agaactcact	41760
gtctcgagga	cagtatcaac	agggatggta	ttaaaccatt	catgagaaac	ccaccccat	41820
gatccagtca	ccttccacca	ggccccacct	caaacagtg	gggttacatt	tcagtatgag	41880
atttgggcag	ggatgtagat	ccaaactaga	tcacaggata	agggaagtag	attccattca	41940
tagagcagat	aatggcacag	atgtccagca	actattttct	tcactttaat	atgctcaggc	42000
tcactactga	ttttggttta	attcaggcca	gtgttaatat	gacctggttt	ttccagaatg	42060
catactctga	tttgggtgaag	ggccaggagg	tgattcacag	atgttgagga	taggccatcc	42120
cagcctggga	ttacttattt	gtactaataa	atctgaccag	agttaattga	gggtttaaag	42180
caaaacagca	tatctgtcta	ctttgctcaa	atattttaca	aatacaacag	attatgagag	42240
tgggtaataa	tatctggaat	aattgttttt	ttgttttgtg	gttttttttt	tttttttttt	42300
gagatggagt	ctggctgtag	cccaggctgg	atgctcagtg	tacagtctcg	gctcactgca	42360
cctctgcctc	ttggattcaa	gcgatttctc	cgcctcagcc	tcccagtag	ctgggattac	42420

200159 PCT SEQ.txt

```

aggtgcccac caccacacct ggctaatttt ttatttttag tagagacagc gtttcaccat 42480
gttgggccagg ttggtctgga actcctgacc tcagggtgatc cgcctgcctc agcctcccaa 42540
agtcttgga ttacaggcat gagccaccat gcctggcctg gaataattgt taataattat 42600
tacattgatg gcattttatt gctgagcaag aagaatctaa catgatgaat ggggtatagc 42660
atcaggtttg ctttgttttt ttgttttttt cctctttctt gatggtgatt tctgtgtttg 42720
tgtgtatgcg tcggcttcag agccattctt tatcattctt ccttttccta gggcatatgc 42780
ggccagcaaa gaatcacatg ccactttggt gtttcataat ctctgggag agattgacca 42840
gcagtatagc cgcttcctgc aagagtcgaa tgttctctat cagcacaatc tacgaagaat 42900
caagcagttt cttcaggtat gatgagaaac tgaggacaag gagaaacagg acccgagag 42960
tcgggtgtta gtgttctttc ctggaagcat ctcttttctc atttggctaa gtaacgagaa 43020
tctatcttgt attttcaatc acaggagaag taattagccc tttctcaaag ctctgtatc 43080
ttacccgtga gcatcattac ctgagaatca ctctcttgtt cacagttgaa gtaataaagt 43140
gattgttatg ttaatcatac atgttagcat gttaacgcgg tccactgata ggaagatgac 43200
tctcactgtt acatgttaaa tgtttgacca taatgggata cttcttgact aagtcagtag 43260
cttcctgcga agaccaggat agtatactgt gtaaagactc agacaaggcc aggcattggt 43320
gctcacgctc gtaatcccaa caccttagga gctgtagggt ggaggattgc ttgagctgg 43380
gagttttgag accagcttgg gcaacataac aagacaccat ctctacagaa atttttttta 43440
aaaactagct gattgtgggt gcatgcacct gtagtcccag ctactcagaa ggctgagggt 43500
agaaaattg ttgagcctgg gaggtcgaag ctgcaataag ccgtgattgc gccactgcac 43560
tccagcctgg tggacagagt gagagccagt cttaaaaaaa aaaaaaaaag actcaggcta 43620
atgtgccttc tgttacagaa atagtaacga cctccccctc gccccccgcc gacagagagc 43680
cttcacccag gctctgaagc ctttgttccg ttgtttccta gaataaatgc tttccttgat 43740
gaatacatta gtttttaagt gccacagttc agtccacatc tccatggctt gctgtgatt 43800
tttattctct ttctctccta cttatagagc agttatcttg agaagccaat ggagattgcc 43860
cggattgtgg cccggtgcct gtgggaagaa tcacgccttc tacagactgc agccactgcg 43920
gcccagggtg gacctgagac aaaacaaatc cctgggtctg gaggaatgga aaatcaaaca 43980
actttataat gagataaatt attagatcta ctaaaaaaga aggaaaagaa attaaataga 44040
tcaataatca taataatata ttgaaaaaat ttccacaaaa agaagttcc acccccacaa 44100
atacattgaa aaactctaaa aaaaagaaag ttccacaaaa agaatccaac agaccaatg 44160
gtttaaaagt tttgttttgt tctgacaaat tttctttggt tttctttttt tttttttctg 44220
agacagagtt ttgctcttgt taccagggtc agagtgcatt tcttgcctca ggcgcgatct 44280
caacctccac cttcagggtt caagtgcatt tcttgcctca gctcaagag gctcaagag 44340
tataggcgtg tgccaccaca cccagctaatt tttgtatttt tagtagagac tagtagagac 44400
catgttggtc aggtgtgtct cgaactcctg acctcagggt atccgcccgc ctgttctgac 44460
cacagtgtcg ggattacagg cgtgagccac tgtgtccggc ctgttctgac aaactttcat 44520
agtacagatt attccaatc cattcaaact ttccaaagt ataggaaaac aagggatgtt 44580
ttcagcttat tttatgaggt tggaaaaaat ctcatatcaa aacctaaaaa acagccaggt 44640
gtagtagctc acgcctgtaa tcccagcact ttgggaggct gagacgggca gattgcctga 44700
gcctcaggag ttcgagacca gctggggcaa tgtagcgaga cctcatctct gattgcctga 44760
ttttttgaga cagagctctc ctctgtcgag caggctggag tgtagtggtg cctcatctct 44820
tactgcaac ctccgcctcc caggttcaag cgattctctt gctcagcctt gctcagcctt 44880
tgggactaca ggtgtgtgct accaagcctg gctaattttt tgtatttttt tttagtagaga 44940
tggggtttca cctgtttagg caggatgggt ttgatctcct gacttcatga tccaccggcc 45000
acagctctcc cctgtgtgct gattataggt atgagccacc acgcccagcc tttttttttt 45060
ttttgagaca gagtcttgct ctgttgccag gctggagtcg agtggcgtga tctcagctca 45120
ctgcaacttc tgcctcccag gtccaagcta tccccctgcc tcagcctccc aagtagctgg 45180
gactacaggg gcgcgccacc acaccagctt aattttttgt gtttttagta gagatggggg 45240
ttcactgtgt ttgagaggt ggtctcgatc tcttgacctc gtgatccgcc ggcctcgcc 45300
tcccaaagtg ctgggattac aggcgtgagc aaccgcacct ggcttaatta aggatctttc 45360
taaacacaag aaagaatatt tatcagaaac caaagggagc atgatgcaca gtggtgaaac 45420
actattctca gtaaaaacag caaaagataa ggatgtcttt taccattgat acttttctga 45480
gggatccagc ctatgcaaaa agaaaaagaa atgagggtac aaatattgga aagcaagga 45540
cagaactctt attatttaca gatagatagg tcttgcctga agatccaaga gaaacaaaac 45600
taacaataac aattggaact agcaaggttt agaaaggcca ttgtatacaa gataaatatt 45660
tttagaatct gcagttcccc taatcagtag cagcagtaac ctgttagaag atgtaatgaa 45720
agtaaagatc tgggccaggc acgatgtctc acgcctgtaa tccaagcact ttgggagggc 45780
aaggtgggca gattcaggt tcaagagatt gagaccatcc tggccaacat gatgaaaccc 45840
catctctact aaaaatacaa aaattagctg ggtgtggtgg tacgcgcctg tagtcccagc 45900
tactcgggaa gctggggcag gagaatcgct tgaacctggg aggcggagggt tgtagtgaac 45960
caagattgcg ccactgcact cctgggcgac agagcgagac tccgactgaa aaaaaaaaaa 46020
aaaaaaaag aaagatctga ttcatagtag ttaaaactaaa tgtatgcaat ttgcataac 46080
tattggtatg tatgggaaaa tatctggaaa cacatatact aaatcattaa agtagtcggt 46140
cataggagac ttttttactt tctgtgaggg gttttaccgt ctttaatatc ctataatcag 46200
ggacattttt tctttttctc tcgtgacccc agctttttta aaaattgtgg tgaaatacac 46260
ataacattac attttcaaatt tactttgtgt tttttttttt tttttgagac 46320
agtctcactc tgtcaccagc gctggagtcg agtgggtgta tcacagctca ctgcagcctc 46380
aaccacctgg gccctagcga tcctcctgcc gagtagctgg gactacaggc 46440
acatgccacc atgcccagct aatttttttt tttttttttt ttggtagaga tgggctcttg 46500

```

200159 PCT SEQ.txt

ccatgtttcc	caggctggtg	ttgaactcct	gggctcatca	actgatgaga	aagagctctc	46560
caggcagaaa	gaagatcatg	ttcaaagaca	gaaacagaaa	tgtgtattct	tgggagaagt	46620
gtagaaggtt	cagcatctga	ttgggtcggg	gaagacaagc	tagtcaaggc	cacatgatgt	46680
tttaattagt	catgcctaac	agtggggccc	tggaagagca	gtttaccaca	aggggccaac	46740
tgcttcggtt	tgaacccgca	gccctgccac	ttgctctgta	accttaagta	aacaattttt	46800
actctctctg	ttcctccaat	gggagtgata	acaatacctt	cttcatagaa	ttaattcata	46860
catgtaaaaa	gcttagaaca	gtatctgaca	cataaatgca	aaataattta	actgctttct	46920
gctgctgctg	acatcactat	catcacccctc	accattactg	taggaaatgg	ggacccagtg	46980
aagaattttt	tttttttctt	ttgagacaga	gtctcactct	gtcaccagtg	ccggagtgcg	47040
gtgacgcat	ttcggcccac	tgcaacctct	gcctctcagg	ttcaagcgat	tctcatgtct	47100
cagcttccca	agtagctggg	attacaggca	tggaccacca	cactgggcta	attttttgta	47160
tttttagtga	gatagggttt	caccatattg	ctcaggctgg	tctcaaactc	ctgacctcag	47220
gtgatccatc	cacctcgccc	tcccaaagtg	ctgggattac	aggcataagc	cactgtgtcc	47280
ggccctagt	aggaatttta	agcagaaaac	tgatattgctc	aggtgtgagc	gaggtggtag	47340
gtacacacta	ctgtgtagct	ccctgtagcc	caagaggtta	gcacacaggg	atttgcctag	47400
gcagacttag	gattttctgc	tttggaataa	tttggataga	tatcctgtctc	cacaagataa	47460
aaataagtgg	tttaagtcaa	tttggataga	ggctccaact	taccatggga	ggtaggaaag	47520
ccaaagtatt	cccaaggatg	ttttcaatcg	tacggattag	gggtctgcaa	actgtgagcg	47580
tggcccaaat	ccagcctgct	gcttggtttt	gtaaattgag	ttttttcggg	accagccac	47640
actcaattat	ttagtgattt	tctgtggctg	tctgtggctg	gcagtggcag	ggctatttgt	47700
ggcagggact	gtatgaccca	ggaaaccaa	aataatttacc	ctctgtccct	tagagaaaaa	47760
gtttgcaacc	cctgatataa	agctataagt	tgggtatttg	tggcctcaac	ccaggcctca	47820
ctgtattttt	ttctgtttac	aataacctggc	atgctcttaa	gtgtctagaa	ttggttaaag	47880
atagaagtgt	ggatgttaac	cctgtaccga	agggctgtca	ggctagtggg	gattataagt	47940
acacaaacac	tcaaagttag	aaaaacacag	aaaaggatgt	gtgtcatttt	gtctaaggaa	48000
gttgaataag	atttctcagg	aaaagaaaac	tttgaactga	atttgaaggt	gagtgaagttc	48060
aggtgtgttt	gggctgaagc	ccaggccatg	ctgagtggat	agcgggtggg	aagagagtgt	48120
ggaaacacac	tgcatgaggt	gaagagtggg	gagctctggg	tgaccaaggc	acaggagggg	48180
aaagttaga	ttatcaattg	tgtgaaacag	ctttctgtgt	tggcctgaga	tgtttatagc	48240
tggaagcagt	ggggagccaa	tacagttttt	tacgaaggta	ttagaggtgg	gtttctgtgg	48300
gtgatcgta	atcatgtttt	ctccctttta	gtgtagtcct	gcttgagaaa	tagacatgag	48360
aaaggaaatga	aggttaaaa	atacagctga	ctttgtgtaa	aactagaatg	gaaagtgtgg	48420
cttgagctgg	taaccatagg	ggcttttcaa	tgctgtgccc	ctgagttaga	tcttggggta	48480
gagagactgg	atgtgcagag	cagcaccccc	accccccccc	agccatccat	atggagcttc	48540
agctgccata	gaccaacaag	gcagagggat	aggcctctag	acctgcttct	agaaaccagg	48600
ctgtgctctt	gggcccctag	gggcccctag	aaggccaagag	tgagaggagg	gaggcaccag	48660
cttaggtgct	gggttctttg	aagatctgtg	tgtacacaga	gtctttctct	ccatcttacc	48720
aatcagatga	gtcactgtca	ctgtgggaag	aagtaggggc	atgggtcacc	ttcccaaaac	48780
ttctaagaag	tttgtattct	gtgggcttgg	atagggacca	tgggaaagga	agagaatggt	48840
tgcccataaa	actggctgta	gtgtggcctc	aaacttcttg	acttaaatga	tcctcccacc	48900
tcagcctccc	aagtgcctag	aactacaggt	atatgccacc	atgccagct	agttaaaaaa	48960
aaattttttt	tttttttttg	ttgagatgag	gtctctttct	atgttccctg	ggccgggtctc	49020
aaactcccag	cctcaagtga	tcctcctgcc	ttggtttccc	aaagtgtctg	gattataggt	49080
gggagctacc	atgcttagcc	caagcctgta	attttttttt	tttttttttg	agatggagtt	49140
tcacttttgt	tgctcaggct	ggagtgcag	gcgcagctct	ggctcaccac	aacctccacc	49200
tcccgggttc	aggcgattct	ccttcctcag	cctcccaggt	agctgggatt	acaggcatgc	49260
accaccaagc	tcagctaact	ttgtattttt	agtagagatg	ggtttctccg	tgtcggctag	49320
gcttggtcca	aactcctgac	ctcaggtaat	ctgccaccct	tggcctccca	aagtgtctgg	49380
attacaggca	tcagccaccg	cacctggcac	gaacctgtaa	tttttaagtt	tcatatgcta	49440
tttatttttt	gttatttctt	taattcattc	attcatttat	tcattcgaga	tggggcctca	49500
ctatgttgac	taggctagtt	ttgaactcct	ggcctcaagc	agtcctccca	cttcagcctt	49560
ccaaagtgt	gatattatag	gtgtgagctg	ctacatccag	ccttctttct	tctttttctt	49620
tttccatgtg	ctatttgaca	ttttccaagg	taccagcctc	cccttctccc	caagataata	49680
tcttttaata	tggaatttca	tccctagggc	aggacttttt	ttttattatc	cctcagaaat	49740
atactggaca	ccacgtttta	gtagacatcc	aacatctgct	gtcataaatt	gttttgat	49800
ttttgacata	cttgcccctg	aggtttttga	aggcatagac	catgtcttag	ctgaacatgt	49860
gggtctcttag	tgccataaag	ggggttttatg	attgatcctg	tgtagtgtca	cctgtgtagt	49920
gacagcacca	ctgcctctgt	ttcccttctt	cttgtgatgg	cagcagcgtc	tcaagccaaa	49980
caagaagggt	agttaggggt	ggatggaagc	tgggttagagg	tattcctctc	cccatagttc	50040
tgtgtctcca	tgtgacttga	cctccttttt	ggcagcaagg	gggccaggcc	aaccacccca	50100
cagcagccgt	ggtgacggag	aagcagcaga	tgtctggagca	gcaccttcag	gatgtccgga	50160
agagagtgcg	ggtgatgcaa	gttacaagcc	tcgggcaggg	agctttcatt	aatttttttt	50220
tttttttttg	agacagggtc	ttgctctgcc	actcaggctg	ggctgcagtg	gcatgatcac	50280
agctcactgc	agcctcgacc	tctcaggccc	aagcgatcct	cctacctcat	cctcccaagt	50340
agccgggacc	acaggcatgc	accaccacgc	ccagctaat	aaaaaaaaaa	aattttagta	50400
gatgggggtc	tccctgtgtt	gtccaggctg	atcatgaact	cctgggctca	agtgtacctc	50460
ccaactcagc	ctctcaaagt	gctggcatta	caggcgtgag	ccactgcacc	tggccaacag	50520
ggagccttct	cttggggata	ctgcctgcag	gtcctgcag	tatctttttt	gaggttttgg	50580

2018 JUL -6 PM 12:17

AMENDED CLAIMS

1. Use of a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3 in the manufacture of a medicament for treating cancer, wherein administering the antisense compound comprises:
- 5 a loading phase comprising a total weekly dose in the range of about 100-750 mg
for the first 1-10 weeks, and
a maintenance phase comprising a total weekly dose in the range of 100-250
10 mg for
at least 1 week after the loading phase;
wherein the antisense compound comprises a modified oligonucleotide consisting
of 12 to 30 linked nucleosides having a nucleobase sequence comprising a
15 portion
of at least 12 contiguous nucleobases complementary to an equal length portion
of nucleobases 3016 to 3031 of SEQ ID NO: 1, wherein the nucleobase sequence is
20 complementary to SEQ ID NO: 1.
2. Use of claim 1, wherein the dose is 3.0 milligrams of the antisense compound per kilogram of the subject's body weight per week (3.0 mg/kg/wk).
- 25 3. Use of claim 1 wherein the dose is administered for at least 1-52 weeks.
4. Use of claim 1, wherein the dose is administered to the subject 1-6 times per week.
- 30 5. Use of claim 1, wherein the dose is administered 1-6 times during the first week and 1 time each subsequent week.
6. Use of claim 1, wherein the loading phase is 1 week.
- 35 7. Use of claim 1, wherein the total weekly dose of the antisense compound in the loading phase is an amount of any of about 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, or 750 mg.
- 40 8. Use of claim 1, wherein the total weekly dose of the antisense compound in

the maintenance phase is an amount of any of about 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, or 250 mg.

5 9. Use of claim 1, wherein the cancer is B-cell lymphoma or hepatocellular carcinoma (HCC).

10 10. Use of claim 9, wherein the B-cell lymphoma is a non-Hodgkin's B-cell lymphoma.

15 11. Use of claim 10, wherein the non-Hodgkin's B-cell lymphoma is selected from the group consisting of: diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mucosa-associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma (MCL), Burkitt lymphoma, mediastinal large B cell lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large B-cell lymphoma, primary effusion lymphoma, and lymphomatoid granulomatosis.

20 12. Use of claim 10, wherein the non-Hodgkin's B-cell lymphoma is diffuse large B cell lymphoma (DLBCL).

25 13. Use of claim 1, wherein the nucleobase sequence of the modified oligonucleotide comprises the sequence of SEQ ID NO: 12.

 14. Use of claim 1, wherein the modified oligonucleotide is a single-stranded modified oligonucleotide.

30 15. Use of claim 1, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

 16. Use of claim 15, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

35 17. Use of claim 1, wherein at least one nucleoside comprises a modified sugar.

 18. Use of claim 17, wherein at least one modified sugar is a bicyclic sugar.

40 19. Use of claim 18, wherein the bicyclic sugar comprises a 4'-CH₂-O-2' bridge, a 4'-CH(CH₃)-O-2' bridge or a 2'-O(CH₂)₂-OCH₃ group.

20. Use of claim 1, wherein at least one nucleoside comprises a modified nucleobase.

21. Use of claim 20, wherein the modified nucleobase is a 5-methylcytosine.

22. Use of claim 1, wherein the modified oligonucleotide is single-stranded consisting of 16 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 12, comprising:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of 3 linked nucleosides; and

a 3' wing segment consisting of 3 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment;

wherein each nucleoside of each wing segment comprises a constrained ethyl nucleoside; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine of the

modified oligonucleotide is a 5-methylcytosine.

23. Use of claim 2, wherein the subject's body weight is calculated as ideal body weight using the Devine formula.

24. Use of claim 2, wherein the subject's body weight is calculated as an average adult body weight of 70 kilograms.

25. Use of claim 22, wherein the total weekly dose of the antisense compound in the loading phase is an amount of any of about 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, or 750 mg.

26. Use of claim 22, wherein the total weekly dose of the antisense compound in the maintenance phase is an amount of any of about 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, or 250 mg.

27. Use of claim 22, wherein the cancer is B-cell lymphoma or hepatocellular carcinoma (HCC).

28. Use of claim 27, wherein the B-cell lymphoma is a non-Hodgkin's B-cell lymphoma.

29. Use of claim 28, wherein the non-Hodgkin's B-cell lymphoma is selected from the group consisting of: diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mucosa-associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma (MCL), Burkitt lymphoma, mediastinal large B cell lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large B-cell lymphoma, primary effusion lymphoma, and lymphomatoid granulomatosis.

30. Use of claim 28, wherein the non-Hodgkin's B-cell lymphoma is diffuse large B cell lymphoma (DLBCL).

31. Use of a weekly dose of an antisense compound complementary to a nucleic acid encoding human STAT3 in the manufacture of a medicament for treating cancer, wherein the antisense compound comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 12, comprising:
a gap segment consisting of ten linked deoxynucleosides;
a 5' wing segment consisting of 3 linked nucleosides; and
a 3' wing segment consisting of 3 linked nucleosides;
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment;
wherein each nucleoside of each wing segment comprises a constrained ethyl nucleoside;
wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine of the modified oligonucleotide is a 5-methylcytosine; and
wherein the dose is about 3.0 milligrams of the antisense compound per kilogram of the subject's body weight per week (3.0 mg/kg/wk).

32. Use of claim 31, wherein the dose is administered to the subject for at least 1 to 52 weeks.

33. Use of claim 31, wherein the dose is administered to the subject 1 to 6 times per week.

34. Use of claim 31, wherein the cancer is B-cell lymphoma or hepatocellular carcinoma (HCC).

35. Use of claim 34, wherein the B-cell lymphoma is a non-Hodgkin's B-cell

lymphoma.

36. Use of claim 35, wherein the non-Hodgkin's B-cell lymphoma is diffuse large B cell lymphoma (DLBCL).

5

37. Use of a pharmaceutical composition comprising an antisense compound complementary to a nucleic acid encoding human STAT3 in the manufacture of a medicament for treating cancer, wherein administering the antisense compound comprises administering to the subject a total weekly dose in the range of 100-750 mg for at least 1 week;

10

wherein the antisense compound comprises a modified oligonucleotide consisting

of 12 to 30 linked nucleosides having a nucleobase sequence comprising a portion

15

of at least 12 contiguous nucleobases complementary to an equal length portion

of nucleobases 3016 to 3031 of SEQ ID NO: 1, wherein the nucleobase sequence is

complementary to SEQ ID NO: 1.

20

38. Use of claim 37, wherein the antisense compound comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 12, comprising:

a gap segment consisting of ten linked deoxynucleosides;

25

a 5' wing segment consisting of 3 linked nucleosides; and

a 3' wing segment consisting of 3 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3'

wing segment;

30

wherein each nucleoside of each wing segment comprises a constrained ethyl

nucleoside;

wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine of the modified oligonucleotide is a 5-methylcytosine.

35